var title_f32_46_33504="Levofloxacin: Drug information";
var content_f32_46_33504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levofloxacin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37043?source=see_link\">",
"       Levofloxacin (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/8/16521?source=see_link\">",
"       Levofloxacin (systemic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9554 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33504=[""].join("\n");
var outline_f32_46_33504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37043?source=related_link\">",
"      Levofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/8/16521?source=related_link\">",
"      Levofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_46_33505="MUNE incremental stimulation";
var content_f32_46_33505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Motor unit number estimation (MUNE) by the incremental stimulation method",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 463px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Setup for recording from the biceps brachii with proximal stimulation of the musculocutaneous nerve (right). Superimposed waveforms, obtained following a series of progressively increasing stimuli (top left), are shown with the full CMAP (bottom left). The amplitudes of each waveform increment are measured and then averaged to obtain the average SMUAP amplitude. The full CMAP amplitude is then divided by the average SMUAP amplitude to derive the MUNE.",
"    <div class=\"footnotes\">",
"     MUNE: motor unit number estimation; CMAP: compound muscle action potential; SMUAP: single motor unit action potential.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeremy Shefner, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33505=[""].join("\n");
var outline_f32_46_33505=null;
var title_f32_46_33506="Small congenital nevus";
var content_f32_46_33506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small congenital nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33506=[""].join("\n");
var outline_f32_46_33506=null;
var title_f32_46_33507="Character photons b";
var content_f32_46_33507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Comparative treatment plans for a large acoustic neuroma using proton radiosurgery (A) and conformal photon radiosurgery (B)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The various isodose lines are indicated in the right upper corner of each panel. The comparison reveals that proton radiosugery minimizes irradiation of the non-target tissues relative to photon radiosurgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Massachusetts General Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33507=[""].join("\n");
var outline_f32_46_33507=null;
var title_f32_46_33508="Mineral oil: Patient drug information";
var content_f32_46_33508=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mineral oil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13316?source=see_link\">",
"     see \"Mineral oil: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/28/20931?source=see_link\">",
"     see \"Mineral oil: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2605148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fleet&reg; Mineral Oil Enema [OTC];",
"     </li>",
"     <li>",
"      Kondremul&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702532",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mineral oil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Appendicitis, colostomy, diverticulitis, ileostomy, or ulcerative colitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take the oral product if you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble swallowing, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to stand or sit up, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696933",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug for more than 1 week unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698608",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding from rectum or rectal pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime. Do not lie down while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kondremul: Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Rectal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use enema rectally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11504 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33508=[""].join("\n");
var outline_f32_46_33508=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605148\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020021\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020023\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020022\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020027\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020028\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020030\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020025\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020026\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020031\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020032\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13316?source=related_link\">",
"      Mineral oil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/28/20931?source=related_link\">",
"      Mineral oil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_46_33509="Dutasteride and tamsulosin: Drug information";
var content_f32_46_33509=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dutasteride and tamsulosin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/8/43140?source=see_link\">",
"    see \"Dutasteride and tamsulosin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10815664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Jalyn&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10329850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      5 Alpha-Reductase Inhibitor;",
"     </li>",
"     <li>",
"      Alpha",
"      <sub>",
"       1",
"      </sub>",
"      Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10571925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Males:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Benign prostatic hyperplasia (BPH):",
"     </b>",
"     Oral: One capsule (0.5 mg dutasteride/0.4 mg tamsulosin) once daily ~30 minutes after the same meal each day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10571926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10571927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Not studied",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10571928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; no specific adjustments recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10572618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jalyn&trade;: Dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10571749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10571930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer 30 minutes after the same meal each day. Capsules should be swallowed whole; do not crush, chew, or open. Oropharyngeal contact with capsule contents may result in irritation of the mucosa.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10329851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptomatic benign prostatic hyperplasia (BPH)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10572615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequencies reported for when products used in combination. See individual monographs for additional adverse effects reported with each agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (5%), breast enlargement/tenderness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Abnormal ejaculation (10%), impotence (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Prostate cancer (high-grade)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10571753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dutasteride, tamsulosin, other 5&alpha;-reductase inhibitors (eg, finasteride), or any component of the formulation; children; women of childbearing potential; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10571754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; causality has not been established and there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery. Instruct patients to inform ophthalmologist of tamsulosin use when considering eye surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension/syncope: May cause significant orthostatic hypotension and syncope, especially with first dose; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators) or a PDE-5 inhibitor (eg, sildenafil, tadalafil, vardenafil) is introduced. \"First-dose\" orthostatic hypotension may occur 4-8 hours after dosing; may be dose-related. Patients should be cautioned about performing hazardous tasks when starting new therapy or adjusting dosage upward.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Priapism has been associated with tamsulosin use (rarely).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Rarely, patients with a sulfa allergy have also developed an allergic reaction to tamsulosin; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diminished urinary flow: Carefully monitor patients with a large residual urinary volume or severely diminished urinary flow for obstructive uropathy; these patients may not be candidates for dutasteride combination therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; use has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostate cancer: When compared to placebo, 5-alpha-reductase inhibitors (5-ARIs) have been shown to reduce the overall incidence of prostate cancer, although an increase in the incidence of high-grade prostate cancers has been observed; 5-ARIs are not approved in the U.S. or Canada for the prevention of prostate cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use caution in patients with ESRD (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute); use has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors: Use with caution with concurrent use of moderate, chronic CYP3A4 inhibitors; use not recommended with strong CYP3A4 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Females: Not indicated for use in women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women/pregnancy: Dutasteride can be absorbed through the skin; women should always use caution whenever handling. Pregnant women or women trying to conceive should not handle the product; if contact with a leaking capsule occurs, wash area immediately with soap and water; dutasteride may negatively impact fetal development.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antihypertensive use: Not intended for use as an antihypertensive drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Other urological diseases, including prostate cancer, should be ruled out before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood donation: Avoid donating blood during or for 6 months following treatment cessation due to risk of administration to a pregnant female transfusion recipient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PSA monitoring: Dutasteride reduces prostate specific antigen (PSA) by ~50% within 3-6 months of use. Addition of tamsulosin did not effect changes in PSA; changes expected are similar to dutasteride monotherapy. If following serial PSAs, re-establish a new baseline &ge;3 months after treatment initiation; monitor PSA periodically thereafter. If interpreting an isolated PSA value in a patient treated for &ge;3 months, then double the PSA value for comparison to a normal PSA value in an untreated man. Failure to demonstrate a meaningful PSA decrease (&lt;50%) or a PSA increase while on this medication may be associated with an increased risk for prostate cancer (NCCN Prostate Cancer Early Detection Guidelines, v.1.2011). Patients on a 5-ARI with any increase in PSA levels, even if within normal limits, should be evaluated; may indicate presence of prostate cancer.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10449394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10571766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Maximum serum concentrations of tamsulosin reduced by 30% when taken with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort: May decrease the levels/effects of dutasteride, as well as tamsulosin. Avoid herbs with hypotensive properties (black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, Shepherd's purse); may enhance the hypotensive effect of tamsulosin. Avoid saw palmetto (due to limited experience with this combination).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10571750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10571751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use contraindicated in pregnancy. Not indicated for use in women. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10571752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not indicated for use in women",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10571929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take once daily, 30 minutes after the same meal each day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Jalyn Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-0.4 mg (30): $151.02",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10571932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Objective and subjective signs of relief of benign prostatic hyperplasia, including improvement in urinary flow, reduction in symptoms of urgency, and relief of difficulty in micturition; for serial PSA monitoring, establish a new baseline PSA level after 3 months of therapy and monitor PSA periodically thereafter.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Combodart (BE, DK, EE, FR, GB, IE, NL, PT);",
"     </li>",
"     <li>",
"      Duodart (AU, CH, CZ, DE, FI, HK, IL, MY, NO, PH, PL);",
"     </li>",
"     <li>",
"      Tamdura (IN);",
"     </li>",
"     <li>",
"      Urimax-D (IN);",
"     </li>",
"     <li>",
"      Uritin-D (IN);",
"     </li>",
"     <li>",
"      Veltam Plus (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10571788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Dutasteride is a 4-azo analog of testosterone and is a competitive, selective inhibitor of both reproductive tissues (type 2) and skin and hepatic (type 1) 5&alpha;-reductase. This results in inhibition of the conversion of testosterone to dihydrotestosterone and markedly suppresses serum dihydrotestosterone levels.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Tamsulosin is an antagonist of alpha",
"     <sub>",
"      1A",
"     </sub>",
"     -adrenoreceptors in the prostate. Smooth muscle tone in the prostate is mediated by alpha",
"     <sub>",
"      1A",
"     </sub>",
"     -adrenoreceptors; blocking them leads to relaxation of smooth muscle in the bladder neck and prostate, causing an improvement of urine flow and decreased symptoms of BPH. Approximately 75% of the alpha",
"     <sub>",
"      1",
"     </sub>",
"     -receptors in the prostate are of the alpha",
"     <sub>",
"      1A",
"     </sub>",
"     subtype.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10571790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andriole G, Bostwick DG, Brawley OW, et al, &ldquo;Effect of Dutasteride on the Risk of Prostate Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(13):1192-202.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33509/abstract-text/20357281/pubmed\" id=\"20357281\" target=\"_blank\">",
"        20357281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chang DF and Campbell JR, &ldquo;Intraoperative Floppy Iris Syndrome Associated With Tamsulosin,&rdquo;",
"      <i>",
"       J Cataract Refract Surg",
"      </i>",
"      , 2005, 31(4):664-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33509/abstract-text/15899440/pubmed\" id=\"15899440\" target=\"_blank\">",
"        15899440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prostate Cancer Early Detection,&rdquo; Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roehrborn CG, Siami P, Barkin J, et al, &ldquo;The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2008, 179(2):616-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33509/abstract-text/18082216/pubmed\" id=\"18082216\" target=\"_blank\">",
"        18082216",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thompson IM, Goodman PJ, Tangen CM, et al, &ldquo;The Influence of Finasteride on the Development of Prostate Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(3):215-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33509/abstract-text/12824459/pubmed\" id=\"12824459\" target=\"_blank\">",
"        12824459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15579 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-2F27AEB7FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33509=[""].join("\n");
var outline_f32_46_33509=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10815664\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10329850\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571925\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571926\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571927\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571928\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10572618\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571749\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571930\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10329851\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10572615\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571753\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571754\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299242\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10449394\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571766\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571750\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571751\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571752\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571929\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322857\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571932\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962023\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571788\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571790\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15579\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15579|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/8/43140?source=related_link\">",
"      Dutasteride and tamsulosin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_46_33510="Succinylcholine (suxamethonium): Drug information";
var content_f32_46_33510=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Succinylcholine (suxamethonium): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/31/31219?source=see_link\">",
"    see \"Succinylcholine (suxamethonium): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/58/39845?source=see_link\">",
"    see \"Succinylcholine (suxamethonium): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anectine&reg;;",
"     </li>",
"     <li>",
"      Quelicin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Quelicin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F223472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Neuromuscular Blocker Agent, Depolarizing",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F223434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Neuromuscular blockade:",
"     </b>",
"     I.M., I.V.: Dose to effect; doses will vary due to interpatient variability; use total body weight for obese patients (Bentley, 1982; Brunette, 2004; Rose, 2000). Use carefully and/or consider dose reduction in patients with reduced plasma cholinesterase activity due to genetic abnormalities of plasma cholinesterase or when associated with other conditions (eg, pregnancy, severe liver disease, renal disease); prolonged neuromuscular blockade may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Up to 3-4 mg/kg, total dose should not exceed 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intubation: 0.6 mg/kg (range: 0.3-1.1 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rapid sequence intubation: 1-1.5 mg/kg (Sluga, 2005; Weiss, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Initial dose of succinylcholine must be increased when nondepolarizing agent pretreatment used because of the antagonism between succinylcholine and nondepolarizing neuromuscular-blocking agents.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F223453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/58/39845?source=see_link\">",
"      see \"Succinylcholine (suxamethonium): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Neuromuscular blockade:",
"     </b>",
"     I.M., I.V.:Dose to effect; doses will vary due to interpatient variability; use total body weight for obese patients (Bentley, 1982; Brunette, 2004; Rose, 2000). Use carefully and/or consider dose reduction in patients with reduced plasma cholinesterase activity due to genetic abnormalities of plasma cholinesterase or when associated with other conditions (eg, pregnancy, severe liver disease, renal disease); prolonged neuromuscular blockade may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Smaller Children: Intermittent: Initial: 2 mg/kg/dose; maintenance: 0.3-0.6 mg/kg/dose every 5-10 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Older Children and Adolescents: Intermittent: Initial: 1 mg/kg/dose; maintenance: 0.3-0.6 mg/kg every 5-10 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Initial dose of succinylcholine must be increased when nondepolarizing agent pretreatment used because of the antagonism between succinylcholine and nondepolarizing neuromuscular-blocking agents.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F223435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13136281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use carefully and/or consider dose reduction; prolonged neuromuscular blockade may occur if reduced plasma cholinesterase activity coexists.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F223436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use carefully and/or consider dose reduction; prolonged neuromuscular blockade may occur if reduced plasma cholinesterase activity coexists.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as chloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anectine&reg;: 20 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Quelicin&reg;: 20 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as chloride [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Quelicin&reg;: 100 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F223415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered by rapid I.V. injection without further dilution. I.M. injections should be made deeply, preferably high into deltoid muscle; use only when I.V. access is not available.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F223478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Etomidate, heparin with hydrocortisone sodium succinate, hetastarch in lactate electrolyte injection (Hextend&reg;), palonosetron, potassium chloride, propofol, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Heparin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Heparin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F223413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To facilitate both rapid sequence and routine endotracheal intubation and to relax skeletal muscles during surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Does not relieve pain or produce sedation",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13136260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To reduce the intensity of muscle contractions of electroconvulsive therapy (ECT)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2973356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"       - Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"       - Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Quelicin [U.S., Brazil, Canada, Indonesia] may be confused with Keflin brand name for cefalotin [Argentina, Brazil, Mexico, Netherlands, Norway]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F223470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, bradycardia (higher with second dose, more frequent in children), cardiac arrest, hyper-/hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Salivation (excessive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Jaw rigidity, muscle fasciculation, postoperative muscle pain, rhabdomyolysis (with possible myoglobinuric acute renal failure)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Intraocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure (secondary to rhabdomyolysis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, respiratory depression (prolonged)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, malignant hyperthermia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Acute quadriplegic myopathy syndrome (prolonged use), myositis ossificans (prolonged use)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F223418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to succinylcholine or any component of the formulation; personal or familial history of malignant hyperthermia; myopathies associated with elevated serum creatine phosphokinase (CPK) values; acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle or upper motor neuron injury",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F223401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia: Risk of bradycardia may be increased with second dose and may occur more in children. Occurrence may be reduced by pretreating with atropine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure (IOP): May increase IOP; use caution with narrow-angle glaucoma or penetrating eye injuries",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignant hyperthermia: Use may be associated with acute onset of malignant hyperthermia; risk may be increased with concomitant administration of volatile anesthetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vagal tone: May increase vagal tone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Burn injury: Use with caution in patients with extensive or severe burns; risk of hyperkalemia is increased following injury. Onset of time and duration of risk are variable, but risk is generally greatest 7-10 days after injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions which may antagonize neuromuscular blockade: Alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, and diabetes mellitus may result in antagonism of neuromuscular blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions which may potentiate neuromuscular blockade: Electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, neuromuscular diseases, acidosis, acute intermittent porphyria, Eaton-Lambert syndrome, myasthenia gravis, renal failure, and hepatic failure may result in potentiation of neuromuscular blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Use with caution in patients with pre-existing hyperkalemia. Severe hyperkalemia may develop in patients with chronic abdominal infections, burn injuries, children with skeletal muscle myopathy, subarachnoid hemorrhage, or conditions which cause degeneration of the nervous system.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Plasma pseudocholinesterase disorders: Metabolized by plasma cholinesterase; use with caution (if at all) in patients suspected of being homozygous for the atypical plasma cholinesterase gene. Plasma cholinesterase activity may also be reduced by burns, decompensated heart disease, infections, malignant tumors, myxedema, pregnancy, severe hepatic or renal dysfunction, ulcer, and certain medications and chemicals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly, effects and duration are more variable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: Use caution in children and adolescents. Acute rhabdomyolysis with hyperkalemia, ventricular arrhythmias and cardiac arrest have been reported (rarely) in children with undiagnosed skeletal muscle myopathy; occurs soon after administration and requires immediate treatment of hyperkalemia.",
"     </b>",
"     Prolonged resuscitation may be required. Use in children should be reserved for emergency intubation or where immediate airway control is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced personnel: Should be administered by adequately trained individuals familiar with its use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May increase the serum concentration of Succinylcholine. Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Succinylcholine may enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclophosphamide: May increase the serum concentration of Succinylcholine. Management: Consider alternatives to succinylcholine in patients who have received cyclophosphamide in the past 10 days, or reduced succinylcholine doses (a serum pseudocholinesterase assay may help inform this reduction) with close monitoring.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echothiophate Iodide: May increase the serum concentration of Succinylcholine. Management: For patients receiving echothiophate iodide eye drops, consider using a neuromuscular-blocking agents other than succinylcholine. If succinylcholine is used, consider a reduced dose, and monitor for enhanced/prolonged effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenelzine: May enhance the neuromuscular-blocking effect of Succinylcholine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5023968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Small amounts cross the placenta. Sensitivity to succinylcholine may be increased due to a ~24% decrease in plasma cholinesterase activity during pregnancy and several days postpartum.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F223440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16571287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if succinylcholine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering succinylcholine to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Anectine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (10 mL): $3.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Quelicin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (10 mL): $2.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Quelicin-1000 Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (10 mL): $20.24",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F223410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor cardiac, blood pressure, and oxygenation during administration; temperature, serum potassium and calcium, assisted ventilator status; neuromuscular function with a peripheral nerve stimulator",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F223420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anectine (AE, BB, BH, BM, BS, BZ, CY, EG, ES, GB, GY, IE, IQ, IR, JM, JO, KW, LB, LY, MX, OM, QA, SA, SR, SY, TT, YE);",
"     </li>",
"     <li>",
"      Anekcin (PH);",
"     </li>",
"     <li>",
"      Anektil (PH);",
"     </li>",
"     <li>",
"      Celocurin (SE);",
"     </li>",
"     <li>",
"      Celocurine (BE, FR);",
"     </li>",
"     <li>",
"      Chlorsuccillin (PL);",
"     </li>",
"     <li>",
"      Curacit (NO);",
"     </li>",
"     <li>",
"      Curalest (NL);",
"     </li>",
"     <li>",
"      Distensil (PE);",
"     </li>",
"     <li>",
"      Ethicholine (MY, SG);",
"     </li>",
"     <li>",
"      Fosfitone (AR, UY);",
"     </li>",
"     <li>",
"      Leptosuccin (HR);",
"     </li>",
"     <li>",
"      Lysthenon (AT, BG, CH, EE, RU, TR);",
"     </li>",
"     <li>",
"      Midarine (IN);",
"     </li>",
"     <li>",
"      Mioflex (ES);",
"     </li>",
"     <li>",
"      Myoplegine (LU);",
"     </li>",
"     <li>",
"      Myotenlis (IT);",
"     </li>",
"     <li>",
"      Pantolax (DE);",
"     </li>",
"     <li>",
"      Quelicin Chloride (BR, ID, PH);",
"     </li>",
"     <li>",
"      Relaxin (TW);",
"     </li>",
"     <li>",
"      Scoline (AU, IN);",
"     </li>",
"     <li>",
"      Succi (AR);",
"     </li>",
"     <li>",
"      Succicholine (KP);",
"     </li>",
"     <li>",
"      Succinyl Asta (HU, LU);",
"     </li>",
"     <li>",
"      Succinyl Forte (IL);",
"     </li>",
"     <li>",
"      Sukolin (FI, HN);",
"     </li>",
"     <li>",
"      Sumeth (PK);",
"     </li>",
"     <li>",
"      Suxamethonium (NZ);",
"     </li>",
"     <li>",
"      Suxamethonium Chloride (AU);",
"     </li>",
"     <li>",
"      Suxameton (DK);",
"     </li>",
"     <li>",
"      Suxametonio Cloruro (CN, PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F223400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts similar to acetylcholine, produces depolarization of the motor endplate at the myoneural junction which causes sustained flaccid skeletal muscle paralysis produced by state of accommodation that develops in adjacent excitable muscle membranes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F223417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M.: 2-3 minutes; I.V.: Complete muscular relaxation: 30-60 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.M.: 10-30 minutes; I.V.: 4-6 minutes with single administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly hydrolyzed by plasma pseudocholinesterase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bentley JB, Borel JD, Vaughan RW, et al, &ldquo;Weight, Pseudocholinesterase Activity, and Succinylcholine Requirement,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1982, 57(1):48-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33510/abstract-text/7091721/pubmed\" id=\"7091721\" target=\"_blank\">",
"        7091721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brunette DD, &ldquo;Resuscitation of the Morbidly Obese Patient,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 2004, 22(1):40-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33510/abstract-text/14724877/pubmed\" id=\"14724877\" target=\"_blank\">",
"        14724877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rose JB, Theroux MC, and Katz MS, &ldquo;The Potency of Succinylcholine in Obese Adolescents,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2000, 90(3):576-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33510/abstract-text/10702440/pubmed\" id=\"10702440\" target=\"_blank\">",
"        10702440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ross MB, &ldquo;Additional Stability Guidelines for Routinely Refrigerated Drug Products,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1988, 45(7):1498-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33510/abstract-text/3414714/pubmed\" id=\"3414714\" target=\"_blank\">",
"        3414714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roy JJ, Boismenu D, Mamer OA, et al, &ldquo;Room Temperature Stability of Injectable Succinylcholine Dichloride,&rdquo;",
"      <i>",
"       Int J Pharm Compound",
"      </i>",
"      , 2008, 12(1): 83-85.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sluga M, Ummenhofer W, Studer W, et al, \"Rocuronium Versus Succinylcholine for Rapid Sequence Induction of Anesthesia and Endotracheal Intubation: A Prospective, Randomized Trial in Emergent Cases,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2005, 101(5):1356-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33510/abstract-text/16243994/pubmed\" id=\"16243994\" target=\"_blank\">",
"        16243994",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Storms ML, Stewart JT, and Warren FW, &ldquo;Stability of Succinylcholine Chloride Injection at Ambient Temperature and 4&deg;C in Polypropylene Syringes,&rdquo;",
"      <i>",
"       Int J Pharm Compound",
"      </i>",
"      , 2003, 7(1):68-70.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weiss JH, Gratz I, Goldberg ME, et al, \"Double-Blind Comparison of Two Doses of Rocuronium and Succinylcholine for Rapid-Sequence Intubation,\"",
"      <i>",
"       J Clin Anesth",
"      </i>",
"      , 1997, 9(5):379-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33510/abstract-text/9257203/pubmed\" id=\"9257203\" target=\"_blank\">",
"        9257203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9952 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-DF7F161079-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33510=[""].join("\n");
var outline_f32_46_33510=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709420\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223430\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223431\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223472\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223434\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223453\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223435\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13136281\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223436\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223412\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223397\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223415\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223478\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223413\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13136260\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973356\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223470\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223418\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223401\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300086\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223405\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223408\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5023968\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223440\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16571287\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323901\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223410\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223420\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223400\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223417\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9952\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9952|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/31/31219?source=related_link\">",
"      Succinylcholine (suxamethonium): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/58/39845?source=related_link\">",
"      Succinylcholine (suxamethonium): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_46_33511="Hypertrophic osteoarthropathy 1";
var content_f32_46_33511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80452%7EDERM%2F61526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80452%7EDERM%2F61526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophic osteoarthropathy - digital clubbing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bulbous swelling of the distal phalanx of the finger with increased nail curvature is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophic osteoarthropathy - digital clubbing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bulbous swelling of the distal phalanges of the fingers with increased nail curvature is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33511=[""].join("\n");
var outline_f32_46_33511=null;
var title_f32_46_33512="Tolmetin: Drug information";
var content_f32_46_33512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tolmetin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/38/16997?source=see_link\">",
"    see \"Tolmetin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/3/13367?source=see_link\">",
"    see \"Tolmetin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F229094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F229068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Inflammation, arthritis:",
"     </b>",
"     Oral: 400 mg 3 times/day; usual dose: 600 mg to 1.8 g/day; maximum: 1.8 g/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F229083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/3/13367?source=see_link\">",
"      see \"Tolmetin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Juvenile idiopathic arthritis (JIA):",
"     </b>",
"     Oral: Children &ge;2 years: Initial: 20 mg/kg/day in 3-4 divided doses; Maintenance: 15-30 mg/kg/day in 3-4 divided doses (maximum 30 mg/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Analgesic (unlabeled use):",
"     </b>",
"     Oral: Children &ge;2 years: 5-7 mg/kg/dose every 6-8 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F229069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg, 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089162.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089162.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F229045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of rheumatoid arthritis and osteoarthritis, juvenile idiopathic arthritis (JIA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14187959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F229092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Nausea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (3% to 9%), hypertension (3% to 9%), chest pain (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3% to 9%), headache (3% to 9%), depression (1% to 3%), drowsiness (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin irritation (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Weight gain/loss (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (3% to 9%), diarrhea (3% to 9%), dyspepsia (3% to 9%), flatulence (3% to 9%), gastrointestinal distress (3% to 9%), vomiting (3% to 9%), constipation (1% to 3%), gastritis (1% to 3%), peptic ulcer (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemoglobin/hematocrit decreased (transient; 1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disturbances (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, anaphylactoid reactions, CHF, dysuria, epistaxis, erythema multiforme, exfoliative dermatitis, fever, fluid retention, GI bleeding, GI perforation, glossitis, granulocytopenia, hematuria, hemolytic anemia, hepatic failure, hepatic necrosis, hepatitis, hepatitis (fulminant), interstitial nephritis, jaundice, liver function tests (abnormal), lymphadenopathy, macular changes, nephrotic syndrome, optic neuropathy, proteinuria, purpura, renal failure, retinal changes, serum sickness, stomatitis, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F229048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tolmetin, aspirin, other NSAIDs, or any component of the formulation; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F229032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) from NSAIDs even at low doses. Avoid chronic use (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent); nonselective oral NSAID use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F229037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F229059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Tolmetin peak serum concentrations may be decreased if taken with food or milk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, fenugreek, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F229038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5735563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies tolmetin as pregnancy category C. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F229072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9642167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tolmetin is found in breast milk and breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F229051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with antacids to minimize stomach upset. Administration with food or milk decreases bioavailability by 16%. Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F229050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Tolmetin Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $118.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tolmetin Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $75.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $375.01",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F229040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor CBC, liver enzymes, occult blood loss; monitor urine output and BUN/ serum creatinine in patients receiving diuretics and ACE inhibitors, monitor blood pressure in patients receiving antihypertensives",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4324206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Artrocaptin (ES);",
"     </li>",
"     <li>",
"      Tolectin (BF, BH, BJ, CI, CY, ET, GH, GM, GN, JO, KE, LB, LR, MA, ML, MR, MU, MW, NE, NG, OM, PL, SC, SD, SL, SN, SY, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Tolectin-gel (PL);",
"     </li>",
"     <li>",
"      Tolect&iacute;n (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F229031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees) include inhibiting chemotaxis, altering lymphocyte activity, inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F229047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Analgesic: 1-2 hours; Anti-inflammatory: Days to weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed, rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Reduced 16% with food or milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: Rapid: 1-2 hours; Slow: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as inactive metabolites or conjugates) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berde C, Ablin A, Glazer J, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):818-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/2216644/pubmed\" id=\"2216644\" target=\"_blank\">",
"        2216644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brooks PM and Day RO, &ldquo;Nonsteroidal Anti-inflammatory Drugs - Differences and Similarities,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(24):1716-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/2034249/pubmed\" id=\"2034249\" target=\"_blank\">",
"        2034249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clinch D, Banerjee AK, and Ostick G, &ldquo;Absence of Abdominal Pain in Elderly Patients With Peptic Ulcer,&rdquo;",
"      <i>",
"       Age Ageing",
"      </i>",
"      , 1984, 13(2):120-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/6731166/pubmed\" id=\"6731166\" target=\"_blank\">",
"        6731166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clive DM and Stoff JS, &ldquo;Renal Syndromes Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1984, 310(9):563-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/6363936/pubmed\" id=\"6363936\" target=\"_blank\">",
"        6363936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Court H and Volans GN, &ldquo;Poisoning After Overdose With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Adverse Drug React Acute Poisoning Rev",
"      </i>",
"      , 1984, 3(1):1-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/6541425/pubmed\" id=\"6541425\" target=\"_blank\">",
"        6541425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2000, 42(1085):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/10951654/pubmed\" id=\"10951654\" target=\"_blank\">",
"        10951654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graham DY, &ldquo;Prevention of Gastroduodenal Injury Induced by Chronic Nonsteroidal Anti-inflammatory Drug Therapy,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):675-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/2642452/pubmed\" id=\"2642452\" target=\"_blank\">",
"        2642452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurwitz JH, Avorn J, Ross-Degnan D, et al, &ldquo;Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(4):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/2366280/pubmed\" id=\"2366280\" target=\"_blank\">",
"        2366280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al, &ldquo;Omeprazole Compared With Misoprostol for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/9494149/pubmed\" id=\"9494149\" target=\"_blank\">",
"        9494149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(10):1108-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/9605782/pubmed\" id=\"9605782\" target=\"_blank\">",
"        9605782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollingworth P, &ldquo;The Use of Nonsteroidal Anti-inflammatory Drugs in Paediatric Rheumatic Diseases,&rdquo;",
"      <i>",
"       Br J Rheumatol",
"      </i>",
"      , 1993, 32(1):73-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/8422565/pubmed\" id=\"8422565\" target=\"_blank\">",
"        8422565",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppmann RA, Peden JG, and Ober SK, &ldquo;Central Nervous System Side Effects of Nonsteroidal Anti-inflammatory Drugs. Aseptic Meningitis, Psychosis, and Cognitive Dysfunction,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1991, 151(7):1309-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/2064481/pubmed\" id=\"2064481\" target=\"_blank\">",
"        2064481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Fraser GL, Coursin DB, et al, &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):119-41. Available at file://www.sccm.org/pdf/sedatives.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/11902253/pubmed\" id=\"11902253\" target=\"_blank\">",
"        11902253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joseph R, Dickerson S, Willis R, et al, &ldquo;Interference by Nonsteroidal Anti-inflammatory Drugs in EMIT and TDx Assays for Drugs of Abuse,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1995, 19(1):13-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/7723297/pubmed\" id=\"7723297\" target=\"_blank\">",
"        7723297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knodel LC, &ldquo;Preventing NSAID-Induced Ulcers: The Role of Misoprostol,&rdquo;",
"      <i>",
"       Consult Pharm",
"      </i>",
"      , 1989, 4:37-41.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000, 13(11):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/11078175/pubmed\" id=\"11078175\" target=\"_blank\">",
"        11078175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(6):777-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/10737277/pubmed\" id=\"10737277\" target=\"_blank\">",
"        10737277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pounder R, &ldquo;Silent Peptic Ulceration: Deadly Silence or Golden Silence?&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):626-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/2642448/pubmed\" id=\"2642448\" target=\"_blank\">",
"        2642448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rose CD and Doughty RA, &ldquo;Pharmacological Management of Juvenile Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1992, 43(6):849-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/1379157/pubmed\" id=\"1379157\" target=\"_blank\">",
"        1379157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smolinske SC, Hall AH, Vandenberg SA, et al, &ldquo;Toxic Effects of Nonsteroid Anti-inflammatory Drugs in Overdose. An Overview of Recent Evidence on Clinical Effects and Dose-Response Relationships,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1990, 5(4):252-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/2198051/pubmed\" id=\"2198051\" target=\"_blank\">",
"        2198051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vale JA and Meredith TJ, &ldquo;Acute Poisoning Due to Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Med Toxicol",
"      </i>",
"      , 1986, 1(1):12-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/3537613/pubmed\" id=\"3537613\" target=\"_blank\">",
"        3537613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(1):44-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/2199127/pubmed\" id=\"2199127\" target=\"_blank\">",
"        2199127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yeomans ND, Tulassay Z, Juhasz L, et al, &ldquo;A Comparison of Omeprazole With Ranitidine for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):719-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/46/33512/abstract-text/9494148/pubmed\" id=\"9494148\" target=\"_blank\">",
"        9494148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10004 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-211.167.112.14-B56043E255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33512=[""].join("\n");
var outline_f32_46_33512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709985\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229094\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229068\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229083\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229069\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229042\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229028\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874842\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229045\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14187959\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229092\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229048\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229032\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300154\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229037\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229059\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229038\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5735563\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229072\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9642167\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229051\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229050\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229040\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4324206\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229031\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229047\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10004\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10004|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/38/16997?source=related_link\">",
"      Tolmetin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/3/13367?source=related_link\">",
"      Tolmetin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_46_33513="Mitomycin-C pulmonary toxicity";
var content_f32_46_33513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mitomycin-C pulmonary toxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/46/33513/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/46/33513/contributors\">",
"     Edward D Chan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/46/33513/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/46/33513/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/46/33513/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/46/33513/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/46/33513/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/46/33513/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/46/33513/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/46/33513/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     Mitomycin",
"    </a>",
"    -C (MMC), an antineoplastic antibiotic derived from Streptomyces caespitosus, is a cell cycle-specific alkylating agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/1\">",
"     1",
"    </a>",
"    ]. Although it is active against a wide variety of tumors, newer agents have largely replaced MMC except in anal cancer; outside of the United States, MMC is infrequently used for treatment of advanced non-small cell lung cancer (NSCLC), and breast cancer. As with many other chemotherapeutic agents, most of the adverse effects of MMC are dose-related, including myelosuppression (which is typically delayed in onset), nausea, vomiting, diarrhea, stomatitis, dementia, and alopecia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Pulmonary toxicity associated with MMC is unpredictable, but more likely to occur at higher doses.",
"   </p>",
"   <p>",
"    The pulmonary complications associated with MMC therapy will be reviewed here. A general discussion of the clinical presentation, pathogenesis, diagnosis, differential diagnosis, and management of antineoplastic agent-induced pulmonary toxicity is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H767182\">",
"    <span class=\"h1\">",
"     INCIDENCE AND SCOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary toxicity associated with MMC is unpredictable, but more likely to occur at higher doses (in most literature reviews, &gt;20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The frequency of clinically significant adverse pulmonary reactions from MMC is estimated to be between 2 and 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/4,7-9\">",
"     4,7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The various pulmonary disorders that have been described with MMC include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute bronchospasm",
"     </li>",
"     <li>",
"      Acute lung injury (diffuse alveolar damage)",
"     </li>",
"     <li>",
"      Interstitial pneumonitis",
"     </li>",
"     <li>",
"      Thrombotic microangiopathy with acute lung injury",
"     </li>",
"     <li>",
"      Pulmonary hypertension and pulmonary veno-occlusive disease",
"     </li>",
"     <li>",
"      Pleural disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with other antineoplastic drugs, the concomitant administration of other drugs, prior thoracic irradiation, or supplemental oxygen creates difficulties in determining the exact etiology of pulmonary injury in a given patient. Most of the reports of MMC pulmonary toxicity are in patients treated with combined MMC plus a vinca alkaloid.",
"   </p>",
"   <p>",
"    Although most cases have been described after intravenous (IV) use of MMC, at least one case report documents rapid onset of pulmonary toxicity (acute interstitial pneumonitis) after two months of weekly intravesical MMC for bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/10\">",
"     10",
"    </a>",
"    ]. The patient died of progressive respiratory failure despite empiric antibiotics and IV pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    . In addition, pulmonary toxicity (interstitial pneumonitis, pleural effusion) has also been reported following the use of intraperitoneal MMC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Pleural disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BRONCHOSPASM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute bronchospasm associated with MMC occurs with an estimated frequency of 4 to 6 percent, and is of unknown pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/13\">",
"     13",
"    </a>",
"    ]. Most cases are reported with concomitant use of vinca alkaloids (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31123?source=see_link\">",
"     vindesine",
"    </a>",
"    ) and MMC, and the two drugs appear to act synergistically to produce this adverse effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. The important role played by vinca alkaloids can be illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In several cases, bronchospasm was temporally related to administration of the vinca alkaloid, occurring within hours of injection, but several days to weeks after MMC administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/13,16\">",
"       13,16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acute bronchoconstriction has been associated with administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      without MMC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In one case, rechallenge with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31123?source=see_link\">",
"       vindesine",
"      </a>",
"      alone in a patient originally treated with combined MMC plus vindesine resulted in a recrudescence of dyspnea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bronchoconstriction typically resolves within 12 to 24 hours, either spontaneously or following the administration of bronchodilators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/13\">",
"     13",
"    </a>",
"    ]. In some cases, bronchoconstriction is accompanied by the appearance of parenchymal reticular opacities on plain chest radiographs or noncardiogenic pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/13\">",
"     13",
"    </a>",
"    ]. The radiographic opacities noted at the time of acute bronchoconstriction may clear or persist; if they persist, patients may develop chronic interstitial lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H420682\">",
"     'Interstitial pneumonitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE LUNG INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relatively rapid onset of acute lung injury has been described in some patients who have had only a brief exposure to MMC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/14,18-22\">",
"     14,18-22",
"    </a>",
"    ]. As with bronchospasm, in many of these cases, the acute lung injury has occurred in patients treated with combined MMC plus a vinca alkaloid, and symptoms were temporally related to the administration of the vinca alkaloid. However, because there are no reports in which treatment with vinca alkaloids alone produced pulmonary parenchymal toxicity, it has been hypothesized that prior treatment with MMC predisposed patients to this complication.",
"   </p>",
"   <p>",
"    A case series of 387 patients reported a 6 percent incidence of acute dyspnea with radiographic abnormalities following combination chemotherapy using MMC and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31123?source=see_link\">",
"     vindesine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    for advanced non-small cell lung cancer (NSCLC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/20\">",
"     20",
"    </a>",
"    ]. The median number of MMC doses was three.",
"   </p>",
"   <p>",
"    High concentrations of inspired oxygen may contribute to the risk of MMC acute lung injury (as it appears to do with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ). As an example, a study of 20 patients who received MMC and thoracic irradiation for esophageal cancer found that no patient who received a fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ) &lt;0.3 developed pulmonary disease, whereas an FiO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;0.5 appeared to be a risk factor for lung injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/23\">",
"     23",
"    </a>",
"    ]. In a patient who had received chemotherapy with MMC,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , acute lung injury, which was presumed secondary to MMC, developed immediately following operative resection of a NSCLC, and was presumed secondary to the combination of MMC and high inspired concentrations of oxygen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28407?source=see_link\">",
"     \"Oxygen toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link&amp;anchor=H9#H9\">",
"     \"Bleomycin-induced lung injury\", section on 'High fraction of inspired oxygen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41150946\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MMC-associated acute lung injury typically present with the rapid onset of dyspnea without other respiratory symptoms. Among patients treated with combined MMC plus a vinca alkaloid, symptoms typically occur on a day when the vinca alkaloid is administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/20\">",
"     20",
"    </a>",
"    ]. Physical examination may reveal wheezes or crackles.",
"   </p>",
"   <p>",
"    In the majority of cases (87 percent in one series of MMC-associated acute lung injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/20\">",
"     20",
"    </a>",
"    ]), chest radiographs show new focal or diffuse reticular or ground glass opacities. Arterial blood gases demonstrate hypoxemia with an elevated alveolar-arterial oxygen gradient, and pulmonary function tests reveal severely impaired diffusing capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H767316\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the data are limited, acute lung injury due to MMC is characterized by the histopathologic finding of diffuse alveolar damage (DAD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/10,18,24\">",
"     10,18,24",
"    </a>",
"    ]. Autopsies obtained from two patients who died of progressive respiratory failure within three weeks of receiving their second dose of MMC showed DAD progressing to interstitial pulmonary fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef57964 \" href=\"mobipreview.htm?30/4/30793\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65804 \" href=\"mobipreview.htm?40/11/41145\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/18\">",
"     18",
"    </a>",
"    ]. DAD, the underlying lesion of the acute respiratory distress syndrome (ARDS), is characterized by edema of the alveolar septae and by formation of hyaline membranes that line the alveolar spaces (",
"    <a class=\"graphic graphic_picture graphicRef53020 \" href=\"mobipreview.htm?15/17/15638\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81916 \" href=\"mobipreview.htm?13/49/14107\">",
"     table 1",
"    </a>",
"    ). No eosinophilic or granulomatous lesions to suggest a hypersensitivity reaction were seen in the lung biopsies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link&amp;anchor=H3#H3\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41150818\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute lung injury due to MMC is based upon a combination of clinical features (eg, dyspnea without fever, productive cough, or peripheral edema), the presence of a compatible radiographic pattern, and the exclusion of infection or pulmonary involvement from the underlying malignancy. When the patient is able to tolerate the procedure, bronchoscopy with bronchoalveolar lavage is commonly performed to exclude infection and malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link&amp;anchor=H6#H6\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link&amp;anchor=H11#H11\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41150825\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of MMC-associated acute lung injury has not been well studied. As initial steps, MMC and vinca alkaloid therapy is discontinued if the patient is receiving ongoing therapy, and empiric antibiotics are usually initiated. Supportive care is provided with measures such as supplemental oxygen to maintain a pulse oxygen concentration &gt;90 percent with the lowest fraction of inspired oxygen possible, intubation and mechanical ventilation if respiratory failure develops, careful hemodynamic management, prophylaxis against deep vein thrombosis (DVT), and stress ulcer prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of systemic glucocorticoid therapy is unclear, as a portion of the patients improve spontaneously following drug discontinuation and outcomes data regarding glucocorticoids are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/18\">",
"     18",
"    </a>",
"    ]. On the other hand, a number of series have reported dramatic improvement after the administration of glucocorticoids, although improvement after such treatment is not universal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/10,18,20,24\">",
"     10,18,20,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with more severe initial symptoms or progressive respiratory failure, we suggest initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    250 mg intravenously every six hours for two to three days, followed by oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for four to six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. After the initial high-dose phase, prednisone is subsequently slowly tapered to zero over four to six weeks, as tolerated. For patients with less severe disease, oral prednisone may be used for initial therapy.",
"   </p>",
"   <p>",
"    Rechallenge with MMC is not recommended and vinca alkaloids should be administered with caution in patients with prior MMC lung toxicity. In one report, both patients who recovered from acute lung injury and were rechallenged with MMC experienced recurrent acute pulmonary toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/20\">",
"     20",
"    </a>",
"    ]. In a separate report, a patient who recovered from an episode of acute respiratory failure after MMC-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    combination developed recurrent respiratory and failure after rechallenge with vinblastine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/6\">",
"     6",
"    </a>",
"    ]. The predominant findings on postmortem examination were alveolar and septal edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41151061\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the severity of the lung injury, patients may improve spontaneously over 24 to 48 hours, progress to acute respiratory distress syndrome (ARDS), or develop progressive interstitial fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/7,20\">",
"     7,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H420682\">",
"     'Interstitial pneumonitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A few patients with acute lung injury have a fulminant and occasionally fatal course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/5,6,20,26\">",
"     5,6,20,26",
"    </a>",
"    ]. In a series of 25 patients with acute lung injury while receiving MMC, four required mechanical ventilation for 1 to 10 days and one died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/20\">",
"     20",
"    </a>",
"    ]. Other reports have detailed fatalities in patients with acute lung injury occurring within hours of MMC administration (cumulative doses of 30 to 133",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    or after administration of a vinca alkaloid in a patient who had previously received MMC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420682\">",
"    <span class=\"h1\">",
"     INTERSTITIAL PNEUMONITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial pneumonitis has been described in patients treated with MMC, some of whom had experienced acute toxicity with bronchospasm or acute lung injury attributed to MMC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/11,27\">",
"     11,27",
"    </a>",
"    ]. In these cases, MMC has often been used with other chemotherapeutic drugs, making it difficult to determine the exact contribution of the individual agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/7,27-29\">",
"     7,27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of interstitial pneumonitis due to MMC is not known, but it appears to be less than 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/7,30-33\">",
"     7,30-33",
"    </a>",
"    ]. In a prospective study to determine the incidence of interstitial pneumonitis, in which serial chest radiographs, computed tomography (CT) scans, and pulmonary function tests were monitored in 37 patients receiving MMC, none developed clinical signs of pulmonary toxicity, and only one patient developed CT evidence of asymptomatic interstitial changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to the interstitial fibrosis caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , MMC-associated interstitial fibrosis appears to be dose-related. In one report of 14 patients who developed MMC lung toxicity, the median cumulative dose was 29",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (range 20 to 39",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    at the time lung toxicity became apparent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MMC is also associated with an increased risk of radiation pneumonitis in patients who receive thoracic irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/34\">",
"     34",
"    </a>",
"    ] and may also increase the risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    -induced pneumonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/49/29466?source=see_link&amp;anchor=H5#H5\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Erlotinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H767606\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and signs of interstitial pneumonitis associated with MMC may develop in patients who are recovering from MMC-associated acute lung injury or may appear in patients without prior lung toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/20,27\">",
"     20,27",
"    </a>",
"    ]. The patients with new onset lung disease typically have the insidious onset of dyspnea and nonproductive cough and on physical examination have tachypnea and crackles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/27,36\">",
"     27,36",
"    </a>",
"    ]. In one series of six patients who developed interstitial pneumonitis while receiving a MMC-containing chemotherapy regimen for lung cancer, symptoms developed 80 to 118 days after the start of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chest radiograph may show bilateral diffuse ground glass or reticular opacities with occasional fine nodularity. Similar findings are noted on high resolution CT (HRCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary function testing typically reveals a restrictive pattern and a decrease in diffusing capacity (DLCO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/7,8,27,38\">",
"     7,8,27,38",
"    </a>",
"    ]. However, pulmonary function testing is not a useful tool for the early detection of this syndrome. In a prospective study, a decline in the DLCO occurred in approximately one-fourth of patients receiving three cycles of MMC-containing chemotherapy, but was not associated with a worse prognosis and did not predict the development of overt pulmonary toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of pulmonary function testing in adults\", section on 'Restrictive lung disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H767613\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who have had a lung biopsy, histopathological changes resemble those of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced pulmonary injury and fibrosis, with intraalveolar mononuclear cell inflammation, type 2 alveolar cell hyperplasia, and a thickened interstitium with collagen deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/2,27\">",
"     2,27",
"    </a>",
"    ]. In addition, nuclear atypia of both type I and type II cells has been described, a finding that is also seen in pneumonitis related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . One report of MMC-associated pulmonary toxicity noted alveolar septal fibrosis and an organizing pneumonia (previously known as bronchiolitis obliterans organizing pneumonia) with intraalveolar masses of fibrous tissue (Masson bodies) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link&amp;anchor=H20#H20\">",
"     \"Bleomycin-induced lung injury\", section on 'Lung biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37415?source=see_link&amp;anchor=H2#H2\">",
"     \"Busulfan-induced pulmonary injury\", section on 'Pathogenesis and pathology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21990?source=see_link&amp;anchor=H5#H5\">",
"     \"Cyclophosphamide pulmonary toxicity\", section on 'Pathology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=see_link&amp;anchor=H2#H2\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H767620\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of interstitial pneumonitis due to MMC is usually based on the history of MMC therapy, the presence of chronic or gradually developing dyspnea and cough, a compatible radiographic appearance, and exclusion of other possible diagnoses. Bronchoscopy with bronchoalveolar lavage is commonly performed to exclude infection and malignancy. Lung biopsy is generally not necessary unless the diagnosis is unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link&amp;anchor=H11#H11\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H767673\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of MMC-associated interstitial pneumonitis has not been well studied. MMC therapy has usually been completed by the time pulmonary toxicity develops, but should be discontinued if therapy is ongoing.",
"   </p>",
"   <p>",
"    In a number of cases, treatment with glucocorticoids resulted in rapid improvement of dyspnea and radiographic opacities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/2,7,25,27\">",
"     2,7,25,27",
"    </a>",
"    ]. For patients with moderate-to-severe or progressive respiratory impairment, we suggest administration of oral glucocorticoids. A typical glucocorticoid regimen consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    60 mg per day for at least two to three weeks, followed by a gradual taper over a four week period, and an increase in dose with any clinical deterioration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/27\">",
"     27",
"    </a>",
"    ]. Approximately 40 percent of patients experience progressive pulmonary insufficiency despite an initial response to glucocorticoids and despite increases in the glucocorticoid dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/7\">",
"     7",
"    </a>",
"    ]. Abrupt cessation or early withdrawal of glucocorticoids can result in a relapse of dyspnea and pulmonary opacities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     THROMBOTIC MICROANGIOPATHY AND ACUTE RESPIRATORY FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy-related thrombotic microangiopathy is a distinct syndrome associated with MMC that may resemble thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS). In contrast to other causes of chemotherapy-related thrombotic microangiopathy, approximately 50 percent of cases of MMC-associated thrombotic microangiopathy are associated with acute respiratory failure due to acute lung injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of thrombotic microangiopathy is directly related to the total dose of MMC; the incidence is higher after a single dose greater than 60 mg, a cumulative dose of &ge;50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (11",
"    <sup>",
"    </sup>",
"    percent versus &lt;2 percent at lower doses), or a total duration of therapy of &gt;5 to 11 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. Patients who receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    or blood transfusions before starting therapy with MMC appear to have an increased risk for this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In addition, concomitant administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    may also increase the risk of MMC-associated thrombotic microangiopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14403704\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise mechanism of the acute lung injury in MMC-related thrombotic microangiopathy is not known. The pathogenesis of chemotherapy-related",
"    <span class=\"nowrap\">",
"     TTP/HUS,",
"    </span>",
"    which is thought related to endothelial damage, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link\">",
"     \"Atypical hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14403697\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic components of MMC-associated thrombotic microangiopathy are the same as those of TTP-HUS (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Clinical and laboratory manifestations'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Microangiopathic hemolytic anemia (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Renal insufficiency due to thrombotic occlusion of glomerular capillaries (",
"      <a class=\"graphic graphic_picture graphicRef63511 graphicRef54840 graphicRef69687 graphicRef78330 \" href=\"mobipreview.htm?42/49/43802\">",
"       picture 5A-D",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef75317 \" href=\"mobipreview.htm?8/3/8255\">",
"       diagnostic image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neurologic symptoms (eg, seizure, transient blindness)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients may have some or all of these components.",
"   </p>",
"   <p>",
"    The clinical presentation usually includes hypertension, anemia (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"     picture 4",
"    </a>",
"    ), progressive renal insufficiency, and sometimes an active urine sediment. Fever is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, approximately one-half of patients are dyspneic, and the main pulmonary finding is pulmonary edema, which is typically noncardiogenic or of undetermined etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients present after receiving IV MMC for 6 to 12 months, although a single case has been reported after hepatic artery chemoembolization using MMC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9712126\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited. In a single case report of a patient with MMC-associated thrombotic microangiopathy, autopsy examination of the lungs revealed unique angiomatoid changes of the septal capillaries, with redundant tortuous dilatations; the latter were not due to pulmonary veno-occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/50\">",
"     50",
"    </a>",
"    ]. The lining endothelial cells had enlarged irregular hyperchromatic nuclei. In a separate case report, open lung biopsy disclosed diffuse lung parenchymal opacities, pulmonary hypertension, and intracapillary thrombi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14403690\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MMC-associated thrombotic microangiopathy is based upon a history of MMC treatment and the presence of microangiopathic hemolytic anemia with thrombocytopenia, with or without renal insufficiency. The differential diagnosis of hypoxemia and diffuse pulmonary opacities in this setting includes cardiogenic pulmonary edema, diffuse alveolar hemorrhage, pneumonia, sepsis, and aspiration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10505?source=see_link&amp;anchor=H11#H11\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and differential diagnosis of TTP-HUS and the role of testing for ADAMTS13 are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Diagnostic criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14403683\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for MMC-associated thrombotic microangiopathy is not known. Prompt discontinuation of MMC is essential along with management of fluid balance and blood pressure. When it occurs in its idiopathic form, TTP-HUS is treated promptly with plasma exchange, and most patients also receive systemic glucocorticoids. However, several reports have noted that patients with chemotherapeutic agent-induced thrombotic microangiopathy have a poor response to plasma exchange and glucocorticoids. The treatment of TTP-HUS and chemotherapy-associated thrombotic microangiopathy are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Exceptions to the use of plasma exchange'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In anecdotal reports, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was successful in two patients with MMC-induced thrombotic microangiopathy who were refractory to plasma exchange and glucocorticoids, but neither patient had pulmonary symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The role of rituximab in this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link&amp;anchor=H33#H33\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420929\">",
"    <span class=\"h1\">",
"     PULMONARY HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension associated with MMC has been reported in isolated case reports, some of which were in the context of a thrombotic microangiopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Thrombotic microangiopathy and acute respiratory failure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Pulmonary veno-occlusive disease has also been reported in two patients with non-small cell lung cancer treated with an MMC containing perioperative chemotherapy regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29385?source=see_link\">",
"     \"Pulmonary veno-occlusive disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PLEURAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural disease has been reported in several patients receiving MMC therapy, often in the setting of noncardiogenic pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/2,8,57\">",
"     2,8,57",
"    </a>",
"    ]. It is characterized by exudative effusions, fibrinous exudates, and fibrosis over the pleural surfaces with occasional aggregates of lymphocytes and eosinophils. Pleural effusion is often associated with parenchymal lung disease. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Acute lung injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Pleural effusions are reported in 64 percent of patients undergoing heated intraperitoneal chemotherapy with MMC following radical cytoreductive surgery for bulky intraperitoneal disseminated malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/12\">",
"     12",
"    </a>",
"    ]. No correlation was found between the prevalence of pleural effusion and the dose of MMC, and most cases did not require treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23608122\">",
"    <span class=\"h1\">",
"     LOCAL EFFECTS OF LARYNGOTRACHEAL MMC",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a literature review including 538 patients, topical application of MMC to wounds in the circular structures of the upper aerodigestive tract to prevent scar formation was generally safe when followed by consecutive irrigations with saline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/58\">",
"     58",
"    </a>",
"    ]. However, local complications developed in 19 patients over a mean follow-up of 14.5 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/58\">",
"     58",
"    </a>",
"    ]. Complications included accumulation of fibrinous debris at the site, synechiae, glottic web formation, stenosis, and partial airway obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. A single patient developed squamous cell carcinoma after multiple procedures for vocal fold keratosis, which itself is a risk factor for squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Application of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    generally follows laser dilation, so it is difficult to know the contribution of each of the therapies to the subsequent complication. It is also unclear whether the dose or the duration of application of MMC are factors in the development of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/58\">",
"     58",
"    </a>",
"    ]. Saline irrigation after mitomycin application may reduce the number of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421115\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several interventions are thought to reduce the incidence of pulmonary toxicity in patients treated with MMC, although supportive data are limited. Pretreatment with glucocorticoids may lower but not eliminate the incidence of lung toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/7,61,62\">",
"     7,61,62",
"    </a>",
"    ]. However, there is concern that glucocorticoids might interfere with antitumor efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other potentially beneficial interventions include limiting the cumulative MMC dose to no more than 30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of body surface area, extending MMC dosing intervals to greater than four weeks, avoiding concomitant administration of a vinca alkaloid, and limiting unnecessarily high FiO",
"    <sub>",
"     2",
"    </sub>",
"    concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using lower doses of MMC appears to result in a lower incidence of pulmonary toxicity, although in some reports, the avoidance of concomitant administration of a vinca alkaloid may also have contributed. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among 186 patients who received MMC (6 to 8",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every 21 days for a maximum of 4 cycles) for advanced NSCLC, in which glucocorticoid pretreatment was not given, there were no instances of pneumonitis or microangiopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/63\">",
"       63",
"      </a>",
"      ]. However, one patient developed pulmonary edema.",
"     </li>",
"     <li>",
"      Similarly, in another series, 216 patients with NSCLC who received an MMC-containing regimen (6",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      intravenously every three weeks for four cycles), no instances of pulmonary toxicity were reported. Glucocorticoid pretreatment was not used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary toxicity is generally not reported in patients receiving MMC-containing chemoradiotherapy for anal cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/65\">",
"       65",
"      </a>",
"      ]. In this setting, the dose of MMC is limited to 10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on days 1 and 29 of radiation therapy, and the dose is reduced or eliminated if the leukocyte count is low on day 29. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38762?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical features, staging, and treatment of anal cancer\", section on 'Role of mitomycin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A safe fraction of inspired oxygen (FiO",
"      <sub>",
"       2",
"      </sub>",
"      ) to administer to patients who have received MMC has not been defined, but one study of 20 patients who received MMC and thoracic irradiation for esophageal cancer found that no patients who received an FiO",
"      <sub>",
"       2",
"      </sub>",
"      &lt;0.3 developed pulmonary disease, whereas an FiO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;0.5 appeared to be a risk factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/46/33513/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7157544\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       Mitomycin",
"      </a>",
"      -C (MMC) is an antineoplastic antibiotic that is used in chemotherapy regimens for anal cancer, and uncommonly for non-small cell lung cancer (NSCLC) and breast cancer. Pulmonary toxicity occurs in 3 to 12 percent of patients treated with MMC. Factors such as the dose of MMC, concomitant administration of other drugs (especially vinca alkaloids), supplemental oxygen, and prior thoracic irradiation appear to contribute to the development of pulmonary toxicity. Several types of pulmonary toxicity have been described, including acute bronchoconstriction, acute lung injury, interstitial pneumonitis, thrombotic microangiopathy, pulmonary hypertension, pulmonary veno-occlusive disease, and exudative pleural effusions. (See",
"      <a class=\"local\" href=\"#H767182\">",
"       'Incidence and scope'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Acute bronchospasm",
"      </strong>",
"      appears to occur primarily in patients who have received a vinca alkaloid in addition to MMC. Bronchospasm generally resolves spontaneously or with bronchodilator within 24 hours. For symptomatic patients with acute bronchoconstriction associated with MMC-vinca alkaloid administration, inhaled short-acting bronchodilator is the treatment of choice.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"       Albuterol",
"      </a>",
"      can be given by nebulizer or metered dose inhaler (",
"      <a class=\"graphic graphic_table graphicRef68683 \" href=\"mobipreview.htm?4/34/4654\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Bronchospasm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Acute lung injury",
"      </strong>",
"      due to MMC is characterized by the development of the clinical picture of noncardiogenic pulmonary edema, which is associated with the histopathologic finding of diffuse alveolar damage (DAD).",
"      <br/>",
"      <br/>",
"      For patients with acute lung injury associated with MMC, diffuse involvement of the lungs radiographically, and progressive respiratory insufficiency, we suggest initiation of systemic glucocorticoid therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with respiratory failure, the usual dose is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      250 mg intravenously every six hours for two to three days, followed by oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for four to six weeks. For patients with less severe disease, the prednisone dose is used for initial therapy. After this initial high dose phase, prednisone is tapered over four to six weeks and discontinued. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute lung injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Chronic interstitial pneumonitis",
"      </strong>",
"      due to MMC may follow an episode of acute bronchospasm or acute lung injury, or may develop insidiously without prior respiratory complaints.",
"      <br/>",
"      <br/>",
"      The diagnosis is usually based on the history of MMC therapy, the gradual onset of dyspnea and cough, diffuse parenchymal lung disease on imaging, and exclusion of other possible diagnoses.",
"      <br/>",
"      <br/>",
"      For patients with moderate-to-severe or progressive respiratory impairment, we suggest administration of oral glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The usual dose is the equivalent of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      60 mg per day for at least two to three weeks, followed by a gradual taper over a four week period. Some patients require more long-term prednisone therapy. (See",
"      <a class=\"local\" href=\"#H420682\">",
"       'Interstitial pneumonitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Thrombotic microangiopathy",
"      </strong>",
"      is a severe and frequently fatal side effect of MMC. The clinical presentation may resemble thrombotic thrombocytopenic purpura (TTP) or hemolytic-uremic-like syndrome (HUS), and is associated with acute respiratory failure in about 50 percent of patients. The diagnosis of MMC-associated thrombotic angiopathy is based on the history of MMC treatment, the presence of microangiopathic hemolytic anemia, and thrombocytopenia with or without renal insufficiency. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Thrombotic microangiopathy and acute respiratory failure'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with MMC-associated thrombotic angiopathy, we recommend prompt discontinuation of MMC (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Careful management of fluid balance and blood pressure is essential. The treatment of TTP-HUS and chemotherapy-associated thrombotic angiopathy are described separately. (See",
"      <a class=\"local\" href=\"#H14403683\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Exceptions to the use of plasma exchange'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link&amp;anchor=H33#H33\">",
"       \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Rituximab'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Interventions to decrease the likelihood of MMC-associated thrombotic angiopathy include limiting the cumulative MMC dose to &lt;30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      of body surface area, extending the MMC dosing interval to greater than four weeks, and avoiding unnecessary high inspired oxygen concentrations (FIO",
"      <sub>",
"       2",
"      </sub>",
"      ). (See",
"      <a class=\"local\" href=\"#H421115\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For all types of pulmonary toxicity due to MMC, we recommend AGAINST rechallenge with MMC (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In addition, for patients with acute lung injury while receiving the combination of MMC and a vinca alkaloid, we avoid rechallenge with a vinca alkaloid. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute lung injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/1\">",
"      Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1990; 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/2\">",
"      Orwoll ES, Kiessling PJ, Patterson JR. Interstitial pneumonia from mitomycin. Ann Intern Med 1978; 89:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/3\">",
"      Folman RS. Experience with mitomycin in the treatment of non-small cell lung cancer. Oncology 1993; 50 Suppl 1:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/4\">",
"      Verweij J, van Zanten T, Souren T, et al. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer 1987; 60:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/5\">",
"      Ospovat I, Siegelmann-Danieli N, Grenader T, et al. Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patients. Tumori 2009; 95:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/6\">",
"      Rao SX, Ramaswamy G, Levin M, McCravey JW. Fatal acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma. Arch Intern Med 1985; 145:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/7\">",
"      Okuno SH, Frytak S. Mitomycin lung toxicity. Acute and chronic phases. Am J Clin Oncol 1997; 20:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/8\">",
"      Castro M, Veeder MH, Mailliard JA, et al. A prospective study of pulmonary function in patients receiving mitomycin. Chest 1996; 109:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/9\">",
"      Linette DC, McGee KH, McFarland JA. Mitomycin-induced pulmonary toxicity: case report and review of the literature. Ann Pharmacother 1992; 26:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/10\">",
"      Wada H, Nakano Y, Yamada H, et al. Intravesical mitomycin-C-induced interstitial pneumonia. Respiration 2010; 80:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/11\">",
"      Gonz&aacute;lez-Moreno S, Lambert LA, Mansfield PF. Interstitial pneumonitis: an exceptional toxicity of hyperthermic intraperitoneal mitomycin C. Eur J Surg Oncol 2008; 34:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/12\">",
"      Chen MY, Chiles C, Loggie BW, et al. Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. J Surg Oncol 1997; 66:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/13\">",
"      Luedke D, McLaughlin TT, Daughaday C, et al. Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression. Cancer 1985; 55:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/14\">",
"      Kris MG, Pablo D, Gralla RJ, et al. Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy. Cancer Treat Rep 1984; 68:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/15\">",
"      Rouzaud P, Estivals M, Pujazon MC, et al. [Respiratory complications of the vinorelbine-mitomycin combination]. Rev Mal Respir 1999; 16:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/16\">",
"      Thomas P, Pradal M, Le Caer H, et al. [Acute bronchospasm due to periwinkle alkaloid and mitomycin association]. Rev Mal Respir 1993; 10:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/17\">",
"      Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994; 21:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/18\">",
"      Buzdar AU, Legha SS, Luna MA, et al. Pulmonary toxicity of mitomycin. Cancer 1980; 45:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/19\">",
"      Konits PH, Aisner J, Sutherland JC, Wiernik PH. Possible pulmonary toxicity secondary to vinblastine. Cancer 1982; 50:2771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/20\">",
"      Rivera MP, Kris MG, Gralla RJ, White DA. Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy. Am J Clin Oncol 1995; 18:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/21\">",
"      Andrews AT, Bowman HS, Patel SB, Anderson WM. Mitomycin and interstitial pneumonitis. Ann Intern Med 1979; 90:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/22\">",
"      Urban T, Bedin A, Baud M, et al. Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non-small cell lung cancer. Lung Cancer 1996; 14:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/23\">",
"      Klein DS, Wilds PR. Pulmonary toxicity of antineoplastic agents: anaesthetic and postoperative implications. Can Anaesth Soc J 1983; 30:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/24\">",
"      Thompson CC, Bailey MK, Conroy JM, Bromley HR. Postoperative pulmonary toxicity associated with mitomycin-C therapy. South Med J 1992; 85:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/25\">",
"      M&uuml;ller NL, White DA, Jiang H, Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 2004; 91 Suppl 2:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/26\">",
"      Ballen KK, Weiss ST. Fatal acute respiratory failure following vinblastine and mitomycin administration for breast cancer. Am J Med Sci 1988; 295:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/27\">",
"      Chang AY, Kuebler JP, Pandya KJ, et al. Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoids. Cancer 1986; 57:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/28\">",
"      Chambers SK, Flynn SD, Del Prete SA, et al. Bleomycin, vincristine, mitomycin C, and cis-platinum in gynecologic squamous cell carcinomas: a high incidence of pulmonary toxicity. Gynecol Oncol 1989; 32:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/29\">",
"      Vrdoljak E, Boban M, Omrcen T, et al. Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer. Neoplasma 2011; 58:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/30\">",
"      Fielding JW, Stockley RA, Brookes VS. Interstitial lung disease in a patient treated with 5-fluorouracil and mitomycin C. Br Med J 1978; 2:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/31\">",
"      Limper AH. Chemotherapy-induced lung disease. Clin Chest Med 2004; 25:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/32\">",
"      Wibmer T, Kropf C, Merk T, et al. Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer. Lung Cancer 2008; 60:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/33\">",
"      Niell HB, Griffin JP, West WH, Neely CL. Combination chemotherapy with mitomycin C, methotrexate, cisplatin, and vinblastine in the treatment of non-small cell lung cancer. Cancer 1984; 54:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/34\">",
"      Rancati T, Ceresoli GL, Gagliardi G, et al. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 2003; 67:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/35\">",
"      Makris D, Scherpereel A, Copin MC, et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 2007; 7:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/36\">",
"      Sagawa M, Takahashi S, Usuda K, et al. [Interstitial pneumonia after CMC (CDDP, MMC, CPM) therapy]. Gan No Rinsho 1988; 34:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/37\">",
"      Raderer M, Kornek G, Hejna M, et al. Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C. Ann Oncol 1996; 7:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/38\">",
"      Gunstream SR, Seidenfeld JJ, Sobonya RE, McMahon LJ. Mitomycin-associated lung disease. Cancer Treat Rep 1983; 67:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/39\">",
"      Jolivet J, Giroux L, Laurin S, et al. Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome. Cancer Treat Rep 1983; 67:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/40\">",
"      Torra R, Poch E, Torras A, et al. Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy. Chemotherapy 1993; 39:453.",
"     </a>",
"    </li>",
"    <li>",
"     Jennis AA, Bauer KA. Coagulopathic complications of cancer. In: Cancer Medicine, 3rd ed, Holland JF, Frei EI, Bast RC, et al (Eds), Lea and Febiger, Philadelphia 1993. p.2318.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/42\">",
"      Abramson N. Drug-associated thrombocytopenia and anemia. Blood 2007; 110:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/43\">",
"      Zetola-Burneo N, Brown C. Cases from the Osler Medical Service at Johns Hopkins University. Am J Med 2004; 116:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/44\">",
"      Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer 1985; 55:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/45\">",
"      Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 1986; 58:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/46\">",
"      Rosenow, EC, Pisano, RJ. Adverse effects of drugs on the lungs. Contemp Intern Med 1991; 3:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/47\">",
"      Montes A, Powles TJ, O'Brien ME, et al. A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer 1993; 29A:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/48\">",
"      Cantrell JE Jr, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol 1985; 3:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/49\">",
"      Onitilo AA, Engel JM, Clouse LH, Gerndt KM. Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab. J Vasc Interv Radiol 2009; 20:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/50\">",
"      Chang-Poon VY, Hwang WS, Wong A, et al. Pulmonary angiomatoid vascular changes in mitomycin C-associated hemolytic-uremic syndrome. Arch Pathol Lab Med 1985; 109:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/51\">",
"      McCarthy JT, Staats BA. Pulmonary hypertension, hemolytic anemia, and renal failure. A mitomycin-associated syndrome. Chest 1986; 89:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/52\">",
"      Gourley BL, Mesa H, Gupta P. Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) with rituximab. Cancer Chemother Pharmacol 2010; 65:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/53\">",
"      Hong MJ, Lee HG, Hur M, et al. Slow, but complete, resolution of mitomycin-induced refractory thrombotic thrombocytopenic purpura after rituximab treatment. Korean J Hematol 2011; 46:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/54\">",
"      Gagnadoux F, Capron F, Lebeau B. Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma. Lung Cancer 2002; 36:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/55\">",
"      Schraufnagel DE, Sekosan M, McGee T, Thakkar MB. Human alveolar capillaries undergo angiogenesis in pulmonary veno-occlusive disease. Eur Respir J 1996; 9:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/56\">",
"      Waldhorn RE, Tsou E, Smith FP, Kerwin DM. Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma. Med Pediatr Oncol 1984; 12:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/57\">",
"      Huggins JT, Sahn SA. Drug-induced pleural disease. Clin Chest Med 2004; 25:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/58\">",
"      Veen EJ, Dikkers FG. Topical use of MMC in the upper aerodigestive tract: a review on the side effects. Eur Arch Otorhinolaryngol 2010; 267:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/59\">",
"      Hueman EM, Simpson CB. Airway complications from topical mitomycin C. Otolaryngol Head Neck Surg 2005; 133:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/60\">",
"      Agrawal N, Morrison GA. Laryngeal cancer after topical mitomycin C application. J Laryngol Otol 2006; 120:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/61\">",
"      Schrijvers D, Catimel G, Highley M, et al. KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study. Anticancer Drugs 1999; 10:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/62\">",
"      Spain RC. The case for mitomycin in non-small cell lung cancer. Oncology 1993; 50 Suppl 1:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/63\">",
"      Danson S, Middleton MR, O'Byrne KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 2003; 98:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/64\">",
"      Booton R, Lorigan P, Anderson H, et al. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 2006; 17:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/46/33513/abstract/65\">",
"      Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14:2527.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4350 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-BB90AC98B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33513=[""].join("\n");
var outline_f32_46_33513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7157544\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H767182\">",
"      INCIDENCE AND SCOPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BRONCHOSPASM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE LUNG INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41150946\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H767316\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41150818\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41150825\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41151061\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H420682\">",
"      INTERSTITIAL PNEUMONITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H767606\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H767613\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H767620\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H767673\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      THROMBOTIC MICROANGIOPATHY AND ACUTE RESPIRATORY FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14403704\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14403697\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9712126\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14403690\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14403683\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H420929\">",
"      PULMONARY HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PLEURAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23608122\">",
"      LOCAL EFFECTS OF LARYNGOTRACHEAL MMC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H421115\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7157544\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4350\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4350|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/3/8255\" title=\"diagnostic image 1\">",
"      HUS IF IV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/4/30793\" title=\"picture 1\">",
"      Early DAD micrograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/11/41145\" title=\"picture 2\">",
"      Late DAD micrograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/17/15638\" title=\"picture 3\">",
"      Diffuse alveolar damage DAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/50/38694\" title=\"picture 4\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/51/22329\" title=\"picture 5A\">",
"      HUS Glomerular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/61/12246\" title=\"picture 5B\">",
"      HUS Vascular I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/49/26389\" title=\"picture 5C\">",
"      HUS Vascular II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/19/34099\" title=\"picture 5D\">",
"      HUS vascular III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4350|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/49/14107\" title=\"table 1\">",
"      Histologic features of diffuse alveolar damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/34/4654\" title=\"table 2\">",
"      Doses of beta agonists for asthma exacerbations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37415?source=related_link\">",
"      Busulfan-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38762?source=related_link\">",
"      Clinical features, staging, and treatment of anal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21990?source=related_link\">",
"      Cyclophosphamide pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28407?source=related_link\">",
"      Oxygen toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/49/29466?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=related_link\">",
"      Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29385?source=related_link\">",
"      Pulmonary veno-occlusive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_46_33514="Clinical criteria for diagnosis of anaphylaxis";
var content_f32_46_33514=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 652px\">",
"   <div class=\"ttl\">",
"    Clinical criteria for diagnosis of anaphylaxis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 632px; height: 688px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAKwAngDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6J8e+K7HwR4TvvEOqxXM1lZ+X5iWyq0h3yKgwGIHVh3HGa8g/4ar8D/8AQK8Sf+A8H/x6uq/aj/5IT4m/7df/AEqir4AoA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD9NPAXiux8b+E7HxDpUVzDZXnmeWlyqrINkjIchSR1U9zxiiuK/Zc/wCSE+Gf+3r/ANKpaKAD9qP/AJIT4m/7df8A0qir4Ar7/wD2o/8AkhPib/t1/wDSqKvgCgAooooA9A+BnhmPxT8RdPt7uBZ9PtA17dRsm8OidFK/xZYqMdwTXpPir4c6X4h+J3gx/wCyrrQNG8R2jmazggW2ktp4omZl2lcKThP4efmPvXh2ieI9V0Oy1S00u6+zwanB9muwI0YyR85XcQSoOT0IzWlofj/xNoVlp1rpepeTBp073Nqpt4n8qR1ZWILKTgh24PHOcZr5/HYDHVcRLEYeoo+64pXfVPXbfmt0ei36GsZRSs0dxN8MNOvNH0a+0CPVLme51uXSJbOW6jUyBA58xJPLwnyxknKtjPfHOm/wi0CZvDU1rqFz9nvtYOk3kUN2tx5bBWbKSmGMZGwg/IRzwTXmdt4+8TWtrbW9tqrxRW182pRBIowVuGDAvnbk5DMNp+XnpWzpPxW8QQatpVxqjw3thYX/APaIsobeG1V5sMC26OMYJ3Nng5Jz1rGtgs2Sbp1FpzW1d3e9lqrdrbW72GpU+qO10XwDotnqtrrGizajFLovjCDSZY7yZJFnAnQB12ou088g5qf4neEdC1PUPHHiW5l1GGbSdYt4rtFkQpNDIY1bYNmUYBjySw46c8ebeIPiRr+q6p9oguFsrSLU21S2tIYYgsUxfcrNtQeaw4G5wSfxqhqHjnxFqFnrVreaj5kGszJPfL5EY850IKnIXK4KjhcCppZZmDqxrzqJNWW7vbmi2r210T+bXa43OFrJHpmsfDHSvB15PqVxd3ssLavZ2+hYkTFwjbZHdzt+YBTjjbyPer/jDwZZa/8AEzxhqWuRSw6XDqENsb0agtuqu0afIE8iVnbkYxgc/iPNfGXxBu/EFt4WtraB7ODw/apDAHm85nkXGZCSoHO1flxxjvmoE+JHipbnUZ21NJX1CZLi5Wa0hkR5UACuEZCqsMDlQDwPSlTy7MpRjVnNc9mndtWXNHa191G73957WBzhslod/pvwf0rUfHvifwbFqF/HqmnGKe1u2UNA0DBGZZFC5DgPwdwBPYd22+kacngH4iWekapq1holpqVnbPHeLE/mfv1RpJB5YcYI3BVK9MHNcBdfEbxXdTalNJqzLPqMsU11LFBHE8rRBRHllUEAbRwCBnnGSabe/EHxLfDVFu76CRNTlhmvUNlAFneIgoWXZjqBn+93zWn9nZlNx9rUTS5Hv1i4uTXu9bO3Z+ui54dF3Om+KHw9svDOkLqGgw3WoaUZI411hdTgnhkJXOPJSMMmT0O8jGO5qz4e0xdR+CNot/rc1jpsvimO2lR0jMEQaJczE7d+QCf49uO3euE1fxfrOq6SNLuZ7eLThL55trOzhtY2kxjcyxIoY47nNR2PirV7LQ00aC4ibS0vBfi2ltopUMwXbuIdTkYGNpyvtXSsDjJYeFOpNOcZJ312Xqnr6JLsLmje6Ou+K3gK38KWkF3pNrdT6TNP5UOqnU4bmKfgkAIkalCQN3LMMetdx4Z0rTNd+DPgLSdZF59lvvEEluGtZVjdGbzAGyysCPbH4141rnivWNb0630++uIVsLdzLHa2trFbRK56tsiVVLe5GamsPGviCw03StPtNQ8u00u7+3Wkfkxnypsk7slcnqeDke1Z1suxlbDU6c5rnjK97vtJLu76q+y7ApxUm+h67beAprjwdN4Xj1u6FonjRtNCNHEI8CPmX7u/fjPG/b7d6z7bwL4cs1uNX0d9XWfR/E8GlAXU8brLiRAz7VjUrkngZOK88Xx/4ikbZdalM1u+qDV5VgWOKRrnjLq4QlTgccFR/dNdF4n+LN1qmif2fptk1pJJqCalPdzvDJLJMuNpIjhiTqASSpJxya5Hl+ZwkoqSak7uzsul29Fe608vyrngdr8XvCWlazqvxF19JL2HVtFurTcC6tDMkiIuAu0MpHruPToM8X/ip4Gt/G3xC8aJYSXH/CSWS2L28O5fKlhdEVyRtzleuc45FeK33j7xLfJri3WpeYuttE1/+4iHnGPGzovy4wPu4z3rb8L/ABU1bS/Gt/4r1VW1TV7mza1WTetuqsQoVmVUwwAUfLgZ4OaiOU5jh4RlTmnKnG0VfypaapaNwlfXZq3ZP2kG9ev/AATE+IekaVoHji/0nQZ7i4s7KUQGad1ZnkUAP90AABsjHt1r3b4t28803xeljv7mCGCHSi9vGsZSfcAPnLIWGMcbWX3zXzJJLJJM00js8rMXZmOSSTkk10+qfEDxPqo1oX+p+aNZWFb/AP0eJfOEX+r6KNuP9nGe+a9HF5ZXrSoSjJNwSTb3fv05N7PpF/Nr1URmlfz/AOCe3/tD+CLaW51HxTqDXUks32WwsYbZ1VY3KkGWclThM8ADBJGMjIrjfGfwt8O+HLHXLSfW1g1nTLWKeJ59Rttt85Xc8aWw/ex8EbSxOfTGM8NqHxI8V6j/AGr9t1Xzl1SBLe8VreLbKiAhfl24UjJwwwfeoL7x54iv7Jra9vYrjdb/AGVriW0ha4aL+4ZynmEf8CrjwWV5nhqVOk6qtHs3suW3TpaS8730drVKcG27HtPxQ8F23jTxj4jhtHuf+EksdKs7mygV18uePgSArtzkAjBB7jivHPiPomjeGvG9zo2lz3d1aWJSG5lkddzygDzNmFAAByADnBB61q+F/ilqul+OD4q1hDqupLZtax/Otuo42qWCphgB2wM8c8VwV1PLdXMtxcOZJ5XMjuerMTkn866spwOMwslSrS/dxikrfzWSdutla6vbWTJnKMtVue86p8D9LSLXpNM1C+lDW8U2hLIyE3R8kyyB8LzwOMbcZGc1qQaDonhPwj8V9Gs5L68sbKOxS4ZpUWR5OS4VgmFGTjlTjB6143D8SPFkP9heXq7r/YalNP8A3Mf7kFNhH3fm+Xj5s1S/4TPX/s2vW51AmLXZBLqIMSEzsGLZztyvJP3cVyPKcyqpQxFZSinF9fsyi+38sb/4pPpqV7SC2R6lffBvSrTW/ELpf3U2kaZp1vexwyXMNtLI024KjTSDy1AKHLFe4GM1WPwy8KF/FNzaazcalY6ZpEepwrZ3kEjK537oZZFVlJGzqAOGBwa4GT4ieKZNUk1CXVN9zLarZShreIxywjojxldjDk9QajPjzxF5WoRJewww31oLGeKGzhiQwDdhFVUAQfO3KgHmtY4DNbe9WW0er6ct+nk9dHrZi5odjR+LHhHT/Cl/op0ee6kstU02HUES6ZWkj35ypZQoPTrgV2GgfCbT9R0IjUnuNL1yTRn1aCI36zmRF24dohAAiMTgAylh6HBx5Z4g8R6r4h+wf2xdfaPsNstnb/u0TZEv3V+UDOM9Tk+9blr8TfFttaxQRaom2K0Ngsj2kDyi3P8Ayz8xkLlfbPHaumthMxlhqdOnUXOr3d38umvndCUoXbaPRNH+EnhzULjwrYNdavHe65oZ1LzhLGY4ZQitjZ5eWX5jxuB46nPGb4d+GGhar4d0TxK97qCaB/Z9zcaw6yJvhnh42IdmBuJBAIY4HvmuJtPiN4qs7vSrq21XZPpdobGzb7PEfKhwBtwVweAOTk+9Ps/HM9l8ML3wda2zqt7ei6uLlp8gqAv7tUxxyiknJzjp6cssFmkVpVvdrZ7JuXM9Utk42t1W3Vvmh2F+FvhK28Z+KZbG6uJraxt7aW8mMeGkKJj5VyMbjkc49eK7vwj8KtA8Tz+D763uNVttI1w3cUtu80bzwyQqxBWQRhWU7f7gx/LyLQda1Hw/qkOo6NdyWl7FnbImDwRggg8EEdjxW7D8RfFMGrafqVvqSQXOnI8dosNrCkUCuCHCxBAgznk7a68fhMfVnJ4aoopqy30dpLs+ri77q23eYSgviR3em/CbSdfg8KTaRfXtoNU1C5sblbpkl2iEOxdCqryVjPykHlhzxzzvxE8H+HtE0CC/0XU1+3C9e1m02XU7a8lCDcVmzDjaDtwVIOCQM+vNx+NvEUVjYWcWpyRQWN017bCNERo5mJLMGA3c5PBOOelR694s1fXrcwalLamNpvtD+RZQW5klwRvcxopc8nls9TU0cHmEK8ZTqpwTemt7Xflro0tdraMblC2i1O48J/D7RLjw74Sv9dm1KSfxNqDWVuLKVI1tgHKb33I287scArx3rqNWsIfBXwN8QWFs94t6viCXTbi6tbkRfacRkDd8hPlbcZiz1z83OK8m0Dxx4h0CwSy0y/EdtHKZ4klt4pvJkII3xl1JjbBPK4NVLjxTrNx4fk0S4vnl02S7N+8TopZpyMFy5G4kj3xWdXLcZXrJ1ZpwUlK13sm2tLaWVlbZtXeoKcUtFqd58K7HQrj4a/EG71nSTez2cdqyyq8ayIrMwxEzRsY2yDk85GBgYyfQZfC2k+NNJ+Fmham99A1zo1w1tNbyIBEyqjfOpU7xx2K/rx4F4b8Uav4cS+j0m5SOG9jEVzDNBHPHMoOQGSRWU4ye3c1p2nxF8U2dzo1xbaoI5dHheCxItov3KOMMMbcHIH8WazxuU4urXnWozSd246vR+z5VpZpe9r5r7hxqRSs/61O70H4V+H10TQLrxPrH2Q6ws7/ajqFtbRWipwmY5fnmJOM7CNufxrE+AljZN8adIs72NL1ElmETIwMZdI3ZX6HcPlyMY5wc8YPMad458Qafp8VjDeQy2kEpngjurOG4EDk5LR+YjbDnn5cc81naH4h1TQvEEWt6XdGHVImd1nKK5BYFWOGBByGPUd66HgcbUo4inVqJuako6vS97dNNGk7X22ve65opppbHqur+GtJ1hX8UeJLrXrtdT13+x7eIXqPLEBkGR5GjO4Ag7UCrgYGe9b6+Hf8AhE/AuuaGJ/tC2fi+0RZcYLKViYZHrgjPvXjej+OPEOkRzx2N+oimuftjRzW8UyCf/nqqupCP/tLg0z/hNfEP2K5tG1KR4bm+GpTeYiOz3AxhyxGew4zj2rmnlOMlaHOuRNWWuyat00srrz3Y1UjvY9c+J/hLSJdf8Z+LfED381tFrEOnRWtjKkT7jFGzOzMjjAVuBjk9xUTfBDT31LxBpFpqN5Pqmm6hZKuGQKbS4KDcy7c71y5JzjCjjmvM0+IvihdQ1G8bUkll1GRJrpJ7WGWKR0xtfy2QoGGBggA8VFpXj/xRpWs6lqtlq8yajqKGO6ndEkaQf8CBx0GMYx2qaeW5pSpKFOsk4pJb205NNtFpLXd3V9hucG7tHpms/DLRPDCya3Z6nqElvJqOnx6FMGj/AHnmbXdnymGwN2MADjkHpVrxv4H0ie88beINfvdYvrjTtXt7QlJYYmlSRYgWbEW0MN/GABwOO9eQ3HjLX7nSNI0ufUGew0mTzbKIxp+6bOQc4y3/AAImrOo+P/E2o2uqW95qXmQ6ncJdXa+REPNlTbtbIXjGxeBgcVUcszHmjOVVNrRvry80dNusYtv+8/mLnh2PQde+FGi+HtQ8c3F/eajc6R4ejtmhhhdI55mnA2hnKMAATgnbz1wMVxvxc8Kaf4P1/TrPSpLuS3udOhvG+0urMGfdkAqqjHA7VNpfxL1M61q+peIZbzUZdThSG5SFreGOZUGFDxvBIjYHT5QRzzzWV8R/GE/jfxH/AGpcWyWqJCltDArb9ka5wC3GTyTnA69K2wNDMqeIj9ZlzRS1d9G+WK23+Lmd7dfQUnBrQ+gPDtloOn/GH4dpo2ktYz3GgLcs8ckYRlaGb76rGpaXIGZMjOPu964CL4b6Frb+FdShuNSgh1rV59Pu4WlRmUqz/PG2wAZ29CGxnqcc8LZfErxXZPpMlvqcYm0qPybOZ7OB5Yo9pXZvZCxXDH5SSOnoMVrPx54ks7fTobbUtkWnXbXtqvkRny5mzublec7jwcjnpXHTybH0ZOdKok7JXu3e3tO67yi/Kz+dOpF7r+tD0OD4beE7+/8AFX9lXWsvbeGg8V3HeXNtamecyuiBJWyiIAhyzjJ4wBnFEfwp8PT3+u3ena4mo6NpunwXflQ6lbK/myl1EL3BzEu0xklsdGXA5rzSw8Ya7YavqWpW19tutSLm8DxRvHcbyWYPGylCCSeNuOasQ+O/EMN+93BewxM9t9jeGO0hW3aHJOwwhPLIyScbe5rqlgMzTfJWVrK17+V09OtnZqzV/JC5odUS/Evw/pHh3X4rfw9qsWp2E9slwGS4jnaFjkNE7xnaWBHUY4IrpfGngzwz4Y1zSvD0razLqlxbW8s12s8Rh8yQgFVj8sHb1+Yscehrz/XNZvdbuY59QeEvFEIY1ht44ERASQqpGqqBkk8DvWzc/EDxJdWtpBcX8UgtYUt4ZTaQ+csaY2p5uzeV46E4PfNdksNjOWkue/KnzatXelndLW2ullcm8dT2Xwz4R8O+GvjWvhzwxq3iS21aCOX7RcyLbMgjMAcBCyNk5PJKjjgep53VPDGiax4C+FtjYacLLVtaeaD7crxj5hKis0wEYaUYJ2jcu3OMtXnKePfEkfjCXxSmpY16Vdr3XkRcjYE+5t2/dAHT9arr4w11fD9roovh/Z9pL51qDDGZLd9wbMUpXenzAH5WH6150coxqnCq6icko3d3q1GafRXV5JpPomtL617SNmrf1oemar8L/C0GoR2MOsPBexa3BpslrJqdrPNdQvIsbSpHGN0TAljtcMQBz3rZ8OeGtB0P4g+ItD8Kar4it7yy0u+S+mnS2KyKPLKImUbIPO44U8DGOa8nuviH4lubhLia9tvtQmiuGuEsbdJZJIiGQyOEDPggH5ic45zVaDxt4gg8QalrcWobdU1GJ4bqfyYz5iPjcNu3aM4HQCm8szGpTcKtVPR6Xur6b3jtv87dNjngnoj0bQPhNp+o6ERqT3Gl65Joz6tBEb9ZzIi7cO0QgARGJwAZSw9Dg45/4A289142uYra/ubFjptyTLbrGWICg7f3iMMH6Z9CKyLX4m+Lba1igi1RNsVobBZHtIHlFuf+WfmMhcr7Z47Vg+HPEGp+G9Qa90W5+zXTRPCX8tX+RhhhhgRzXQsDjp0K9KtNNzXu7tLfutttNeouaKaaPRB8N9On+HcGuaGbjX737E1xei11KGH7C4XJVoDGzuF4zhlJ7YzmrH7OX2SK98X3k0M5vLPQ55oJ4ZgjRAY3FCVbD9MP254OeOCg8aa3baTNp1nNZ2ltPB9mmNrYW8MssWMFXlRA7A98sc981S8P+I9V8Pfb/wCx7r7P9utms7j92j74m+8vzA4zjqMH3p1cvxdbDVqFWafM9Hd7XvZ/lokrbgpxUk0et2Hw00bXtU+H1xd3uss3iz7bPevLcpJIpjTepVzHyST8xYHPtXS+GdOsF0H4YafeQNdWkev3sSI7DkrI+0tlSCMgEjAz7V4tovxE8UaLaabbadqapFprO9nvtYZWgLghgrOhYA5ORnHtwKhg8e+JIF0xYtS2jTbmS8tB5ER8uVySzfd5ySeDke1cVfKMfX9yVRcqvbV9faJdNLKUV8n86VSK6f1oe06xc3Oq2/jC4Oqaubez8U29t9luZ450Yi4AyGMYdFH8KKwA6HPWr/i6wfVLb4uafE6pJd6xpcCs3RS8kSgn25rwIeNfEAh1CIX/AO71C9XUbkeTH+8uA28P93j5ucDA9qkvvHfiS/i1mO61MsuryxT3u2GNTK8ZBQghQVwVH3cdKhZBiIyTg4pJq2/R0321+B/h8j2q/r5noniX4U+H7I6jptnriW+t2l1b20CXeo2shvvMZVYrAn7yIqWzhicj9N86FpPhfwR8XNC0c30rWMVjHcXF1KpEz5YkogQbACSMEtnjmvHtS8e+I9ThlS9vopJZVRZLkWkK3MgUgqGnCCQ4Kr1bsKsan8SfFWp2Go2d7qUTw6iiJeEWcCPcBPu73VAxI9c5rWWWZlVjCFaopJOLer3UoO+2vwy0eib7WsueC2Ri+JP7C+1wf8Iz/af2XyE87+0PL3+dzu27ONnTGeetZFa/iTxFqniW7gutbuvtM8ECW0beWqbY1ztXCgA4yeetZFfR0IyjTSnv63/Gyv8AcjJ76BRRRWoj7/8A2XP+SE+Gf+3r/wBKpaKP2XP+SE+Gf+3r/wBKpaKAD9qP/khPib/t1/8ASqKvgCv0m+KX/Iqwf9hfSv8A04W9aNXGPMTKVj8yKK/Teiq9n5k+0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0PzIor9N6KPZ+Ye0OH/Zc/5IT4Z/7ev/AEqlorp/hZ/yKs//AGF9V/8AThcUVkaB8Uv+RVg/7C+lf+nC3rRrO+KX/Iqwf9hfSv8A04W9aNa09jOoFFFFaGYVzPxL8Vf8IT4J1HxB9j+3fY/L/wBH83yt++RE+9g4xuz07V01eY/tK/8AJE/Ef/bt/wClMVJ7DW55l/w1T/1J3/lU/wDtNH/DVP8A1J3/AJVP/tNfMdd74B+FXibxtBLdadbpaWKRmRbu9DxxTYOCEYKdxyD04GDk1xYnG08LD2teajHuzZU+Z2SPX/8Ahqn/AKk7/wAqn/2mu6+Dvxq/4WP4mutI/sD+zfJs2u/N+2eduw6Ltx5a/wB/Oc9q+Ka91/Y8/wCSman/ANgiX/0dDXTGTbJlFJH098R/7T/4QnVV0DUbbTdUaMLBdXDhERiwGNx4BIJUH1Irxmfx9rPgzSPEEU2lanaeJdJsYJ2t9S1WTVLWdHnjjMpbduRuchQwGCeK+hbu2gvLd7e7gingcYeOVAyt9QeDWbZ+F9AsrC6sbPQ9Kt7K64nt4rSNI5v99QMN+NW0Zp2PLPE3xd1TRb7xqiWNlcwaPbWL2hUMMvcKmTK24jYC3YDsM965T/hLNW8HfEH4h3r/ANn32r3M+k2YmSJ47VGkiOHK72baAMfe5PpnFe+W3hTw7awXMNtoOkww3UYinjjs41WVB0VgB8wHoeKZb+EPDVvbXVtb+HtHit7pVWeJLKJUlC/dDgLhgO2elFmO6PBrDxhqfgjV/HtwkVrf6peeIbWwMwi8uBGdHy5RpOB8uADIBk8sBXX3HxB8aWWoaJpWqaZpNlqF/rBsGeQCTEJUMjmKOdvLfB5Uuc9j3r0628K+HraxubK20LSobO6AE8EdnGscoHTeoGGx2zRaeFvD9mlslpoWlQJbS+fAsVnGoik/vrgfK3uOaLMLowPhP4uvvF3hq+vNUgt0vLK/nsn+yqypJ5ZGGCsSRkHpk1w2i/FvXL2Dw/qc9ppn2DXLm7torKNH+0WpiBwzuXw/TLAKuARzXqOpX3h7wNpL3VxHbaVYS3IDG3tiA80hxkrGvJJxk4+ppLzTfCuh3M2sXllomnXFw3lSXssUULyl+NrSEAkt6E80ai0PL/B/xV8TarN4LN3Y6TcL4jtb90gto3hdJbfftG9pGGG2gcjjOc1Wk+M2taVoWsy69YJDr9lAkv8AZL6bLB5QeVUEhmMzB0G4dAhJPbnHq8GkeEnu00qDT9Ba506JwlmkEJe1jlB3YQDKK4JzwA2TnNW9P8MaBpttcW+naHpdpBcjbNHBaRxrKPRgBhh9aLMLo8Q+Jvi3xz/wrzW5L7ytGltp7OS2urGVY5p4ZGIOViuZDH8w4O5gwyOO3qvxB8TX3gj4dX+uXEUGpahaIgIijaGJnZwobaWYqo3ZI3Hp1Fa9t4T8O2thdWNroGkw2N1j7Rbx2caxzY6b1Aw2PetC302xt9NGnW9lbRaeEMYtUiVYgh6rsAxj2xRZhdHz38XPGmv3PgzxnoF9Npzy2drY3LXmnxPGkkU0iAxYMjbTlh82SGXPyjOR61qWo23gT4Xm9lk0+wisrdMNbWDeQrMwA2wCQHlm6b+pyT1rah8KeHYNMn02HQNJj064YNNapZxiKQgggsmMEggdR2rSvLK0vbKSzvbaC4s5F2PBLGHjZfQqeCKLBc8GufjN4mtLPX4Z9N05dQ067sYozNA0YaO4BPzxpNJtYYHSQ9eQCMV6P8PPFepa54h8XaPq6WZm0S7SFJ7WNo1lR1JGVZmwRt9e9bkPg3wxBDJFD4b0WOKQozoljEAxT7hI28lcnHp2pumX/h2Lxdqmk6cltDr7RJd3yxWxR5FPCu77QHPPqSM0WYNo8O1zW7jWde01LldosfiOlpH+/mkyq9D+8dgv+6m1R2UU74c+K9V0OHSNI0hbEDW/EmpQSy3UTyeXt2EFQrr6nOT+Ve9/8I5onmeZ/Y+m+Z9q+3bvsqZ+0f8APbOP9Z/t9fesa8fwTo63txLDocT6GWvbgQwRvLZs4BMhRAWVmABzjLY70rDuebWfxh8QX2keGYbfSrQ6zq1/dWbSRpuhHk4+4jzRgs24YBlHQ9SQKvav8RfGulaNpt5q2g2thCgmXVb23h/tGO2dGwAY4p1KDoTlzjkdq9IsNG8Max4btVtdH0ufRLwLexQtZIIn3gMJPLK8MQc8jNZmraX4Ds9W0XSdQ0TRDf3AaPT7f+zUkZVXLNtAQ7FBJOTgZNOz7hddjk774laxZeJNPS/ihsvDF99lWy1X+y5Z474yqrHkTKYCcnCsrng5zjnW+Mv+n3Xg7QbnI0vVdYRL1ckCVEUuIm9mYD8q7EeF/D41YaoND0oamGDC7+yR+cCBgHfjdnHHWmeL/DVn4p0yKzvZbm3aC4jure5tnCSwSocq6EgjPUcg8E0WYro808ffEnXvDmseLbTSrfSPsXh+ztLlEmgkZpRIyqUysihcbsg47YweoyvGHxN1mLRfG9rcwWbS6ZaWF7ayWzz2x2zvGSjtHKHyN4G5WXODkYOK9nufD2j3ZuWvtLsLuW7jSK5knto2a4VcFRJx8wBAIB4Ham3HhnQbn7SLjRNMlF1GkU++0jbzUTGxWyPmC4GAemBiizC6PHvEfxZ8SaSvjK4trfSGs/DlxYxiKSGVpJ0nHzfP5mAwPQ4P0qz4l+LWt6XB4xa3tdML6NqtrZW6yRv80cucs4DjJ44IwPY16xP4Z0G4S9S40TTJUvSjXSvaRsJyn3C+R823tnOO1Mv/AAr4e1C7kur/AEHSbq5kCh5p7ON3YL0yxGTjAx9KLMLo8Yg8beI/C9z8U9Xu7xdVt9JvIo4rORJMIznahQmQiOMZyygHOOq10cfjX4grourSDw1ZXl8sMFxp/kyRK0sb8M7QJcSkgHOCHG4elelP4f0Z9Rn1B9J09r+eMxS3JtkMsiEYKs2MkYAGDVOPwX4WjspbOPw1oiWkzB5IFsIgjsOhZduCRnjNFmF0Zfw38UyeLvD19cJeRSX1vcSWrhtMktPs8iqPkkiaVySCcnDj04IJryj4f+O/E2l+ANIkur2LUbrWNe/suC51BZXFrlyGaRjJlx02oNmMHk17DZ674R8P3GoaJbT6dpA0yNJ7mERC2ggWQgKxbATkkDg9TV9PC3hww3ix6FpHk35D3IWzj23BGSC/Hz8knJz1NFguY3w18VXviWPXbfU4YBdaRqUunvcWyssNxsx8yhixU88rk49ea4N/i3r2knWB4o0tdP1K1tZ7m20k2EmZkQ4VhdCUqyjq37sdDjtn2XTdOstMs0s9Ns7aztEztgt4ljRc9cKAAK5u0tvBfh7xLBolhpelafrGpW7skVtp6xmaJfvBmVNuOOhNGoKxwK/ELx8vhnUdVfRdJKR6bHqlq5Kfvowy+aoiS5kYgKxIk4Hy4KgkCo7/AOMeqNot9reladaS6TcavBpGlyupzkpmSWQmRVIzwoyg9W4zXoenxeDNJ8Uz+HtN07S7LWruzN1NBb2Aj8233FSWZV2kbsjaTn2rQhsfDKRP4XhtdGWPyjO2kLHEB5ZblzD/AHSx64xn3os+47rseY6n8Q/HdhNpWmXGj6Jb6xe6q1iguZPkaMoGjdkimkMTc8gs3HSq/jP4s694ae6CR6bqM2km0i1eKGydIopZVG5UnacMckNtxCcAc9M163aeFvD9mlslpoWlQJbS+fAsVnGoik/vrgfK3uOabqfhPw5ql493qegaReXcgCvNcWccjsBjALMpJxgflRZiujh/hP8A8lE+J/8A2E4f/RZrz/wr4r1PwheeI7qzSynsb3x5Np9xDLG3mYkJ+ZHDALjb0KnOe1fRFpp1jZ3F1cWdnbQT3TB7iSKJVaZgMAuQMsfc1i3tl4QtLh7S+ttAhneRtWaGaOFWZ1zuuSp5yOcydRzzRYdzzqw+K2tXF1pt9JZ6d/Zd94ibQRYoj/a4/SUvu2nB5K7BgEc80zw18WNc1OPwd9qtdMSXWNXudPuVSNwUSLGCoLnDc85yPYV6jpuleHLy8j8QaZYaRPdzgsmpW8MbPIDxkSgZIPTrWZZ23gtvGdzp1rpelDxHaqL+Urp6rIm7gSeZsxuOeoOaLPuF0eeeHviF8Rdb8GXXiGw0PRL6FZWto4LRZmnDLJguYywDKF/hD5J5yBkUzxl4hi8UfBq88Ux3iPrGgX6y28yWL2T286OgMZR5HOSHwcNg5HGRXqQ0fwjdRzeHRp2gzJbsLmTTPIhYRM2cSGLHBOT8xHOai1zwPo2radpummI2ek2Vyl0LGyVIoZmU5VXUL93POARk9c0WYXRtWeq2VzdyWSXVudQijWSa0EqmWIMMgsvUD3Irx3xn8WvEPh3xJr2hx6ZY3N/Z3CXFsojcCTTxC8srn5+XUIFyMDJ6V6xo3h6y0nVdZ1KAyyXurTLNcSSsCfkQIiLgDCqBwOTyeasXGi6Vcag1/caZYy3zQm3Nw9ujSGI5ym4jO05PHTmm02JWPG/+Fiatrt74dvLeK1j0zUPEcthp8iPcIXt0GBK4SVVky2flYFeOneuG1G+13Uvgzfz6xqov9nidYY/OWQyIyydN7SN8nIwoAxzya+mYvD+jQwWMEWkackNi5ktI1tkC27k5LRjGEOSeRjrXJ+ILz4eaLqt/aarpumC9aH+0r0R6SZyEQkiWZkjYDBzgsc5PHUVLXcaZL8PPFepa54h8XaPq6WZm0S7SFJ7WNo1lR1JGVZmwRt9e9cDD8RtastYurOyhs83XjSTRN9y9xOEiOAGAaX5Tz91dqeiivZNBj0ie3/tjRba2RdVjjumuYoBG9wpXKM/AYnB/i5GaT/hG9D83zf7G03zftX27f9lTP2j/AJ7Zx/rP9rr707MV0eS23xc1q10xNT1m200adY+IptE1SaCGQYQKPLmQFzt5JDA7u2MVPpXxI8Vao3heza20fTb3XLW61FZrmGR4ooEyY02iRSzFQGLbgAGziu+0IeEPEVnrlhpVhptzaRX8kOpW5sQsb3SkFy6soDtkKd3OcDmrrWPhnxLYfZWtdG1eysZTb+UY4riO3kUAFMchWAxxwRxRZ9wujw/S/FureLfGvhfxHptjBBrM3hq9eK3lVnieVJXUAAEHaxXjnjPfHOrD8bNUu/DWs+ILHS7WbT9J021M67XDG/mYBlB3cRpk5GCenIzXtUWj6ZFd211Fp1mlzbRfZ4JVgUPFH/cVsZVfYcU2x0PSbC2ubax0yxtre5Znniht0RZWIwSwAwxI6k0WY7o8f1j4l+NdF0C6u9R0nSUkaS0NlKxQCWKY7WLRR3MhAzna+7B9M8Ump/FTxJpcuufaINHni0bWoNOmMdvIhnilz8y5kOxhjvuBz2xz6pb+DvDNtayW1v4d0aK3kdZHiSxiVGZfusQFwSOx7VYn8N6HP9p8/RtNl+0yrPPvtUbzZF+67ZHzMOxPIosxXR5jo3xJ8Va14juRpuh2n9h2es/2XdefJHFLEm4Lv3tODvJIwnlYPQMTxWfo/wAVvEt3NoclxBo4ttS12bRdiW8oeMLgJJuMmDyeVxzjqM8euy+GtCm1dNVm0XTJNTVgy3jWsZmBHQh8bsj61l6xH4P8Ovo8Woafplq11qKpYBbEH/TH6Mu1Ttc4++ce5oswujlP2e77W9S8O6vPreq/b1TU7iFPNVzKhUjI3tI3ycjC4GPU1mD4ray1y16LKwGlr4k/4R77B5bm86f63dv25z/Bs/4FXong2XwvqR1DVfC1tYh5Lh7e7uYLTyXklQ/MHJUFsE9eRzWj/wAI/o39r/2t/ZOn/wBq/wDP59mTzumPv43dPei2gX1PL/2dYLi4HjHVdRaynvpNbuLeS5W2KzOV2kgyFifL5G1P4cHk54868Z32vXvgL4ux6vq32y0tNXigSJ0kzGftMePLLSMEjxn5MHqDu4wfp7TtNsdMSZNNsrazSaVppFt4ljDyNjLsABljgZJ54qhd+FPDt5cXdxd6DpM892oS4kls42aZQVYByRlhlVOD3Uego5dLD5tbnkmtfFrW/DLeKNPubHT7yfSRYrazRI0SYuFB/ehnOduQMhlBPpnj0P4e634j1SXVbfxVp1rZy2zxtbvDJGGmicHBaJJpdh+Xu5Bzx0NdA+g6Q8t5K+lWDS3iLHcubdCZ1UYVXOPmAAAAOcUujaHpOhxSRaJpdjp0cjbnS0t0hDHpkhQMmhJiujyjWvH2tprmr6D4ltE0a3uRdw6ejafJKL2NY2wy3IlCq3QkGPgEc85HE/DH4gagPhpqOk2sVvbW+h+H5boLP50dxeOWk+eJ43UrGpwCwO7PQjt9B23hTw7a3s15a6BpMN3MHWWeOzjV5A33gzAZOe+etKfCnh0xwxnQdJKQwtbxr9jjwkTZ3RqMcKcnIHByaLMd0eOy/FHxJa6ddrYRaSsWm+GrPV/9JinmeR5FTchYy5x8x+YknjnJOa9h8N+IrLWbLTj9otk1K6sYr9rITKZY43UHdt67cnGcYqQ+GtCKyqdF0wrLbrayD7LHh4VxtjPHKDAwvQYqLR/C+m6Rreo6pZxlbi9jhgK4UJDFEu1I4wANq9Tj1P0AEmJtM26KKKoRnfCz/kVZ/wDsL6r/AOnC4oo+Fn/Iqz/9hfVf/ThcUVzM3QfFL/kVYP8AsL6V/wCnC3rRrO+KX/IrW/8A2F9K/wDThb1pGtaZFQSiiitDMK8x/aV/5In4j/7dv/SmKvTq8y/aV/5In4j/AO3b/wBKYqUthrc+Fa+iv2TdV1C5vNd0+4v7uWwtrENBbPMzRREuSSqE4XOT0HevnWu68O/Fjxr4c0a20nRta+zWFuCIovssD7csWPLISeSeprwM8wNXH4OWHopXdtZNq3nonr06b7nXSkoyuzha91/Y8/5KZqf/AGCJf/R0NeR+K/E2r+LNVOpeILv7XelFj8zy0j+UdBhQB39K9c/Y8/5KZqf/AGCJf/R0NetRc2k6iSfWzuvvsr/cjKezsfSXxf8A7V/4Vtrv/CPfbv7V8lfs/wBh3+du3rnZs+bOM9K8i8Q2XjaFPGK6dJ4uIh0+wudO2TXTk3J8vzghyS3V8pyBzwMDHsvxP8Q3fhXwFrGt6dHBJd2cQeNJ1LISWUcgEHv6iseP4naRZ/2kdfurS0i06CzkneITyOrXCBgGQRYAyeNrvx129K6Ha5krnm/jO68dRnx4kEfig3F/ZabNpX2KK4ZI3Hl+esZQYjbO7I4J5rqNB/tb/hNNT/4TL/hJ9u+2/sj7J9s+y7dgz5nkfLndjd5vHXtmu0PxF8LLaajcS6mYRp8yW9zHNbTRypI4yiiJkDsW5xgHODjpXQaRqUGq2n2i1S7jj3FcXVpLbPkf7Eqq2PfGKLBc8J8MHx0NQ0I3cniWLXRdXn9uvcRzSWSwc+WYlP7liONoi5JzmoNFvfGmlaZ4hjl0jXvEk0diXi1A3Op2ZndplygglKlXVSWzCB8q4B+Y16NofxU0u91XxTbanbzaXaaFLse7njl8t17liYwI2zgBCSWzxmtGT4neEYdOvL641R4IbMxCdZrSeOVPMx5ZMbIH2tkYYDHvSsu4XfY8L1Cx8aalo/iOwurXxBqFit9plxZCazu+OSZfLE5eXap65Y9M8ZxXq/7Q+h3et+BIl060vbue2voJjDaGQuUDYY7EOWIHPQkdRXRn4ieFlstXupdU8iPSZFivVnt5YniZvujYyhm3dsA57VXHxP8ACX+kCTUpoXt7mG0mjmsbiJ0lmDGNSrRgjIRu2BjnGRRZBd9jz7WI/Ec+s+LIdH1LxRpmjyabZLp1zLa31yUbK7wqFTJvIyGONwzk1myy+MbnwdERFrWlXNvqDt5Q/ta4GpxqgGd3NxboT0BKg5z2NewT+PfDUCam0upgf2bdLZXC+TIWE7fdjRduZGPYIGrR8OeItL8SW1xNo9yZhbzNbzpJE8UkUi9UdHAZT7ECnYLniV1d+NYrqG5k03xNY2954TuYIrSCa6vPIv8AfIUZm+ZlkK7SGY5GQM8VnmDx7cxaRHrGo+J9MsjokRjuLayvLqZboHL+YkMit5n/AF1DLjt3r2jU/iH4X0xdba+1Tyl0SSKK/wD9HlbyWl+4OFO7P+znHfFOm+IHhmFbsy6kVNrfrpkqfZ5d4uW+6gXbls9iAQeuaVl3C77CeDPEq6rcXOjvHfS3+lW9st7dzQpEjzSRBiu0OSH5yy9FPGTXl3jX/hOP7e8T/Yv+Ej/tj7da/wDCP/ZPN+w+Ru/eeZt/c9M7vN5zjHGa9JsvHPg6FDLZ3kMQvNXOmM0dpIvm3xABVsJycbRvPHA54rL8DfERtT8N3up+ILeVDDqVzZp/Zun3FwAkZGGcIHIOD1OBT3FsZ/gbR9fvPiV4o1HW9T8RwWNjff6BaNM62dwjRspwrD5lB5G0gA4Ncn8SNP1eL4j+ML+wsvEgmuNFhh0250uG5Ae5BBAMkQxgYOQx24684r0LxX4/Sz8KaT4t8PTWeoeG3uo0vpCjbxC7+XvQ5G1lcgFWU/hivQKLXHex89eIx4/WXVRqR8RnVRpliNFOk+abf7TtT7R5vl/u8793+t425x2qhrXhfV4td+JbX2m63NfarpMLWj2y3MsFxN9n/fKSuUOGyFV/u8BAOK+lKKOUOY8Z+Fdl4h0nxrpNnPHrSaE/hS1eWO7MzQRXgKKUXf8ALG4XOUGPpW4xWD9odDflc3Xh7y9PLcDKzFpUHq2MN9K9KqreadY3txaz3lnbXE9q/mW8ksSu0Lf3kJGVPuKdhXPB/DUPj1tb+06tqmu2+uR3k6tZLp1zLZzoQdh80y/ZljHGCqhgeu6s7whrmsaZ438Ex67f+JYroWeoXWuQajNcCNmRJCrBHPllBgYKDb0719J1iWHhLw3p63K2Hh/SLVbmMwziGyjTzYz1VsL8ynuDxS5R3KR1q98Q/Di41jw3a3Vrf3mnyzWEN2irIHKN5RIBK8naRz0IzXg1nqPi8azZ6doV74k/t5vDEs91a6lNcZ+2biGdUmO32UqNucY5zX079nh+zfZ/Kj+z7PL8raNu3GNuOmMcYrP0bw5omhvI2iaPpunNIMObS1SEsPfaBmhq4k7HgrQeMovBHiCSw1Xxdc6lLpkBFo2m3sLwXAmjDGOWWV2Zyu/Ii+QjJ44Bt6xH8Q7J/Fdv4dOvSI+m2M0BuGllIkIXzxC0h4fBbKqR3wAQK+g6KOUfMfOeq2njBdAkXRdZ8YXPn6rYttGnXlrJaRlZBKFaeSSR14UtnKA45OcC18TbTxXpRl0jw+fFk5stPElrqwmvrqW8lMpYxnyXWFWAZvmkRsqoGPu19BUUcocx83eKbLxgZfGuqafZa5Fqt1omlCK4tIJUkeYNF5qoUAO4DduA6DOa6u6N5e/FG0XPi/TdNsfLeWRRqMkOo3JAwmFzEkKnG44API6ZNezUUcornzz4Tg+IBu1utR1TXofEkcl2ktjJp1xJZzEqxjYzNL9mCAhdpjUNk4IbrR8OtO1mf4i+C9S1Oy8SvdxaddJqlzqcVzsjuG3fKrSDYqkEYCYX8c19DUUco+Y8Q+JWh6vefFXVtQ0611hUj8HzLb3dj5sebpZHZI1kTGWzg7M8+hFUNKsvHWvTta3d14isXm8Gx7ZmeaBE1BZVIyeAJSBhv4ipOeCa9+oo5RXPneOT4max4I17Xlj1ux1OVrSzi04iRJI4Y1Xz5Y4yV+Z2OcjDYBANWbiz8Tjw7fR2HifxIym+hmiW40TU4wV2OXgDhpLkITsy2QBjAJzx7/S9qOUfMebfDbxZcNBoehaxoeq2Gs3kE940U08lz5EKvgPK8zmVdxIAU5I6cCs34n6fr+q+NXsLFdXfR7jw7eI627ypbtcHd5YYqQu48DB6jjoa9UFnbC9a8FvCLxoxCZ9g8woCSFLddoJJx0yTU1Owrnzv4Ys9a0/w14EtJLfxZbaBEZV1yG2S9S5Sfyx5YAH7wQ5x/qfkznvmmeKND1aTxP4v1Pw5a+KI4x4fgGnXC/bI5pJVdflLNiR2AzlWyfUdK+i6KXKPmPnHxXJ8QZtM8Ty2o8Ti5fRtKa3Fus6kXBaIz+WF6P8Af3Beeuau+Io/H1jL8QbTw+fEMlv5NhJZPI0sr5ZVNx9nd8/Ny2VU8dgCBX0DVfULK01KzltNRtYLu0lGJIZ4xIjjrgqeDRyhzHk/wd1Ge7+I/ju1gvdauNGs1sltotUmuHeFjGS+VmO5WLAk5x+WKw/E3/Cdf8JJrn2b/hIP7b/teD+xvI87+z/sWTnzNv7np97f82cYr27SNH0zRbY2+j6dZ6fAW3GK1gWJSfXCgDNXqLaCvqeU/CvR9em8VeKNW8Q6l4kSO31i7hsbG6mcWsluxG11RhlgP4SDtHYda5jxz4X1G58efEW8ttP1eWK48OFLZozO0c8xTb5agHa5wThOcHkAHmvfaKfKFz5xuF8Z6Tpdza28HiZI5vCFnFYR2kVwyw3aJGHXCD91Jw3XB7d8Ve1t/GNvqXh+5gXXtZ/4l9lFPpONRsjHKUUyObiPETNnO7zGOCSMcYr6Aopco7nzZbaP4q0m41TUNJtPEFtdS+O2cpCkyxzWTklpGjHyvGcL85BHoea0LSDxrc6lYQ3TeKFtZPGN2sxD3Cf6DtTZlgQRD97ByF64r6Doo5Q5j5504+Nl0TRrfV/+Ep/siHxDcx3zRC5N4bQBTD8yfvmjyXyy57c8Ctz4IeNmfSrHTdRl1XVL7VdTvhaySS+cYoItvMjSPuCjOB154r1vWdF0vXIEg1rTbLUYEbesd3Asyq2MZAYEA4J596dZaRptgYDY6fZ2xgiNvEYYVTy4yQSi4HC5AOBxkUWsxXPNfjb/AMJAl3pdxoNzqc0dvHI8mlWkF8q3bdBm4tRlG64DMFzgnjJrkPEll8Q59XGl6OPEFhba7p1rcmQXc0y6XLDG5eHziflZmVATnLbuc19DUUOIJnz3bS/EHUvD41zUI/ENpFqGuQC/sIRMlxb2EaBWMMY+dAzbifLAY4BGeaSbTvFWoDw411Z6xc6bbeNYp7A3cUr3MViCcPLuG9VHYyc+vavoWijlHzHzRpumeNNO0SwgtrfV9O0iTX7+TUTBaXDTbG2+S5jheOZoydxyjD1Oeh17bTvF0mraDZS6p4uv9Mj0y/El20NzYtI43+SZAHLBs427yHIxkV9AUUcocxx/wfl1ib4baG/iYXg1fymWcXiMs3DsF3huc7QvJ5PWuwooqkSFLikooAU0lFFABRRRQAUUUUAZ3ws/5FWf/sL6r/6cLiij4Wf8irP/ANhfVf8A04XFFczN1sHxS/5FWD/sL6V/6cLetGs74pf8irB/2F9K/wDThb1o1rT2IqBRRRWhmFYXjjwxZeMvC17oOqS3EVnd7N727Ksg2OrjBYEdVHbpW7RQB4X/AMMx+DP+gn4h/wDAiH/41R/wzH4M/wCgn4h/8CIf/jVe6UVPKh8zPC/+GY/Bn/QT8Q/+BEP/AMarrPht8HvD/wAPtdn1XRbzVZ7ia2a1ZbuWNkCllYkBUU5yg7+tekUU+VBzM5/x/wCHP+Eu8HanoX2r7J9tjCef5fmbMMDnbkZ6eoryv4kfCbVJ9F8TTaDN/ad9qq6bEtptSHyxbKqlt7Pg5AzjjHTmvdO/AJ7cV5z8QvjD4a8GXJsWMmraspw9pZOp8n/ro54U+3JpSt1HG/Qr3fwta/k8RXmrX2l6lqWuSwNObrTXNvHHEpVFSNZ1YN0+ff26cmtLwj8MdI0jw/DpuuxW3iJ4ppJYZdQtllEAfGY4hIXKJ8o43HnJJry+b9ozVJn/ANB8M6fEn/Te7d2/8dUCrth8ftUdx9t8N6fJH3+z3bq34blIrJ1qa3ZapTZ1+s/CVNUfxjBNq+3TPEkkdxLCLb97BNGQVZZN+CuRypTkdx1qj4i+Dlx4jt9Zl1fxEjarqMdtB9ohsNkUccJBA8syElmIyTu+grpdC+K/g7VltIm1aLT7+fCmzvcxvG5/hZvu89jnBzXdMCrEMMEdRWi5ZbEPmjueReMvhW16/jHU4ry7uLnWZ7K5gt7WCPfBJb5A5klVXB3EkEpwOCTWLpnwt13xGfFN94lmTSb7UtTtL61IiR9rW4cAvGkrABt5G0SEj1r3ainyoXMzyLUPgwmp2utf2jrSS3l/qyaxG4sR5UUqqw2NEzsJEIY8Ej6+vUaJ8PNHgs5odb0jw1fB5fNSK30SK3hi+UL8qEuSTjklj+A4rtaKdkF2eReLfg22tTeKk0/XYtPsPEBtXmtzYeaYWg+7sYSKNp54x6YPFa958LbW5+J9v4tOoOsCGKeXTvK+SW5jRkjm3buCobpg8jrzXo1FHKguzyMfB2VL6Iw+IEXTYfEY8RR25scyB8jdEZPM5XAGDtyPemP8GX+w2VsNejlit9TudRe3urDzbafztuFki8wbim3IJOOTxXr9FHKguzxy9+G2p6d8LNJ+H+nSf2ja3F6pv9RKrCILcTecx2FyxYkBQBnuTivY6KKErBe4UUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFZmt+INF0Hyf7c1fTtN87d5X2y5SHzNuM7dxGcZGceorTrCH/JVNB/7A2pf+j7GlJ2VxpXdir/wsHwZ/0N3h7/wZQ/8AxVH/AAsHwZ/0N3h7/wAGUP8A8VXolFZ+0Zfszzv/AIWD4M/6G7w9/wCDKH/4qj/hYPgz/obvD3/gyh/+Kr0Sij2j7B7M87/4WD4M/wChu8Pf+DKH/wCKo/4WD4M/6G7w9/4Mof8A4qvRMUUe0D2Z53/wsHwZ/wBDd4e/8GUP/wAVR/wsHwZ/0N3h7/wZQ/8AxVeh1yXxB+IPh/wFp/2jXrsLM4zDZxYeef8A3U9Pc4A9aPaMPZmT/wALB8Gf9Dd4e/8ABlD/APFUf8LB8Gf9Dd4e/wDBlD/8VXlOoftN3MrkaR4WjVOzXl5yfwRT/OmWv7RfiB2Bl0DSWTuFuJFP/oJqHXS3KVFvY9Z/4WD4M/6G7w9/4Mof/iqP+Fg+DP8AobvD3/gyh/8AiqxfC/x38NX1s58Sb9AuVxtWYmWOYf7DKOo7ggEda9S0rUrLVtPgvtMuYbuznXfFNC4ZXHsRVKtzaoTpW3OH/wCFg+DP+hu8Pf8Agyh/+Ko/4WD4M/6G7w9/4Mof/iq9DpcU/aC9med/8LB8Gf8AQ3eHv/BlD/8AFUf8LB8Gf9Dd4e/8GUP/AMVXolGKPaMPZo87/wCFg+DP+hu8Pf8Agyh/+Ko/4WD4M/6G7w9/4Mof/iq9Eoo9ow9med/8LB8Gf9Dd4e/8GUP/AMVR/wALB8Gf9Dd4e/8ABlD/APFV6JiuU+E//JLPBv8A2BbP/wBEJR7Rh7Mxv+Fg+DP+ht8Pf+DKH/4ql/4WD4M/6G7w9/4Mof8A4qvQ8UYo9ow9med/8LB8Gf8AQ3eHv/BlD/8AFUf8LB8Gf9Dd4e/8GUP/AMVXomKMUe0D2aPO/wDhYPgz/obvD3/gyh/+Ko/4WD4M/wChu8Pf+DKH/wCKr0Sij2jD2Z53/wALB8Gf9Dd4e/8ABlD/APFUf8LB8Gf9Dd4e/wDBlD/8VXomKKPaMPZo87/4WD4M/wChu8Pf+DKH/wCKo/4WD4M/6G7w9/4Mof8A4qvRKKPaPsHszzv/AIWD4M/6G7w9/wCDKH/4qj/hYPgz/obvD3/gyh/+Kr0PFFHtGHszz3/hYPgz/obvD3/gyh/+KpP+Fg+DP+hu8Pf+DKH/AOKr0SjFHtGHszzv/hYPgz/obvD3/gyh/wDiqP8AhYPgz/obvD3/AIMof/iq9EoxR7Rh7NHnf/CwfBn/AEN3h7/wZQ//ABVH/CwfBn/Q3eHv/BlD/wDFV6JijFHtGHszjPhHcQ3fgxrm0mjnt5tU1SSOWNgyupv7ghlI4IIOciirPw0/5Fy8/wCwzq3/AKcbiiszQj+KX/Iqwf8AYX0r/wBOFvWjWd8Uv+RVg/7C+lf+nC3rRrWnsZ1BTSUUVoZhRRRQAUUUUAFL60lKOvNAHh37SHxNu/C0UHhvw/K0Gq3sHnXF2pw1vCSQAno7YPzdh05OR8t2/X3JyT3J9a9Z+Mmn3HjD9pF9AicRNLJa2KSHnYnlhmb8ixxXe3H7Ofh8JstPEerxT9mliicEfTA/nXHVmk9Tppx00Pn227Vt2fUAda9wg/Z50NbMxz+Idae5J/10SxxgD02YOfrmtOw+CvhbTAsmoXWq6kM42SyiJGHoyoASPxrknaWzOiF72sfPOoQtJctdPButDA0CTMMpI4ILqp6ZUMMj3r6E/Zt8cy+IdDufD2pyvLqOjorRTOctNak4XJ7sh+XPcba3viP4JtPFPgF9K0W0t7W6sgbjTI4lEaJKo5TA4w65U/UGvA/2ZLxrf4yW0JDL9qs7mB1PbC7sH6FK3w2j0Mq2q1PsKilNJXoHGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAKwx/yVXQf+wNqX/o6xrcFYY/5KroP/YG1L/0dY1M9iobnc0UUVgbBRRRQAUUUUAcP8YvHUfw98E3OseStxds629pCxwrzNnG7/ZABJ+mO9fCGsazqHiDWbnVdau5LvULht0kznn2AHZR0AHAr6T/bXvTHoPhez/gkupp2HuiAD/0M1keFv2fdHufDGm3uta1qcWoXdsk7pbiPy4i43AAEZOAR1qJyUVqVFX2PB7XtWzadq90039nfRYnY3viLVbqMg7Vhijhx6HPNX7D4C+HrMsbnWdcu4gc7N8cR/wC+gpNcs2pbM2joeD6hDJdW0cUMXmrHIs9wQMiGIEDe47LkgZPc16D+z54+fw347XQLx2/sfWptiITxBdH7rgdg/wB0477T617joXhbw1Y6HeaNY6XFHYXkbRXYOWknVhg75D8zHn147V8f+MtJvPAnxAOn3TlptNvIpoZgf9ZFvDRv9SuM+4NVQVnYVW/VH6GDpS01GDorL91hkU6uswCiiigAooooAK5X4T/8ks8G/wDYFs//AEQldVXK/Cf/AJJZ4N/7Atn/AOiEoA6qiiigAooooAKKR2CqWYgAckntQjB1DKQykZBHQ0ALRRRQAU0sFBLEADqTVLV9UttKtTPePgE7UVRlpG7Ko7mqFraXmqsLjVgYLfrHZq3b1c9z7VLl0RrGndc0tF/WxopfLOxFoplA6uPuj8e9W03bfnIJ9qI0VFCooVR0AGAKdTREmugUUUUyQooooAKKKKAOV+Gn/IuXn/Ya1b/043FFHw0/5Fy8/wCw1q3/AKcbiigCP4pf8irB/wBhfSv/AE4W9aNZ3xS/5FWD/sL6V/6cLetGtaexnUCiiitDMKKKKACiiigBaKSj2oA+W/Ewaz/bEsZGRj517auo9Q0IXP0r3/Wb3T7O7UXd7HHMV3+UAzvt9dqgkD3NcJq9kk3xIXU5IU/taLxHb2cJaIFvs4iB3BuoUI2BzgkkYzyOp8Z6TrWqFU0PXZ9CBx5kttEpllIPBZupAHG3pzXnVWnM76HMvh3NPTNb06/1N7a0v/MuUQM1u8bowHrhgKNT1nTrK8S01W6jimmGYIgrM7j6KDTfC9nqdjZrBq2pzau6LxdXMSrJnnPK9Qc/hiqWtwapqN1qtppmqz6W6eUPPt4keRQyZGC3QZBPv7VjZXL95O3U2tE1PTbq4jgsrpHkyGEbKyOR6hWAJH0r5T+A0Xk/tDW8ODmGa/Uj0wsnWvpDwTo+taXIset67c62mdyy3cSiSNieSrDkDHGK4rwNpNrZ+PbTVobRU1m/1fUYr0bAPKUBjuB/uldp9M/jW1FpSsZVk7e8e1mko6UV6JxBRRRQAUUUUAcH8XPiGnw90qyuE019UvLuVkjtEl8slEQs752twoAzx3rJ8Z/GGy8N2/hG9TTZL7Tdeha4eeKbDW0SiMs2zad+A5JGRjafw2PEvw7tvE3ji113Wb+4eytLJ7WCxt2ktyrOfnkMqOGOVJUqAARjOec4fh74QLpj+Gor3WRqGn6J/aEcdtJaY82C6Tb5bNvP3ctzjkHGBipdylYZqnxiW30/Ubqx0aK7W21uPR4T9u2pOJE3LNuEZwOnAB69a6zwv4wk1LxNqfhzWNOXTtbsY1uDHFcefFNCxwHR9qnrgEFQRnvXCW3wLSw8MXGjadr5jjbWY9Wgeaz8zyxGpVYmAkG7t82R06V3nhfwhJpviTU/EWsaguo63fRrbmSK38iKGFeRGibmPXkksScdqFcTsYHxN+LFp4F8R6VpcunSXq3CCe9mSXYLKAyLGJCNp3ck8Er0AzzV/wAZ+M9Y8PeIdG0630TTryDWLn7NZztqbxHdtDEyKIGCjqBgtn26Vma98IbPxDrHivUtb1W6nn1mFLe2ERkhWzRR8oKrJiUbgrYYYyvTmtOTwDcXEHgcXutefP4akEjSm2wbvCbBkb/lOAMn5s0ahoX/AIheLZ/BXgC68RXenR3NzbLD5lpFckJud1QhZCmSAW6lRnHQVV+JXjz/AIQvQ9H1D7DBc/2jexWf7+7+zxw71Zt7Psb5Rt546c9qv/Ezwn/wm/grUPD/ANt+w/azGfP8rzduyRX+7uGc7cde9YXirwJrnibS9JttQ8Qaak+l6jBqFtJBpTqpMSsNrqbgk5LA5BHQ+uQO/QFbqO134kLovgGTxE8Gl6lO1ytpa22kan9qjuJGIAUS+WvzfeJG0/d96oT/ABgsE8CeHfEK2SLJrFyLMQz3QiitpQWDebMV+VRtPO3JHOK0vEXgK/8AFeo+H5/E+uQyW2lXD3Jg061lszM5UCM7/PZkKEE5U5Oe3Wqmi/DGfQrLWNP0vWLaXSL69a7Sw1LT/tkSbhhkctJuccAg5U9c7s0aj0Leq+OdVs/Bl74ittI0e9tbJHkla31nfHIiqDmJ1hO7kkYYJ075rpPCGr3+s6BbapqljaWCXUKXEKQXbT/u2QMC5aNNp56DI965PTPhZb6f4I8UaDDfxxya88ksskFqI4LcuAMRQhvlUAdN2feu40HTBpXh/TtLaQTraWsdsXK7RIEQLnGTjOOmTTVxOx56nxYc+HY/FL6EU8ISXn2Vb37XmfZ5nl+cYdmAm7j7+72qnqXxstdO8ReKdIvNIaKTSIp2tZWucJfPEgdowdnyNtIP8X8s3F+E0g8Ox+FX10t4QjvPtK2X2T/SNnmeZ5Jm34KbufubveovEvwZsfEFj4ohvNRxPq9+uoW8623zWbhdpH3vnBGQfu9fYGp94fujbj4vbNfstM+xaLZfadIg1X7Rq2s/ZIh5mP3QPktuYZ9sgE8Yr1W2kMtvFI2zc6hj5b71yR2bAyPfArznT/hzqej+J7TXNF1+yjuIdGh0Zo7vTWmVlj2neNs6EElRxzjnrXpEQcRIJmVpAo3Mq7QT3IGTge2TVK/UTt0HCsMf8lV0H/sDal/6Osa3BWGP+Sq6D/2BtS/9HWNKew4bnc0UUVgbBRRRQAUUUUAfM/7bkROh+FpsfKtxcIW9yi4H6GvTNKvbY+B9Au76dLRJLG2H7zgljEuFA6k8dBVL41Wdrqeo6bZ6zGp0tLG8ugzRCTMiIBt2nqxDYGOeTgirNpDqlz4D0RLedNP1M2UGZ1jWQw/IMhM9CVwN3UVz1ndpGtK6d47ko8RaRE1tbvqTQyPJsTzIJEV29MlcdxWnrWo22lQfaNSnjt7LIVnkz1J4HGTmuc8KaJr+lSt/aXijUNdhYjMV7FHtUexHOc9/at3W3uftWnRWcoikm8/5ygfBCAg7Twcc1i0rmz57+9a5Daa7oiyDZerEXIUGaN41yeR8zKB3HevmL9qeIx/FeMlWHnWFqw/2sFhx+Ve+6Z4d8S2mrtcXXi7U9StHf57K+t43iKZztx0/HtXPfFfR7PUfE9zdajaK8unaGJ7EFciRvOO9Oe6/KV75PHetKdoyM6ilb3j6AtRi2hBBBCDr9KlqG0aV7WFrhQkxRS6js2OR+dTV1GAUUUUAFFFFABXK/Cf/AJJZ4N/7Atn/AOiErqq5X4T/APJLPBv/AGBbP/0QlAHVUUUhoAz7yWSe6Wyt3ZOA80i9UXsB7nB+gB9q5vQrWaw1bUNOvp75Szma2n3nFxHjON3PzL0xxxziuk0ld/2q5PLTTNg+ir8oH6H86nvrY3MaBJDFJGwdHAzgjI5HcYJFAGFY+ddzRQXsc82LcXCh5AYsk8BsAE9O+azNU07XrC90xtIknkjKv5+1wUVuoG08bSfT9K6vTbh5XmhnjSOeAhWCHKsCMgj268VePNAGVpV5fMsEGrWscF48ZdvJk3xkjGQO46jrSeI9bttCsPtFzvkkdvLggj5eeQ9EUf5xUcklxb6nLeXcDfZNnlIUG5owDkuQOzfpgUNpGnz65Hr8kpmlSHy4S8mYogerKOgJ6E1Mr20NKPJzXqbfn5FTQNHuZLoax4hKyao4/dwrzHaKf4V9T6tXTUyOWOVd0bq49VOafmmlYKlSVSV3/wAMFFGc0UzMKKKKACiiigAooooA5X4af8i5ef8AYa1b/wBONxRR8NP+RcvP+w1q3/pxuKKAI/il/wAirB/2F9K/9OFvWjWd8Uv+RVg/7C+lf+nC3rRrWnsZ1AooorQzCiiigAooooAKXtSUUAec+PbJ9M13+2ts7wTvayLJGm5YLmKRUG/HIR4z34yvbNdBdMxmkDE/KxFbmrWEeq6XeafMSqXUTRFh/DkcN+Bwfwrm/DU39r2EE8zqLpGaC7RSCUnjbZIP++hn6MK4cRDlfMehgqkVdSNCG5uku4IPsUklpJGCblXUCNs8hgTk9sYz39KjBul8QXkiW00do1uqySs6lHdT8pTByDgsCCOmDXjviy/8c3Gu3j3cPk6bbMyR/wBjqt48QB4yhZSD3OeaZ4WvfHdtrdrPaxiTTpnVGOrILN5lPX5dzHPpiuble51/V09b672t/T/A9khuH+0KWYkbgcE8YrnPhrpzXt3DrrLOsS27nfLGU+0XMzkySLnkqqhUHQZJxnrWh4nd7K0aK2kVLq9nSxs95xmaU4H5Dc3/AAGuxsraKxsra0tyTBbRLDHnrtUADPvxXVh4XfMcmNnHRRJqSlpK7TzwooooAKKKKAPMfF93d3/xh0Hw3d397Y6HNpst2Ftbl7Zru4D48vzEIb5Vw2AR15rzLUfEfiG70/SNPtdVv7m1Txk+lW10NQkt2vrYHASSeP5iMnG8AnvyRX0ZrGjaZrVusGs6dZahCp3CO6gWVQfXDAimnQdIMFjAdKsDDYuJbSP7Om23cdGjGMIR6jFS0NMqeH9Klh8PPY6jHLbvLvV1j1e5u2UNxlbiTbIDj0xt7HvXk+gx3CH4qzHVtdd9EM8en+Zq904hH2dj0aQhiDyC2SDgjkCvdKoppGmxi+CafZqL8k3eIFH2gkYPmcfPxxznim0FzwnRfEPimVPg/wDb7ho7W+kIkmi1KWWS9Hlg/v0KKPf7z81r/A1da1lrrVNRlur2CHVLqL7TPr93uRV+6otcGJgMgcsOuccCvXV0PSVSwVdLsQun82YFumLbjH7vj5OOOMVTtPCHhqz1Bb+z8PaPBfKxdbmKyiSQMepDBc55PNLlHc86+Ks+rTfFjwTpGmXFybe8t7tpbNNVnsI5iqbgWkhBYYxkcH06E0o+233xQt/C2uX+oaZplpoou4Le01acG4mL4djckrLKFGeCR0yR1r1afTbGfUba/nsraS+tgywXLxK0kQYYYKxGVyODjrUGtaFpOuRxx63pdhqMcRLRrd26TBCepAYHBosK54JoHizxBf3vw3W51S9e3l1q/s/OWUqL+3j2hGkxgP3GcdvXNd/qupXyftC6JpyXtyunyaJLK9qJWETOJGAYpnBOAOcZrt9S8M6Dqdra22paJpl5b2o2wRXFpHIkI4GEBBC9B09KqTeB/Cc0MEU3hjQpIoFKQo+nxERqWLEKNvA3MTgdyTRZhdHBXVzPrnxH8dWOt61qOl2ei2MEmnxWt69soRoyz3DbCPM2sAPmyozgivPtU8eeJ9J8L+D/ABTf3l+z6zo15p7wrIyx/aVLfZ5/L+7vb5TuAyRX0NeeFfD19Fax3ug6TcR2iCO3SazjcQoOioCPlA9BVvUNH0zUobeHUdOsruK3cSQpPAsgiYcBlBHBHYiizHc+fvhrqfifVPHmkeDNa1bU3m8ONfSanKt3IDdoSoi3vnLAFxjPQfhVa+1HVLP4VfE6+t9b1wXlh4ibT7WZ9TuHeCBbiEBVLOcHDMC3Ug4JNfRKaLpaX13epptkt5eJ5dzOIEEky4xtdsZYYAGD6VnweC/C1vb3FvB4a0SKC4CiaNLCJVlCncoYBcHBAIz0NLlDmPCtO8YeMdO8ZX+i6hNdz6v4e0C8XaXYw3zphobjZn5mKkdeTjrk10/grxFY26eBjf6h4pvdS19Ef7eL9ZLSWbZmSJojIQgUtj5Y1PA5PNexNplg2qLqbWVqdRWPyVuzEvmiPOdgfGduecZxVK08LeH7LUjqNnoWlQagSSbmKzjSXJ6/OBn9admF0Q+DNRvdT0qabUrzRbuZbmSMSaRK0kIUHAViT98fxD1pw/5KroP/AGBtS/8AR1jWnp2nWWmQNDptnbWkLOZGjt4ljUseSxAA5Pc1mD/kqug/9gbUv/R1jRL4QjudzRRRWBsFFFFABRRRQBx3xH0VtStbC8ihluGsZw0sES7nmt3+SVVHXdt+YY5+XA61zPhi6a48K6Qd8hUQbAXBDYVmUA55yAo6816sRmvNRbpYeJ9W0ZpUDs/9pWyk8mGViGGOwWUN+DisasdLnRhpKM9SyJ7u2tRLZ2bXhEih4kYK2w9SCSBkcde2adrf2t201rG0mkuEnSUMroFjB4YSZOSpUtyueQK4P4pTeLor200/w5DZnTmjEshEo+0SNnnEZIyB2wa4OObxo0wfSH1VpYWwz6nYraJER2D+Yc/kawUb6nZ7BVfe5rX8v6/C571dzyfaHCuwA6c9a5S40xvFXjOexMc7CI2kc8wQmKK2AMrrk8bncqBjLYyeBW3pk15caBaahrotILkwGW6Nu5aFQuSXDHHGBk10Xw3tyfDo1OU5l1aQ3+Ou2NgBEv4RhPxzWlKN3cwxDioKPU6tegzS0AYorpOIKKKKACiiigArlfhP/wAks8G/9gWz/wDRCV1Vcr8J/wDklng3/sC2f/ohKAOqoNFFAGfpTbEuLY/fhlYY9mO4H8j+laHas+7tpluRd2e3ztux0fhZF6gZ7Ec4PvQupBRie1uoWHXMRYfmuQaAOS1iTV49SvyhvwXdVijgti4lQdAJM4Qf1zmul0GcbHjuHaO6YiRreQnMeR0GevIPI4yanOqQEYgjuJ27LHE38zgD8awtZu4rO4spNatRPealOtlbW0WCYlOSTu9gMkjpgYpN2V2VCDnLljqzrTz0qmdLsjKZDawlycnK8Z9cdM0mkO7WrJK5kaKRot56sFOAT71epklGTSrKTl7aLPqq7f5UxtPeAbrG5ljYdI5GMkZ9sHkfga0aQjIxQBRs78SSGC5T7Pdj/lmxyGHqp/iH6+tX6hubaG6i8u4iSRPRhmqRt7qx5s3a5h/595W+YD/Zc/yP5igDToqrZ3kV3GzREgqdrowwyH0I7GrQORQAUUUUAFFFFAHK/DT/AJFy8/7DWrf+nG4oo+Gn/IuXn/Ya1b/043FFAEfxS/5FWD/sL6V/6cLetGs74pf8irB/2F9K/wDThb1o1rT2M6gUUUVoZhRRRQAUUUvegBKWsvVPEGl6XdC1u7kG8Iz9mgRppsdvkUEj8cVTOsarecaZocluh6T6rIIR/wB+l3OR9dtRKpGO7KUJPZG9LLFBFJPcyCK3hUySyMcKiKMkk+gArzTRoL3ShDrtjau8mol7q/04EBpRI7Mjx54EwQqCDgOBg4IBrpptFmvyG8Q6jJqESkMLKNBDa5ByNyDJkAwPvsR7VKVkmuy8gyS2a4q1ZT0Wx24aja7l2MDUYPBXiG6Nxeyw2+oABZPNlaznHs6tjJ/P60yxtvB2gXgn00f2hqhBEUdtKbycn/ZAOFPuSAPWul1SyW5UGWKOZR0EiB8fnRpFsLdm8mGOFD1EaBQfwFc9la51c8/Z253bscvrEdziLX9ZCm+064iu4bOBt8dnErDzAD/HKULFn6YGF45PowKOoeJleNhuR1OQynoQe4x3rKmhiil85j8o7EZz9RWNp+mz2YYeHtRexhUkrp9wnn2w9kBIeMeytgdhXTRrKGjOStQ5kpQOuorAXWtUtONU0GaVccz6XILgH38ttsgH4Gr2la7pmq3DW9jdq10oy1tIjRTAeuxgCfwyK7I1Iy2ZxuDW5o0UtJVkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAKwx/wAlV0H/ALA2pf8Ao6xrcFYY/wCSq6D/ANgbUv8A0dY1M9iobnc0UUVgbBRRRQAUVn61rOnaLbCfVLyG1jY4Xe3Ln0UdWPsAawn8Xy3AI0bQ9Rux2muVFpCR67pPmP4KaTaW40rnWE815V4rtv7d8VahqGnTrb3mkiKytbsDcnm/M8sbj+JCGRWHY8jBFblzHrmqDGpauLG3PBt9KUox+sz/ADf98qtQGzitILexsLdYbWEFY41zxk5JOeSSckk8kmsZ1U9Eb0Kd5psyL2/0HXLaG08XWS6fdqciK7YqgbuYZx8rKfqD6gGqJ0DwDYlbi5urWVV5CS35mz7BFJLfTBrrpoVlsXiyjhVO5Mgjp3FcR8NbRFlvXhgijkDr86IAe/cVkoJxcux0wnOK5YzaWptXySeJF+z6hby2Ph0/J9mlXy5r0dt69Y4f9j7zd8Dg9j8Pr4XnhSxRsC4tF+x3EY6xyR/KQR26A/Qg1UurUS8nII68VkTWccmqNdabe3OmXzKFe4tyCs20YAkjYFXwOAeDjvTp1FE55U+aPu79T0aiuNh1rxDY4F3p9tq0I6y2T+TLj1Mch2k/R/wq5a+NNIknjgvXuNMuZDhYtRhaAn6MflP4GumM1LZnO01udNRRRVCCiiigArlfhP8A8ks8G/8AYFs//RCV1Vcr8J/+SWeDf+wLZ/8AohKAOqooooAKMCiigBGHFcVY41r4mX10fmtdDgFrF6efL8zn6hdq/nXY3U6W1tLPKcRxIXY+wGTXK/C2Bx4Ujv5x/pGpzSX8n/bRiV/8dC1nLWSXzOuh7lKdT/t1fPf8E18zf0ttr3sLcOk7MR7N8wP6/pWgKz72KaK5W8tE8xwuySIHG9c5GD6jn65IqW0vYLolY2IkX70bgq6/UH+daHIWnBKkKcEjg+lVNMuHuLf98AJ42McoHTcO/wBDwfxq4elZl5HJaTvfWys6kDz4R/GB/Ev+0B27j8KANOkIBpkEiTRLLEwaNwGVh3BqSgCjfWRllFxasIbxBhXxww/usO4/l2p1hei5EiOpjuIjtliPVT6j1B7GrlUr2zjuGWQu8M6A7ZozhgPT0I9jQBdornbHW28hrqd4p9OEnlLdRZBz03Mvpnjj64xXQRurqGRgynkEHINADqKKKAOV+Gn/ACLl5/2GtW/9ONxRR8NP+RcvP+w1q3/pxuKKAI/il/yKsH/YX0r/ANOFvWl2rN+KX/Iqwf8AYX0r/wBOFvWjWtPYzqBRRRWhmFFFFAFLWdTt9IsGurkSuC6xxwwrukmkY4WNB3Y/4k4ANYjQarqh361fS6fCR8un6bLt2j/prOPmc+oTav1603WpvtHi+CPrHpdqZgPSebKqfwjVsf79KJH/ALxzXFXqyvyxO/DYXnjzssWEdno9u1vplulrEx3MI+rn1ZurH3JJp4vST7VTOScmkNc1jvVCKRtQSlyA3SnOFjUvt5qrYgnFWJ5URSHPWoe5yyjaVkUJb2Qv8uAtXbSbzU7fhVNrUyENEcqaswobd1jCls9WHQU3Y1qKHLaO5PcRedEUJx71XtLRoJN+4Hjp61adtoyaqvfBXwMUlcyhztOMSOG6ka5KkHFN1HTrO+hWLVYlvFRt8ZfIeI/7DghlPuCKuW+yQ7wADVK+Enmjrj2prcuynLl2Kyw6vpQ83SruXVbUfesdQkBkx/0ynPIP+y+QfUVt6RqNvq2nx3lmX8pyVKyIUeN1OGR1P3WUggiqDSNFbAN1NZ/hmU23ijUrQk+XfwLfoOwkQiOT8SPLJ+hrrw9WTfLI5a+HtFzR1dFL9aSu04gooooAKKKKACiiigAooooAKKU0lABRRRQAUUUUAFFFFAAKwx/yVXQf+wNqX/o6xrcFYY/5KroP/YG1L/0dY1M9iobnc0UUVgbDZZEijZ5HVEUFmZjgADqSa4OXWdT8QgSabO2kaK/+rutga6u1/vIrcRIezMCx6gDrWh8SpmbRINMRip1S5S0cqcERctKf++FYfjWTJMzuT90dFVeAo7AVlUm1ojooUHU16DrXT7HTLo3MMby3zDDXlzIZpyP99iSB7Lge1WHvmJJOSfWqLMWPzGiue19WdsaEYo1IbkEFnYBQMknoBUMhe++Y7orY/dA4eUepPYe3U96zQ/n3Qt+sSYaQf3j2X6dz+FXdRv1sWthIpKzSCMuei5/rQ1bbcwnBc2hkaheJY3sbxKsSAMjFRjgqRz681geCryWLS9WaNijs0S716qCTkitPWWhuts1u2VI3fUYrE8Kyi3sNRiZN0twYwq+2eT+FdcFen935ilyrQ7qztIWjGQyv/fVyGH40RQPBdRpPIGVziOUjGT/db3/nSPdfZbB5VVWkVd/lk8lRjdj6CnXN5bTwSJGyzRHhiOh79fyrkvLrsEFJfCXLu4eOZUUEDpUssaTRMtziW2kXa8Eih42+qng1U0i7W+g2zYaeFtjMereh/EVYvw3ljZ09qlqzsNa2jaxnwaVLYBW8N6lcaeU+7azMZ7Qj0MbHcgP+wwx6Guj8M+IDqU1xY6hamx1a2VWlg3b0dCSBJE/8aEgjoCCMECsayZ1Us/QVlXN21jrekaqpwIrgW0xzgeTMQhz7B/Lb8K2pzd7MznQsm49D0+ikXgUtdJyhXK/Cf/klng3/ALAtn/6ISuqrlfhP/wAks8G/9gWz/wDRCUAdVRRRQAUUUhP1oA5f4n3T23gPWDCxEssXkIR6yEIP/Qq39LtVsdNtLVAAsEKRAeygD+leefGXWm0+ysrO6s5WtJrmGcTxkEHy3DNGR2Jxx2r0HSbie7sIbi6tjayyLv8AJZssgPQH3x1rKMk6jO6rSlDCQk9m2/y/4JcqnqFmLpQyHy7iPmKYdUP9R6jvVykyK1OEqadd/aUZZV8u5iO2WP8Aun1HqD1Bq2T6VSvbL7QVlhkMF0gISVRzj0I7r7UWV40kjW90giuoxllzww/vKe4/l3oAjtf9C1B7XpBPmSH/AGW6sv8A7MPqa0gQaqX1ut5BsDlHBDpIvJRh0IrPj1eWzu0tdaiSDzG2w3SH91IewOeVb2PHoaANuszVX+0f8S+Ll7hT5h/uR9Cfqeg/+tU+q3bWdjNNHH5sqjEcecGRz0UfU1g2GpMsbxuoXWruTbhvu7gOQPZBzg8/XNAEtlpYGuRm2lIsrFdm0jlm24Cbv4lUHvyCRzWqdLhDlrd5rYnkiF9qk/7vIqxZ2y2lvHDGSQo5ZuSxPUn3JyasUAZ4t7+Mny71ZB2WaIfqQRSebqEePMtIph3MMuP0Yf1rRooA5P4YMW8M3LFWUnWNVJVuo/4mFxwaKd8NP+RcvP8AsM6t/wCnG4ooAj+KX/Iqwf8AYX0r/wBOFvWjWd8Uv+RVg/7C+lf+nC3rRrWnsZ1AopaStDMKX+dJSigDiLdvO1vxDcH7zagYc/7McaKv8z+dWxzUNrCRqXiFQPu6nI2PUNHG39auwwNu5HFeZUfvM9yhJKkiQWZZAVyDRHaNu5p2lXMz6prNlOwK2jwmIBcYSSPdz68hqvwmXDecoBzxjuKyuzL28tRqBYVG44qtdRrccxsMj1ov0ck46VXtEffnGKEuo4Rsue+pdiUWtuS5qaGVZk3KePSm3IX7M3mAkY5wOaiihPlxtAxVc5OR1pGekld7k8jIcoxAas6WzbzOPWrU9o0lwHDcCrWQiAk4A7mi9thxnyfCyC0QRj7wJ9B2qZlB4YA02JI13NFj5upFUdQu5Yda0W0hYBLpp2mBXOUSPI57fMVo3M5PW4mp5DqD93FZJPl+I/D8+etxLbH3EkLf1UGulniWQfN2rGvUiOt+GkiOc3csv/fEDn+ta0X7yRpOovYuJ1JpKU0leoeUFFFFAC0lFFABRRRQAUUUUAFFFLQAlFLSUAFFFFABRRRQACsMf8lV0H/sDal/6Osa3BWGP+Sq6D/2BtS/9HWNTPYqG53NFFFYGxwfjdhL4s0iI/8ALvaXFwPqxRP5E1TrQ8YRD/hLNMfHzTWNxGD/ALrxNVQQuWxiuaq/ePSwskqZJb2/mrnHNBtSmWf7igsfoKa9xLaavotuCBb3f2hJQRyWWMMgB7dG+tT67NLDpl4ygbDDgE8HLcf1rNXbS7kuu03YzNDXdE08nWRi5P1pnieVpLFoQFaJxgYUlw+flxzjr60WMsZtkQOI3Axtfg1DLe28Ubu93AgHdmBAI9qpp897BSipK7ZyGppq9k9npzmB5ZlJxEPmxnkE/wBalv4J9CnsrqBhcwsu+UKMYB6j/wCvVrSplufEEt7czb0KFbeSQbdyA4Ygema6G6gjfTbC5U7Qp8py44G4cfhxXW5uNk0YySk22R6jq2mSaAbhLuPzduYB/Hv/ALuPccEVDpEV3cadayj7KtpHF5YjiYlgf9odj7VFqGjw6N5eq2kabYyFniYZAUn7yehFakc+jJMZ4ZoXuZecoDluOuPWuZ25fc1NYPl1T1INFc22uKjHCzDyz9eoP9PxrrzzwRkelcPMyC5lnGDJFt2+v3hXTeKr6TTfD+p3tuwWeKImEkZG8kBeO/JFTVV7MxlK7uye/XbbYQYrmvEMPn+H9SjzjFu759Co3g/morrpI+DG/wAxHBPv3rC8SrHB4b1pkILpZyjHplSP61EWbQqJQaZ3+nz/AGqxt7jGPNjWTHpkA1Yqvp8P2ext4P8AnlGqfkAKsV3HAFcr8J/+SWeDf+wLZ/8AohK6quV+E/8AySzwb/2BbP8A9EJQB1JOKbJIkaM8rKiLyWY4A+tcB8cfFt34R8Dy3GlOseqXcgtbaRgD5RYEtJtPXaoJA9cV4t8M/HNjraweHvF11eDWpGaGxurqdpbYswOG+YnEhY5y+cngYGBUSmloVGLZ7l4n8aT2X2ubRYLe9s9PCm7lZziRyR+5iI4LgHJPIHAwSeOWv/Ffj238WNpUFlZMLq2e8tna3Z4otpwIGkVhuOCCW474B4rY0DSNQtJVnuLq5SF7JIzZyYVYbhWO50RQFAIwcjvzWjBJdpLskLlM/MCeKwdV9DejTTTb1JvOGu3tppPiTTIY3Ure27wz+bHJJEw3LyAQRkHB6gn0NdLqupWek2bXeoXCQQKQCzdyegAHJJ9BzXG3LX1xqmnXWmNaK1m0pYXO7Dhk2gDbz6mpJI7ltQTU9auYri5hBFtDAhWG3zwWXPzM5HG44wMgAZNUqqSu9yZQndQ6Fq78S6jeSCPTLP7BCePtWooQ5/3IQd3ocsV+hpi2+psMzeIb92PUpFDGPwG0/wAzRDdR3EmGj+YdCecUsCNDIZZJf3bHAz3rOVST8i/YpKz3KE8DzXflXmp6xcL93Z9o8pT9RGFJ/Op4NE0uFjJa2yxTjpOCWkX8WJJ9x3q/IrZDQhfMPdvSnup2YQKGx+Gahzb6iajpZDLC8hkuBa3tvDFcE4V1XCy/7vofb8q0p7JZo5YJGbyHG1o2O9SPcNmsudENqRcIsmR82R1qra6xNanZPvmth0lxukQf7Q/iHv1rWE2w9k5axWg8yT6DqEI1CcS6Wqn7NcTZCwv3VyOmRwrHjqOposdW82+XULyyiN1IpSLY4zFH1xz3PX9K3C1ve6ZKT5c9vJGwbByrDHINcCsVxpclsUSW7sFG5UXmWHj/AMeX9a7KK573OSo+XY7eXX5jxBaqvvI/+FR/25e/88bb82rCstQtL1M206Oe6/dZfqDU8sscKbppUjX1ZgK6FTiY88jYXXrgfet4m/3XI/mKlXxAf4rNh9JAa5CXXrBCQjSzY7xpkfmajXxDadDFdAeuwH+tP2CfQXtrdTo/hbJ5vha4kAID6vqrYPbOoXFFQ/CCQTeCfMTIV9U1NhkYODf3FFcj0Z0Im+KX/Iqwf9hfSv8A04W9aNZ3xS/5FWD/ALC+lf8Apwt60a1p7EVAooorQzCiilHt1PFAHKwyxw+JfEiNyDLbPj3MIz/IVq2zJJytc1YP9pv9bvO02oyqh9UjCxj9UP51v6WhAZiODXl1rczZ60aajRT6mNNetZ/E+C0ZQLbUNJxv9J45WKg/VN4H+7W3FcyG5KOvGax9X02PVPEtxazPJEx0qOSKaI4eGVblikin1U4Pv0PBrfjkGEWVhJKFAaQLt3Njk47ZPbtWbMoPe6uSlcjB5pFRV5Ap345qGadIhluTUgk3oiVmC/eYCo5EZpEaOQKo6jsaqSlbzbsbaRV2FSkQUnJFO1inHlXmPPU4qK4i86LbnFBmUNg1ICCMjpSJV46kNpCYIyGOa523vZLz4n3dsgH2TTtKCb/WeSVWcD6KEB9zXTyh2idYXEcpUhHK7tjdmx3x6d65zR9Oi0vxNHaQvJLt0svJLIcvNI9wS8jH1Y8n04A4FUuopNt3Z0hxznp3rIuAn/CW+HUTARY7x1x3by0H8ia0JWaUyRBSuOjHvWNfI9nqPh27c5Cah9mb2WaNk/ntq6Ok0FSP7t6nWn9KSl/nSV6p54UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAKwx/wAlV0H/ALA2pf8Ao6xrcFYY/wCSq6D/ANgbUv8A0dY1M9iobnc0UUVgbHHeM3WPxH4cdvS7XHt5Of5gVHBLHI4GKq+MpfP8Z2MHa0sZJ/8AgUjqg/RGosULT5HauWtudtGmvZczM34h3cumaTpeo26bzaatbSOoHJi+YSY99hY/hU/jK5K6XthIeGR42VhyGHUEfhU/iv8A1Oj55B1e1BB7glgR+XFZ+p2KaTokFlHNJNbRXQ8hZB80MXOIs/xBeQCecYHalS+JMyW70L+nkvZKwjEpK5CHGD+dZerWsb3O1rO3WduYoEHLkfxu3aMfrV6zCRwiCZ3S2kI2SI23b/sE9vY1YgsorC2uMj97MT5jAknHYAnnAFK/I7o0jqc9plrbxS2b7UYrECX7epI9K1dcYP4QtUVhmVkx9Mk/yrnb+8hEj2trgLtK8dFHpXQ6zaPb6HZgnIjkQEDtlcVu07pshqxHprm4gNheEyoYyUY9cqOh9R3/AAqppd1qA0iNJYIbsRoAVHyyovZufvDHcVY0qOKa5dZmI2x8KrYLZPP6DH41avIoIoYo4m3TxsxhWM4Kof4SewHvWcrXtYqO12Ytvbn7ZMWbou9gORnoK1fHl4yHw/pkSq0moapbiUHkCCN1Zyfx2KPc1XsEO2cMQ0jsoJx1O4dKta9py29/DqEs0k9zc6pZxqXUAQwrJkRIPTOWJ6knnoKKju0ZtuTuzqHJLnuSawPGwT/hFtU6AssYcj0MqA1tTSFGVQhIbqR2rF1zTprrRtWt9xIltpNv+8FJX9QKwjo7lqN4vU9GFFUdEvP7Q0axvcAfaII5uP8AaUH+tXq9A5QrlfhP/wAks8G/9gWz/wDRCV1Vcr8J/wDklng3/sC2f/ohKAPNv2p4i+keHW5wt1KD6cxH/CvlzUo8kgjivtf44eHLnxJ4CuYtPjaa+tJFvIYkGWl2Z3IPcqWA98V8Y6ioYbkOVPQ4xXLUuqlzeGsLHR/Dv4meKdF8UadFNqV9q2nyzCOaxupy4dW4LBjkqVHzA9OK9/t/iFDqesRW1k4s7GSZRby38RiW+h/5ayBn27Qo+YFc54B5OK+QJDJBMssTFJEO5WHUGm6zqWq+Ib2BtUu7vU7oKsECyEyMB0VEX+gFXyKWpHM0feAtleGOaxuI5oZPuPG4ZX+hHB/CnXMMgtF80/MvFc38EfhvBo/wx06z8S6bE+ozh5pUlTD24c5EYPVSB6Ywc1tWrzCGfSL2Rn1Ow+Vt/wB6aL+CYeoIwCezAg1E6bjqdFOu5SSkPtJEil3vUt3BdTXa3enXkKDy/LktrqMvC3OQ4wQVbtkdR24quInJwFNX4bd/szLkg4rNm1aMXrcy5T4hEyssGlXKjtDPJGf/AB4EVZOrzWyltR0jU4B1MkKrcxr75jJIH4UkJmt5eFfPcetazSqiCRztGOPUUmZ1YNWSK9he2WqwubC6huVH3hG2WX6r1H4imiwHmA5OOtRXul2Wqz+de2sMr9Y50yko/wCBrhv1qCPSImaQf2nrhC8FWvmwPoev60tjOMpR2GeK76Lw/wCH9Q1USratHHjk4SZjwFYdyc8Ec1FpWo22pxQ3FlKrIFZSAc7WBGRSal4U0bVbKS21I6heW2QzRy6hKw3DoevUetUNE8JaTpV9LNo8+owzsu3ZPdvNF1/ut0+ua68PXjTTTuc9SjOo7oua3pdtdxtO22C4QcS4/Rvb3rlHQQlvPRY2VirbzjBHUZNds0CSO28SrcAEeSZM5GMtEfVWAJVuvY81nW2m6S99dTS6fa3Z8wLHcTKJGaMAYyTnkZxXasaoK6Vzn+pyquyZzSOsoJidZAvUowbH1xTsVseKNI055A0dgLURR586PTZQnPcTw/MpH0I9RXO+H4Nb1G4uLGCyhv5oAJEu4rqNYbmI5AcHrkEFWG0YPUDNb0MdCr8WhzVcLKG2p6P8Ff8AkQIf+wjqX/pdPRTvg3FLB4FWG4QJNHqWpo6htwDC/nBGe/PeiuGTu2d0dkWfil/yKsH/AGF9K/8AThb1o1nfFL/kVoP+wxpX/pwt60jWlMioJRRRWhmFSQ/61D6MDUdPiGXUepxQwOH8FWbP4c02RiT5iNKT6lnZj/OuklkS3jGeF9qy/BXPg/R8drcD8iRWrOkciHzcbV7148neTuemp81lLYxpJN/jGFo/+WmkuP8AvmdT/wCzVNGJDNznrVC5uobfx7oNpGrE3On3bBx0wrRkD68E/hXRQvHKC6Lgg4ORRsVCfLeyK8l08VwE25FQ38Tbg68g1pMqsclQTTCHM/8AD5OOhFJMI1FF3SMyxjdpMgHFa3RevNCqFGAMVUvJpY5FEYOO9G4Sk6sijclvNJGa0LJiU+apBEsqglcE1BPO1tKERcjvTvfQty9ouVLUsSrIxQxvtAOSMdazIznxlds2NqaZEM/WZz/StdW3KG9a53T547vxt4ktCDutLSyVj2w4kekjnvsmdECGAIII9axvGh2eG7iYcNBLbzIe4ZZ0wf1NaqhYYCI/4RXP+Krl5/CmpKV+b90B+M0dOC95DlFuLa2O0mGJX/3jUdST/wCuk/3j/Oo69hHnBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYQ/5KpoP/YG1L/0fY1u1hD/kqmg/9gbUv/R9jUz2Khud1RXFfFLx5F4C03T7qazWcXt0tqJZpTDBBkE7pZAjlRx2Uk0zR/iVolzb2o1G7s4Lu5huLiJbKc3sMkUAzI6SouMAdmCt/s54rA2Kl7E914315iMiKO1iU+212x+bVqRRpbxHAyR1rnfHPxf0TTPBtxqPhy8S/wBTk046jZwmznkUxbtoeUKoMaZ4y5XmqfjT4vRaToNiNIa3utfMliL2E2s0kFuLjBw0i4VGIJKqz59jWM6XM73NlWaio9EaniW5SXTbV+jQ6jaOD/22Uf1p/iGzmuo3iiwXDB1B6EjtntWsfiV4TXVZNPOrf6RHJNCW+zy+UZIl3SRrLt2M6jkqGJ9qm8M/EDw14n1COx0bUHmupbUX0UctrNB5sBbb5iGRFDLnjjPOfSiNHld0xqsk20jmN2q2tqEGnw4YYbfIGB/Cq0+m6rdWYB3iMcBWmAUe2Bziuo1n4neDtF8STaDqutxWuqwqHkhkikAVfLMmS+3bjYCSc8dOpFRp8VPBzWF3dtq7RRWohaRZrSeOQiX/AFRSNkDuG7FQQatRttb+vmL2vW2pyWl+GmjuxLdSBiCCI0HH4mu1aBZrZ4bhA8cgw6nvTb/4keGtONst9PqVvNcxyzRQSaTdrKyR43t5flbgBnOSOnPQGs+7+K3hqynuJ7vU7JdGj06DURdxmeSQxyyiNSYxFgDcQOHLA9VHWpnCU3dscq3NpYyNW0SaN/8AR5RIg+6JDhx+I61WsrDVo8rbIyg9R5ikH6g11MnxT8IpokGsm/u20eYErfppt01uMSGI7pBHtT51I+YjsehBOfp/xZ0eTxB4vsNUil0+x8PNHuv3jlaKVWXJJPlgJyQFGSZM5XIq0pWsHtly2sV9K0vVElBvBBFGHEmQ2WJHQYHvVzxArEaDG7bmOrQEn1wrt/Srt38U/B1nps9/e6u1rBb3KWc63FpPFLDK6lkV42QOoIBIJAHHWktvit4LubeWaHWgyxm2BX7NNvb7QMw7V2bm3Z7A474qJU3J3bI59LF1JFcsqMNw6ipoB+/jHUFhx+NdJRWf1fzDn8jmvhuSfBOlgknYjRj6K7D+ldLRRXSZhXK/Cf8A5JZ4N/7Atn/6ISuqrlfhP/ySzwb/ANgWy/8ARCUAdSwzjpXj/wAR/gbpfinUZdT0i9Oj305L3CrCJIZ3P8ZXI2se5B57jPNXfD/xftdY8T3ulm0sbRbW7ktWiudREd7hM5k+ztGAV4PCuzf7NdHa/EzwhcpZvFrMYju7GTUoXkhkjU28ZIeQllAXBU8HB46Umk9xptbHilh+zDdS3ZOr+J4ltQeBaWh3sPq7YH5GvWvh98IvCngaYXWlWbXGpAY+3XjebKB3C8YT/gIHWsjTfjFps/ivXBeXEVt4UsdMt76K8ns54ZpDK2BhXALKcjbtTnPBNTeGfixaXWo+JhrzCzsrLU4tP05Fsbhbqcum4KYSDIX68BAcdqErbCueo444rM1rQrHWI4xeRHzYiWhnjcpLC3qjjkfyPfNc3J8V/BiW0E41aSSOa3lulEVjcSMscTbZGZVjJTaQchgCBz05rc1HxboeneEf+Eou79V0LyUuPtao7gxuQFIVQW53DtTAo/8ACPavESsOtQyx/wALXVkGkA92RlDH3xTh4f1ctl9fUDsqWEYx+JJNZS/GDwK9otzFrnnQFGlZ4rOeQRxrJ5Zkfah2Jv43NgHsay/iH8V7PRZbSy8Nz29/qX9p2lndg280kEMcx/56rhA+OQC2fY1Hs49h8zOoGga0g/5DdrMfWWwA/wDQXFMuNH17bhJtJnX0kikj/UMf5UkXxI8JyyWqLq6g3V5NYRFoJVBnhGZFJK4AUfxHA9DTYfiT4Wl0mfVVv7hdMiwBdvYXCRTEttAhcxgTEtwBGWJ7Uezj2GpNDZIdet8KdHtZwOM299j9HUVC6675oZNBfA4w1/GAfrgGpx8S/CbWcdwupSs0l4+nrbLZTm5Nwoy0fkbPNDAYJ+XjI9awvB3xGvtQ+BsvjrVbK2kvIbe6uHtrYtFG/kySKFBYsRkIOeefyqfYw7D55G1b2GuKpWLTLOIMcky3pP8A6ChqSLRNdMhJfR7YHuqSTH9StcNpnxxF5ofiC/8A7Fs5TpWlxan/AKFqguIn34/cs/lLskXPI2tiut8C+PbjxB4ju9D1LSYbG9hsINRVra7NzG0Uo4DMY0KuOOMH60/ZR7B7Sb6l2bwld3WGvdckd1+4Y7SJAp9uCf1pIvC+p24Cw6nZOi/d8ywwR/3w4H6VMfiD4YGu/wBkHU8Xn2o2WTBL5JuAMmHztvl+Zj+Ddu9qXwR8QPDHjk3f/CK6ot+bQI0+IZI9gcsFzvUddjfl7iq5I2tYSk1szOuvBN3PcNc/2hALpuskcc0Jz2wUlGPyNX/B/hM6FcXd9e3v27VLtVSW48lI/kUkqPlHzH5uWPJwM11dFCilsK5yvw0/5Fy8/wCwzq3/AKcbiij4af8AIuXn/Ya1b/043FFUIj+KX/Iqwf8AYX0r/wBOFvWjWd8Uv+RVg/7C+lf+nC3rRrWnsZ1AooorQzCpIcCVCegIqOs7xNd/YPDeqXQOGjtn2f75G1f/AB4ikwRkeBwf+EP0vqA0TMv0MjFf0IrUjtgqSRyMX3HNQ6VBJY21pYbMR21vHCW91UA/qDV/tXjt3bZ6KvBWOP15BB410e5QbRaR26nH92ad4j/MV2AGBXIeJyWk8STqebS209V9iZ/M/qK7G4wkrjsCauovdizOLu2VL1pFQeUMmlExFqXkX5h1qrdXTbsL1p9tN5q7X6HjmotodXs2optDra782TBFXT0warw2yRMWz+NTqQ33WDD1FDt0M5uLd4iMwUZY4FIQsgBwCPWo7qEzx7Q2KijcWsYRm3GkCjdaPUmnl8ooApYscACuR8OP/wAVR4ivAP8Aj8Lup9UjmaJfy2kV2VpKkskZwMhh/OuN8IJiXRpJCSLvTbrr3Iu93/s9aQXuy/rqRJqMopo6C1nZ5CCOKr+MgqeGrqQjCpLbu+P7onjzWrFbxxMSB9Kp+IY1vdIv9PAJluLd1QD+/tO3/wAeAqU/eTNKj5/hR0U4xM+f7xqOqukXo1LR7C+U5+028cp+pUZH55q1XsI8sKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAFYX/ADVTQP8AsDal/wCjrGt2sIf8lU0H/sDal/6OsamexUNzovEeiNrUMaJqmoacyBhutDGQ4bgh0kR0YY4+ZTjJxXER/BXw5bwWK2N5q1pcWwug9xDJFvuBcjbLvVoygyOBsVcdqvfGLUvEenaVp7+FZ7iKYzlrhLawluJZYwv3EZLedYyTjl0wfUYNefa54p+ItprfhbSrSa8t5fFVlEkC3sFu8+mTxyKbh32RqHHlEnlRgn7oxisDY6+b4I+HzpyWVvqet2sR0saROYpYSbm3DbgH3REBge6hamvvgzoV1NcFNS1m3t7mS0muLaKSEpLJbgCNyWjLA4HIUgHPTpXLyap8Sm8SMq3OtJYHxW2mhBpcWxdOKcThjDnCnpITtz1z0rn5PHXj63udE0zV73W7O7nh1TIttHSS6uWhb/R28ryW4PAJVQpBzx1AB6TB8GPDVtrF7f2bTQG7mlneP7LaSbWkBDbJXgaZBzkAOAO3etXwt8NdH8Nato+oWNzqEk2l6WdIhWaRCrQmTfubCAl89wQMdq8q0uDx5D4+i8R6jaaomuXfhNUjSOzVraS8Uki3lZY2EQJAc5ZDuONwGFqWbxN8UV8Oa3Lpqa5dzR6NbTrLd6MsU8OotMglhhj8pfNjCFzna+MfeNAHq978PNFvtU8VXt6bqc+JLaK0vYWcBAkaFVKYAIODnJJ56YrD034OaHpuk3OnWl5MtvOkcb50zTGZlQ5AYm1+fnBy+45Gc5ya5O91f4mWOpauIJtZvbex1bT0tlfSoiLq2lXM4JWIEqh43LgrzuJ7bvgDW/GN38Qryz13+1brSm8+WK4Wxa0tIl3YjjZJrVJC2M8rK49fWgClL8E/smseHotC1i7stFsbW9guJRKhu2Nx1EYMRjVTyDgLjPy881r6h8EfC95pstgs+qW9tJptvpe2KZOIoZhMrAsh+YsOSeMHgCsLx14o8eWvxCS38Oafr/8AZkOoWkcySWazW08DYEjRlLYkAcEs1wGBJ+XH3YdG1v4mDWNKnuRqc9vPrl9Zz2c+mIkS2qjMEhYRhlGeA5bB4685AOl+I3w18KeNvE6DXdYuYdTubIwR2STwMxjVtxkiSVHZCDjLR7fQ9Tm3qHwj0G+l17zrvUxba3FAl3bLJHsLwACKVSU3q67QeG2nuD0rz74eL4r1j4oeFNZ8U2+ttexaffRX32nTDbW9nIX+SONxGoZSuCCWfPr2rqfEGt+Mrf4rwWtn/at34ekuraEW9jYtEsC4zLJNNNatHImf+ecyEA4AzyADWk+Eei3E8t3fahq13qU+p2uqT3sskQlmktwViRgsYQIASMKoPvSa/wDDhdZ+Mei+LpxarYadafNGGbzJ7lWby2ZcbcIGJDZznAxgV5na63460HwrpYlt7/QNLjh1S4uJrDRI1KzJI5hWSPySsUZG0l9q5ySW71Jb+KPifqnhx9R0+61UlfDVrqNu0GlRSJdXbSDeg/dHdlDnauMcEY7gH0fRXjOk+IPHE3xJs4L1NVn0a5dA0Vrp7W0NmBFl/Oae1PmAv3jnB9B2r2agAooooAK5X4T/APJLPBv/AGBbL/0QldVXK/Cf/klng3/sC2X/AKISgDOu/hlpmo61YahrOpatqgsHMltb3TxFY2IIz5ixiVgMkgM5AJ6Vj2HwQ8OW0UMM1/rN3awafPpcUE8sW2OCVizKCsasSCxIJJ/GuesNV+I2paz4gsIrzVVdre5m0++XThbWcDg/uYmjubRXYnGNyyyDnPvWX4e8ZfEbxT4O0/xHYyXkEOoazY2KW9rYxzGO2VSt1OSYz8rSZ5PC7e3cA7aT4KaFcW15Ff6rrl49xZ29kJpZYVeJIGDRFdkSjcMAZYHPfPWnX3wV8Pail62qXup315d30eovdXAt2YTKmz7nleWVI6qyEH0rlNP174lWlxZSX0mrXFumsX9jP5+lxorWiJmG4YrEuOTwwIQ4HHXPMadrfj/x74DuYI59Y1O01Hw5cvePJpsUEa3QYhI4H8pRJvVdrAF8bjgqcbQD1u2+EGgwSI4urwMlhdaeBDDa26mOcYc7IYUXcOxx9c1r6j8P9Kv/AIaJ4HmuL5dJW1itBKrp5+yMqVO7btz8oz8teULq3jrSvDGjWmkv4mjtoPDwNuRogkmk1JSFFrMhgzHEoGA2FyOfMNT+I9e+KyPrlxbR6lbzWcGkyW9na6ak8Mssir9qRWMbM6qS2drZXHUCgDv/ABX8JvD3iTXItYujLFfparaM/wBntbhZEU5GUuIZFDD+8oBxx0qve/B7Q7q+mnXUNWt4Jr231CS0gaFYWuIQAr48osMgcqpC88AcY4/Wte+I1mmt2sNzqjLZ6wy2050d2nvLQRg7I3itZYx83Ado8H14rsPEGreMI/g7b6jo1jqC+JXihaWK5ijmuoVLDzGCIio7hckKFH+7nigCjqfwr8IaRKNV1jWry10q31CfUfIvLqGO1jknG2RS7IG2twMF/oavL8KtE1HwSnh6fWdV1Hw6VSSxid7d1tgDuRonEWXGDgby4Knoa868UW/jbxPbabDOdfuNLtvF9l9ivJdMSG6a2wS88sRhG0RsBhmRVO47g3FeifGLU/GOlW+gr4RjuJLaSdk1G6gh82aNQo2EKsM3BOckRNjA4Gc0APtfhFotoNNks768tL7Trt7u2u7S1srZ0ZkCMpSO3WNgQByyFvQ9qtL4M8N+FvhNd+FL3VJrTw75E0E17eXEcboszsSTIVCA7pMDI9OteeXGsfFKa0iVby/WaLw1dXjT2WjEJPfRzOI02z24cMyBRs2rnOVGCDWH8VLrx94n8H6npupafraxz6Lps9tZWOktIl3cs0b3AlYRs0bIwbCbk+6OvQgHqDfB3RbmzuIdQ1bWr5pdJXRYppZIFaC0DBgibIlUnIHzMGNdp4Y8NaP4X05bPQtOtLKLaokMECRmUqMbn2gbm965jx3J470zwvrV74en06+uFiH2K0h01xcR5dctuaZlkZU3/LsXJx/unz+91v4nXDG10O41gafLr9naWurXuiKLj7K8T+e8sBjTEaPsw+1M/wB6gDvz8KdCOtLffadR+ypqp1tNN8xPsy3pGPOHyb899u/bntXQ+BPC1j4K8KWHh/Spbmaysw4je5ZWkO52c5KgDqx7dK8T8a+LPiB4Y1G6t9R1jUImgu9NsrGaPSoha6irgCeVpDEwWRmyfLDrt5wDjNaj+KviC/xFSGy0/wAQR6Gbu7gmhvbJXVUEZMUiOlsqqm4YX99KTxu9wD3eivGPhjq/xCm13wuPE7anPZajpM02oLdaakK2tyshCDcsalSVA+Vic8kdsez0Acr8NP8AkXLz/sNat/6cbiij4af8i5ef9hrVv/TjcUUAR/FL/kVYP+wvpX/pwt60azvil/yKsH/YX0r/ANOFvWjWtPYzqCmkoorQzCqmq6fDqdqkFzvMazRzFVOA5RgwVvVcgZHtVuik1dWY07O5n3qyGIhc7s5PvTbMS+ViXO6tP64NHHbiuR4TszoWJfLy2OI1e1n/ALK8QPcRtG+papa2sIb+KJXiRGHscPXV3GZC57kk1W8QWVxftpUcCgxw6hFcTktjCIGP4/Ntq4YX64H51FenK6jFXsOlNatswJ0ZHOe9OtiRKMVsy2ZkHKjP1qOOwKNnaPzrLkn/ACs7vrUHGzY7bvi2t3FJDEsERVOg5+tT+S/pR5T+lT7KfZnL7RbXKkUkrxu0ihSDxisy4LGTLVveU/cZqF7Lcc7RTVOa+yzaniIRdyrpKkSxlum4E/nXP6DbTiw8NTQRvJ9gvL6yuNv8CM0g3H2BVPzFdeluyDCqKp+H7KexOrLOgVJtQmuYeQfkcKfw+YNW1GnJtqStc569VSfMi336UiofMDqq+YDkGrhA7gH8KBgdKpYNX1Zn7fsinpOnQ6VYJZ2xfyY2dkDHO0MxYqPYEnHtVulNJXalbQ59wooooAKKKKACiiigAooooAKXtSUUAFFFFABRRRQAUUUUAFYX/NVNB/7A2pf+j7Gt2sIf8lU0H/sDal/6OsamexUdza8Xazdaa+j2WlpC2o6peraxGZSyRqEaSR2AIJxHG+BkfMVrOuPFXg4+JC91JbjU7JbiFb6aycLGI1LTRpclNmVCsWVWyNpyODWj4u0e61J9HvdLeFdR0u9W6iEzFUkUo0ciMQCRmOR8HB+YLXI6h8LfCltq1/eSPDHLrL3UQtporRPOluI5PMVJzCZwSC7YVzgA4G0EVgbHYeGvFuj+JZ7qDSZrlprWOKWVLiyntiEk3eWwEqLuVtjYIyOKZ4m1DQNG1DTr/V7YSamxeCyeGwe6ueVy6xiNGcDAycDGBzXH+FPAXiKC41W61zXp45717CMmC686XyLVnbZ5yRQY3l9pwmducklsjrvG/hO28X6YljfXU1vAr7z5UFvKWOMD/XRSBSOoKgEetAGL4e+IlleeItV0nVC9tMmprZWJ+xTorq1vFKqyOV2rIS0g2sVPygbc9bsfxK8JyQzzf2oyQQxibzZLWZEkj8xY/MjZkAkTeyjchYDI5xSWHw90mytlginv3jXUodU/eyq5MsUKQqpJXJUrGpOeSSeaz4vhVpKW0dtLqesXFrb24tLKGWWMrZwiWOXZHiMEgmGMZcs21QM0APg+KWinVdct7yDUrOy0uGKZrubTrpVZWDE7gYhsxgYyfmz8ucVpL8QvDjQM63V40q3H2U2o065Nz5mzzMCDy/NI2ENnbjHOaZr/AIEs9av9WuJdS1K3i1W3jt7u2gMXlyCPOxstGzBhuPRgD3Bql4o+Fug+JNQu76/a4+1XFyl1uMcEyxssIhwI5Y3QgqoJ3KxyMgigDVs/Hfh6+ubeCxu7i7aaKOcPb2U8kcaPnaZHVCsWdp++Vxg56Ve8NeJdN8S27XGkG8ktgqus01lPbpKrAlWjaRFEgIGcrkcj1GebX4Y6WuoaNdLfXSHSQgt0htbKAAqSfvRwK4BJyUVgh7rjIN3wB4U0nw7Nq1xpOpSX0l1KI7k7beNEkjLZGy3jjQPljuJXceATwBQBn+KPinoWl6Drd3p80t3eWFtcTQxm0nWK4eI7WCSbNsgDkBihO0ZJwATUuteLNQ0LwNpGr3jQ3FxPf2lvcsNNuLf93LcKjbbd2MoYI3AOSSM4521Bd/CnSbuyurG41PWH054bmC3tDLFss1uDmQxny9xPJA3l8AkCup8WeH4fEmlx2U93dWZiuYbuKe12eZHJFIsiEb1ZT8yjgqaAOZ1fXPAHiSTTV1mxttVuXadLS3u9HknnRozGJlETRF0I3xkggHHPQEjU0zx14bu0li0ya6lW3t/PRINOuD5sKsE3wAR/vlBKjMe4DI9abongPTtJ1W21MXV9dX8Ru3kmuGQm4e5MRkZwqAZAhQAKFAAxiuWsPg94Sgh1TSdOvZIt8KRSRQQ2Qmt0MiyKGcQeY6ny8YlZwwzkHqADbPxO0eTW9IsbGDULmO+kuIZJFsLkPbSxbMo8XlbgfnGd23aME8HNP+G3j6z8V6fYxXL+VrUtu9w8ItZoo2VX2MYncbXAJUHazYJ5xVbQfhXpegfZG0jU9TtZ7a8lvFkiS2QMZUjSSPyxCIwhEa8KoIOcEVaf4eWsOmWdvpOqahZXNnp1xplvdBlLpHO6M78BT5g8sbWBGM5waAO3opkMYiiSNSxCKFBdixOPUnkn3NPoAK5X4T/8ks8G/wDYFsv/AEQldVXK/Cf/AJJZ4N/7Atl/6ISgDkfE/wAV9OXxVoWkaO0OoaZdXdzaapM9lO6KIoizLE4ASRuCCF3/AE5FbOn/ABI8AaboludP1O0tNKjsBfxJBaSJHHbmXygdoTCkyfKEwGJ6CqWjfDHw5a+JbefT9Z1CR9Gv5dQj00TwtHay3CksGATzMMCCAzduO+c/wJ8H4NF0nxXbX0sMD63es6rapHcJBaBy8cAW4iZTyzZyhHPHIzQBY8cfEwwXPhrTdBtrhZNbvHtXl1PRLwhI1TLEQlY2kzkDg4xk9AcbWlePvA1hY6ZZ6VeW9rZzvdQWcFvZSRx7rcbplChAF25z2B7ZqnoHwh8P6HNo8tpc6kX0u/n1KIF4lRpZUCsCiRhVQADCoFAqhpvwi8MXE9rfafrOp3FnaXN/JbxRXELwxSXAMc6hhHuOCCMFiQy4PcUAdDpvxR8HaiJDBrIjVLH+0i1zbzW6tbZx5qmRFDLnjjPPFY+vfF/StPu/DiWWm6veW2sXPk+c2m3cJRNu4PGrQ5mzkYVee/anJ8GfDP2a1triTUbm3t9GbRBHLKoDQGTzNxKqDvDYwQQOOlXbz4bQ3tlpEV54l1+e40i4S4sLtja+bblU244gCuCOu9WPHXrQBLbfErRFS9OpXMUcsOrT6TFBZR3F1LLJEAWHliEPuAOWCh1HHzmnXHxT8HQWtpcnVnlhurWS+ia3s55swxnbI5CISoUg5zgjBz0qmfhRo6XbX1nqOrWmpjVrnWIr2F4jJDLcKFlRQ0ZQoQo4ZSeOtQ2Xwd8N2UVrHaS6jEtvp11poxKh3pcEmR2JTl8scHoPSgDvtL1C11XTbXUNOnW4s7qJZoZV6OjDIP5GrVZnhjRbfw54d03RrF5ZLWwt0tommILlVGAWIAGeOwFWNV1Kx0iwlvtVvbaxsoseZcXMqxRpkgDLMQBkkD6kUAW6KitriG7tori1ljmt5kEkcsbBldSMhgRwQQc5FJdXdvaCI3VxFAJZFijMjhd7scKoz1JPQdTQBNRUNnd299ax3NlPFcW8gyksLh0YeoI4NTUAZE3hnQZ9aXWJ9E0uTV1IZb57SMzggYBEhG7gcda16KojWNMOsNpI1GzOqrH5xsxOvnBP72zO7HvjFAF6iiigDlfhp/yLl5/2GtW/9ONxRR8NP+RcvP8AsNat/wCnG4ooAj+KX/Iqwf8AYX0r/wBOFvWjWd8Uv+RVg/7C+lf+nC3rRrWnsZ1AooorQzCiiigApRSUUAHFLSUUAKfaikooAXNGaSigBc0Z+tJRQAtA4pKKACiiigAooooAKKKKACiiigAooooAKKKKAFNJRRQAUUUUAFFFFABRRRQAVhf81T0H/sDal/6Psa3awj/yVPQf+wNqX/o6xqZ7FQ3LnxBv/EOlpo914atnvd10be4tFi3hlkjZY5GIGVRJPLLEEfLurh9Rj8X+J7/SJNRjv9L+yeJI4I2trVD5KR2U6y3Sb0YeW8j4UvuAG3uee58beKz4Z1PwzG8Zez1G8kt7jy7aWeUBbeWRfLSMFiS6KPungnjuJIvH/hmaxlvI9Tzbx28N0WMEoJjlcxoVG3LEupXaASG4IBrA2PLdT8QfE6ODTUjF3Bi3kH2ltPkbzp0uZUHnRxWkxCmJYm+XyQd5IbsNIa946XxlqsepnUrXSopbxRDZ6fJOxt1RzA9uRZtGZThD887AkkbAcAd7H8Q/DD6hcWZ1F4pIHuY3kmtZood9vu85RKyBGKBGJAY8AnpzTbf4jeF5lDNqMtuvmRxsbuzntwhkBMbN5iLtRtp2ucKTwCTxQB5fP4g+II0mxls7zXpUuJZ2uXuNIeGey+VPJi+WwbzAcuWZYcZG3cuAW9Z8Ha/Nqca2F/FI2qWdnbPfXCRGOAzSR7iih9rhgMMVZAQHXPPFQy/ELw1ELVnvbgJcwpcK4sZyscTsVR5SExErEHBfaD1HFVJPil4TSdoftl88geZF8vSrtxI0LbZQhWIh9h+9tzgcnjmgDndU1jxZHN4pMM+uLq8DzjTdPi0kPZPAANkom8o75NuWCmUZYbdvYwWPiLxVZ6rZXMjeItR8Lx6iYpp7nRSl5LE1o5GYUhV9iz7AHEa9cHI5PbQ+NtMlN1LC0l3ZxQ208b2FtcXUrpOrMjGOOIkKQMggt77eMwjxhFcX/hi6054rrw/rby2qTeU6SRzqrOuQ2MAiKRSpUEMBz1FAHl2s+L/G9noBvtUutd0uVLKOS2EWjoyTztcSKy3DNCwi2oI8D5M7sgk8V0vh6DxHoviQ3Kz366TfeI79bq0ltEEEVuY5ZFuN+zeMuiDcX2EMBjPJ9I1Dw/o2o6jbahqOkadd39tjyLme2SSWLByNrEZXnng1p0Acre65c6v8O5dZ0L7Vp89zaGa0ae0aaVM/dYxRhycjBAAY4IyOorzfSX8Qah4r8H6vq8viuCOFr6zeY2CSlizWxQMBZxskT7XBd40I8vO5c5PuVFAHign8ex+GvDmrtHdaj4hl0e7nliudMiT7LceUmxBiMMjMc5UsNzDHA4FOyuPEVrqmr39lc+KpLK8udPiutUn0QLeLAsU+8xW/kANiTy1P7tiAxPPBr3eigDx7TPEfiu2FvfeIpdZi0yC2WQRx6fDHPfSNevFDGwdQqPJGYtyAqQW4K17COnpRRQAUUUUAFcp8KP8Aklngz/sDWX/ohK6uuU+E/wDySzwb/wBgaz/9EJQBwUt/4i0/wRdSeGopm1Z/Et4mryRIXmiTzZSrKohmP3BbgYif5COO4xvFHi3xxpXhCS91DUdVs5YNJee3ubHR2dLi6E8qhbgzWwMQEYhPMcQYsxBxgV6HD4+8K6es19eNFb3l158lxJY2VxcFo7aVoDJI6wg4XZglhhexK4Yy6xrXgTUdXabVbWzv7jSVMjahLpbzw2e1PNP+k+WY4yBg43g5x3IoA6bSNZh1W91WC2hnC6fcC1eZ1ASV9is2w5yQu4KSQPmBHOK8l8Pad4207S4LbSb/AFC0+3T6ywgubGPybNxcSyQOWMe4Bz/eYgq/ygcGu+b4jeGlt1le6vVZrhLVbdtNuRcGR0aRB5Pl+Z8yo5B24OODWVf/ABN0WW7FnDbTXmn3OkzX4uWtLgxYRyjRygQsUHDBiw+XGCuSAQDlpfGmv6lY+G9Yk1DU9I0vX9SkSKCx09Lu4itktJCNqiKRmLyxl87ThSOgBpp1/wCIf2K2e7TWINQ+xQvZQW+lLJHezGZwwu28s+QfLERIDRgbmwTjA7i18XeEG1HTNMIiS9tHggtwmnymG0lmhBjRJvLCIWjkCjlSQ23HUVZb4j+FlS7kfUZUhtonnaV7OdY5I0YI7ROUxKAzAEoW6igDznSD4i0FNQs0vPFMFvJ4ivHvpodHWd4Ld5J3jlt8W5EvmN5e8gSbM8KmeLE+p/EabTbq8WbVreez0eK6ht002I/bLj7TOu2QGNiGMKwlo0KlS3GO/fj4h+GzCXF3dmUXH2X7KNPuftJk2eZgQeX5pGwhshcY5zViLxxoMmqw6cLm5W6laOMB7KdESR0DrE7lAqSFSD5bENyBjNAHnHi3VvFulpq0WiWOsW88+q3bw3FjYL5bIsUWzzAtpOz7mJwxCg7SDIMCuo8W3N7efCrQrrVYmh1Ge60WS5jZChSVry2LgqeQQSeO1dJ4N1m51aDU4NRSFdQ0y+ksZzCpVHICujqCSRujkjOMnBJGTWrqum2Or2EtjqtlbX1lLjzLe5iWWN8EEZVgQcEA/UCgDgdY1TxHH4s1yFJtZhMKA6NaW2miWyvP3AP7+48lth83cpG+PAA65zXNW8/ifWLjS47oa7qNjDf6XcyTahpX2SSGfzG85FVY03RKAp3EEDP327e1W1vDaW0VvaxRw28KCOOKNQqooGAoA4AA4wKkoA+eY9W8baBoHhyw0PTdfglt7aEyQmyLwzbp23qQLWRgwTrumhwCpUNznY07xN4uv9Y1MadqepzrBf6vbTLLo+60tIojMtu6OkIaaQOsYKK7lhkEA817dUFpaW1mjpZ28MCSSPM6xIFDO7FmY46kkkk9STmgDw6bxF8QRodp9nXXSPtkkd1fS2hEhAiQx+VGNO8wRliwJa3PIwHxzXTTatcWOqeCtX8TOn2m30DUbm9eOJ4wSq2zMQkioy5wTtZVI6YFepVQXR9MXWG1YadZjVWj8k3vkL5xT+7vxu2+2cUAT6dcm90+2umt5rYzRrIYZwBJHkZ2sASNwzg4JqxRRQByvw0/5Fy8/wCw1q3/AKcbiij4af8AIuXn/Ya1b/043FFAEfxS/wCRVg/7C+lf+nC3rRrJ+LlvDd+DFtruGOe3m1TS45IpVDI6m/twVYHggg4INZ//AAr7wZ/0KPh7/wAFsP8A8TWtMzmdNRXM/wDCvvBn/QpeHv8AwWw//E0f8K+8Gf8AQpeHv/BbD/8AE1pqZnTUVzP/AAr7wZ/0KXh7/wAFsP8A8TR/wr7wZ/0KXh7/AMFsP/xNGoHTUVzP/CvvBn/QpeHv/BbD/wDE0f8ACvvBn/QpeHv/AAWw/wDxNGoHTUVzP/CvvBn/AEKXh7/wWw//ABNH/CvvBn/QpeHv/BbD/wDE0agdNRXM/wDCvvBn/QpeHv8AwWw//E0f8K+8Gf8AQpeHv/BbD/8AE0agdNRXM/8ACvvBn/QpeHv/AAWw/wDxNH/CvvBn/QpeHv8AwWw//E0agdNRXM/8K+8Gf9Cl4e/8FsP/AMTR/wAK+8Gf9Cl4e/8ABbD/APE0agdNRXM/8K+8Gf8AQpeHv/BbD/8AE0f8K+8Gf9Cl4e/8FsP/AMTRqB01Fcz/AMK+8Gf9Cl4e/wDBbD/8TR/wr7wZ/wBCl4e/8FsP/wATRqB01Fcz/wAK+8Gf9Cl4e/8ABbD/APE0f8K+8Gf9Cl4e/wDBbD/8TRqB01Fcz/wr7wZ/0KXh7/wWw/8AxNH/AAr7wZ/0KXh7/wAFsP8A8TRqB01Fcz/wr7wZ/wBCl4e/8FsP/wATR/wr7wZ/0KPh7/wWw/8AxNGoHTUVzP8Awr7wZ/0KPh7/AMFsP/xNH/CvvBn/AEKXh7/wWw//ABNGoHTUVzP/AAr7wZ/0KXh7/wAFsP8A8TR/wr7wZ/0KXh7/AMFsP/xNGoHTUVzP/CvvBn/QpeHv/BbD/wDE0f8ACvvBn/QpeHv/AAWw/wDxNGoHTUVzP/CvvBn/AEKXh7/wWw//ABNH/CvvBn/QpeHv/BbD/wDE0agdNSiuY/4V94M/6FHw9/4LYf8A4mj/AIV94M/6FLw9/wCC2H/4mkB05pK5n/hX3gz/AKFLw9/4LYf/AImj/hX3gz/oUvD3/gth/wDiaNQOmrCJx8U9B5/5g2pf+j7Gq3/CvvBn/Qo+Hf8AwWw//E0f8K+8Gf8AQo+Hv/BbD/8AE0mrqw07O512qaLa6lqui6hPJKs2lTyXECowCszwvEQ2RyNshPGOcfSuRHw5tYtc8KPA4bTNESdy0spM08jSK8asAoUor5cHOQyrgck0f8K+8Gf9Cl4d/wDBbD/8TR/wr7wZ/wBCj4e/8FsP/wATUezL9oVdM+GEFwdS/wCEn1Ce9t577UriCxjdFghS7aUFgRGshfy5WByzAFjjsavyfDPTLyK5i1nWdZ1VLpYYbkXU0S+fDEH8uFvLjX5Azs/GCx+8SMgxf8K+8Gf9Cj4e/wDBbD/8TR/wr7wZ/wBCj4e/8FsP/wATR7MPaDdT+E2h6nf2V9f3lzdX1vbx2z3F3bWd09wiElS/nQPhuSCybSRjJJANbNh4G0uyFgIri8P2Jr5o9zpybuQySZ+XsWO3pgdc1kf8K+8Gf9Cj4e/8FkP/AMTSf8K+8Gf9Cl4e/wDBbD/8TR7MPaDLr4S6Dc6TBp5vtRWGGKziG4wShltomij3pJE0b5DkkMpGQCAMVb0jwJFox8K6bYXGdB0KWe8QSsPOluH8wKCEVVCKJpDx32jHGag/4V94M/6FLw9/4LYf/iaP+FfeDP8AoUfD3/gth/8AiaPZh7Q9C3L6ijcvqPzrz3/hX3gz/oUfD3/gth/+Jo/4V94M/wChR8Pf+C2H/wCJo9mw9oehbl9RRuX1H5155/wr7wZ/0KPh7/wWw/8AxNL/AMK+8Gf9Cl4d/wDBbD/8TR7Nh7Q9C3D1FG5fUV57/wAK+8Gf9Cj4e/8ABbD/APE0f8K+8Gf9Cj4e/wDBbD/8TR7MPaHoW5fUUbh6ivPf+FfeDP8AoUvDv/gth/8AiaP+FfeDP+hS8O/+C2H/AOJo9mHtD0LcPUUbh6ivPf8AhX3gz/oUvDv/AILYf/iaP+FfeDP+hS8O/wDgth/+Jo9mHtEehbh6iuU+FBH/AAqzwbyP+QNZf+iErI/4V94M/wChS8O/+C2H/wCJo/4V94M/6FLw7/4LYf8A4mj2Ye0LsPw60eG0vLdbq+KXVle2LkyJkJdTNNIR8v3gzkL2AxkHrTP+FdacLfUrFdV1VdH1FGW603fCYZGaMIXDGPzFbgN8rgbhnGMiqn/CvvBn/Qo+Hv8AwWw//E0v/CvvBn/Qo+Hv/BbD/wDE0ezD2hoWngGxj1O21K91bVdR1KC7iu/tN08W5zHDLEiEJGq7AJ5DwASTkk1WPw00xbeOG11XVbZBbXdnL5bwnz4biVpXVt0ZxhmOCu0juTUH/CvvBn/Qo+Hv/BbD/wDE0f8ACvvBn/Qo+Hv/AAWw/wDxNHsw9oaUfgHSYzIRc3vz39nqBzIn+stY4o4x937pEK7u+ScEcYw7L4OeGLOO/htXligu4nh2Ja2avErOG+WYQCU9MfO7cHnOBiz/AMK+8Gf9Cj4e/wDBbD/8TR/wr7wZ/wBCj4e/8FsP/wATR7Nh7Q0tT8B2F5rtxrVtqep6fq0tytytzbPETGRAISqq6MpVlUZDA8jIIqlF8MNEj8WJ4iaeSXUfMjnmea0s5DNKiqvmF2gLoTtBIjZBnkAZqP8A4V94M/6FHw9/4LYf/iaP+FfeDP8AoUfD3/gth/8AiaPZsPaHReDdIuNJg1OfUZYH1DU76S+nELFkQkKiIpIBO2OOMZwMkE4FdBuHqK89/wCFfeDP+hR8Pf8Agth/+Jo/4V94M/6FHw9/4LYf/iaPZsPaHoW4eoo3Ke4rz3/hX3gz/oUvD3/gth/+Jo/4V94M/wChR8Pf+C2H/wCJo9mw9oehbh6ijcvqPzrz3/hX3gz/AKFHw7/4LYf/AImj/hX3gz/oUfD3/gth/wDiaPZh7Q9CyPUUbh6ivPP+FfeDP+hR8Pf+C2H/AOJpf+FfeDP+hS8O/wDgth/+Jo9mHtD0LcPUUZHqK89/4V94M/6FHw7/AOC2H/4mj/hX3gz/AKFHw9/4LYf/AImj2Ye0Nn4af8i5ef8AYZ1b/wBONxRVb4R28Np4Ma2tIY4LeHVdUjiiiUKiKL+4AVQOAABgAUVmaEvxS/5FWD/sL6V/6cLetGs74pf8irB/2F9K/wDThb1o1rT2M6gUVyuq/EHwzpl9eWdzqLvPZDdd/Z7Wa4W2HrK8aMsf/AiKl1vx14b0XSdO1O/1NfsOoyLFaS28T3AmYgkBRGrE5wau6M7M6WuZ+Jfir/hCfBOo+IPsf277H5f+j+b5W/fIifewcY3Z6dqm0DxnoWvardaZp15J/aVqoeazubaW2mRTj5tkqq2ORzjuK5L9pb/kifiP/t2/9KYqG9NBpanmP/DVP/Unf+VT/wC00f8ADVP/AFJ3/lU/+018x16R4b+Eesa5p+mXX9seHdObU13WVtfX3lzXAzj5ECknkYrhxOOpYWPPWlyo2VLm2R6p/wANU/8AUnf+VT/7TXdfB341f8LH8TXWkf2B/Zvk2bXfm/bPO3YdF248tf7+c57V8g+KvDup+FdcuNJ1u3+z3sOCVDBgwIyGBHBBH+c167+x5/yUzU/+wRL/AOjoa3pVlVSnB3T2a6kygkfYVFVNU0yw1eza01aytb60YgtDcxLKhI5BKsCK+dfA0dz4e+AV34n8KwWlrrlndSvPcLaxNJPbJP8APEzFSdu3n22jGK3bsZpXPpWivnnR/iN4x1rxPpOmQ3DW8HiG/S+06QW8ZMOmq8wkQ5U5YrGhycn5qteGviB4pvfEeiRXF75mqXesTWeoeHvIjH2G1XGJeF80YHO5mKtngUuZBys98orzD4oeJ9S0jxdoWnNq/wDwj2g3VtcSz6r5UbfvUUlIt0qsi9jjGW6DmuM0jxd4+8TXvgfTV1dfD95q+mXFxcO2nxzbjG7BJAj4ILKoPXHOcdKfMFj6Corzz4p63q+l6z4JsdJ1B7JNU1MWt06RRuzRle29WAPvj868+8MfEHxXJceFpbzVTeJea9c6PPA1vCiyxoBtclUBD5PYgcDjqScwWPoSivnrw98RfFV3d6KZtS87Vru4vItT0P7NGv8AZkcYOx+F8xccHLsQ2cdqr2XjPx/F8JdL8WTa6l6up3KW8p+wRxDTohLIrzM6qwOdqjJjIUH7pPVcyHyn0bRXCfCrVtW1LS9U/tbWdK1wwXRFvc6fMJRsKhgjyLFHG7DOMooHqAeK888H+PfFOq6z4dguNUaTVNRvbq31TRVtolOlxLwkg+TepHBzIWDZxjinzCse4afrGmaldXdtp2o2V3c2jBbiKCdZHhJzgOAcqeD19DT9S1Kx0uKOXUr22s4pJBEj3EqxhnPRQWIyT2HWvK/2ZYZm+Gs7ve3DmW9uAuVj/dHccsp25JJOTu3DjgAcV5Aq+R8PTYy6tK99D4zjEljJ5QeH5mxKVChgW9zt44A5pc2g+XU+vqK+fNX+IPi/TdM8U28F39q/s3xDHYHUZYY1a1tGBJd9kZUY2gbzG2N3Q8CvSPhVqerarpeqrq+u6ZrBiuStveabKJgqFQQrSCKON2XPVVx6gHimpXE1Y62y1nTL++urKx1Gyuby0O24ghnV5ITnGHUHK8g9akvdRsbGa2ivby2t5bqTyoEmlVGlf+6gJ+Y+wr5s8Da3rPh7wlbG21ae003UPFE1rqGoyQwsLOMHmTcU2qzk8s+5RtGAOc3jr+q+Ib7wLPq8v2uK38WzW1lf+WI/ttuoGyXCgLzyMqADj61PMPlPoXTdRstUtzcaZeW15AGKGS3lWRdw4IyCRkdxVqvmP4f+JdS0fQvD1gNS/sLQL7U9SN7q/lxt5TKSUj3SKyJuPdhz0HSrt18SfHdnoXhjUrpth1u1ubCCP7KgDXYfEFxgrkbgy/LnacZxg0+YOU+j6K+ab/xr4r1jwj4z/tOaEx+HtOSxvIp7KCSOe/8AtJBkKshBGxR8uNo3DipvEHj3xXY2/jmaw1k20OgWuky2lulpBs/fJGJFbKZ2ncTgEY4wQOKOZByn0hRXzb48+Jniey/4SiaLXf7IvbKazTT9NW3gPnxSAF5f3iM7jnqpAH413H7TVvLL8PIZo55oorfULd5fLVSoXdjc2VOAvXsPXNHMKx6hDqVjNqM+nw3ttJf26q81skqmWNT0LLnIB7E1ar5j1/WL7SfGHxG1zw54gkmns9J0+aK+VIJhdDEYy2E2EEE/cC+3pWh8Tfivrmly3TaLqEtld2VnZXUkFy0AhuPNCEiGMwmSQfMdx81QuDj3OYfKfRlFeJfCnMHxo+ICXurSxXNy9rPHZymFTdKY2bcBsDEICACpHB+bceah+I/jvxFpPifxVaxar/ZJ063tpNGsvs8b/wBrO5G8fOpZ8ElcRlSOvY0c2lxWPc6K8h0HxfqWo+NtTsvFWv8A/CMPbPbCy0vFvH9s3qC3zTIzPlvlwhBGfWsfSPGuuaj4G17U7jxO1r4ygiu3Tw4kVsptjHnbiNozK2FG7JYg570+YLHu1FfNt78VfEE0NxJpeuxSrD4Ni1FmjhhYLfeZGsjH5eoywK9Ae1ex+Bm1yPwUL/X9ct9SvLqEXkU0lqttFbq0SkIwU8qDkluDz2xQpXBqx19FfNkHxI8Wnw54oRdUnvdfsbD7Ylzp7WV3p6L56A7THHuVghYbXZuAx9DWhqXxR8RZ8Xz6DexanFYaJZXVsscSOscsmwSyZUZbaGZiCSAR04IpcyHys95h1Kxm1GfT4b22kv7dVea2SVTLGp6FlzkA9iaS31Kxub+6sbe9tpb212/aLeOVWkh3DK71ByuRyM9a+ZX8U6hoviH4ha94d1X+3btdLsCNSZImADbA8myNQp2AkYxxj5s4NNbxPqmh+JviJqnhfU/7aeSTS45dXKxsEhaI75v3abAFIC52EDqQxByuYOU+p6q32o2OntbLf3ltbNcyiCATSqhlkPRFyfmY9gOa8Gk8beK4ZtBs18V6Xfx33iKCyN1ppiuiLeQcxtJ5CRlh1yig884rNuPEOq68nhqPW7s3s+mfENNPjuGjRGeNMbdwQBc8noBT5g5T6VorxTwd4p8Zal8Rl8IX90+7Rbm5n1O8NvEv2q1O37Mo+UBSd3O0A4HXrV742+Nb/wAPajbadpGoXOnXslhPdpM8tvFbNsBwuZIZGeTIwEXbncOR1D5uordD0++1nTLC9tbO+1Gytru6bbbwTTqjzHOMIpOWOT2q9XzX4cvdV8XfErS9RudRuYb6+8FNM32aOLAYyMhVQyNgEjd65OM7flqh4K8Vav4e+FHg610XV0jhuL2aDUpppIUXSv3rlEZvJfyvMyW3SK/tgHhcw+U+o6K+fbfxT441PXvCPh+08Y6Ws+oi+SbUrC0S7ik8pdyMNyIGYcjKYU9eeRXefGTxFrvhfw5pEmkuq+fexW97qDgKtvGRzIfkcICR94owX0PFPmFY9GorwpPGvii00jTJIPEWl+INXfV5LaCz04pNHfweWGKtKIkG6MHJeMBT0IzwMsfEPU/P8KpceOxFY32lXN1e3v2W2jKXC5xGA8ZClWwm08t9SDS5kHKfRNFfO6fEXxZLpugt4h1M+GobjQZ74Xptoh9su1dxHH+8VlGUCPtUAndxjIwmsfEnxXZx6DeaxeLawXFhC1xpuky2q6iJ3bG4wTo7MpGCFQD73J4NHMh8rPomivnjxB8SvEmnXHiOzbVhb39v4kgtrW3eCLzFsnz/AAleVIx8xyffmtGHxR45uLn4h6lp+rLc2/h68uYLbSv7PRjKMEJ864bCfexglsYJ5o5g5T3aivJfg54m13XNVkXVfEej6tay2CXH2e3mElzbS5UMH2QRKgOT8jZYEdSMmuRu7/UvDXxV+Kl3p19NJrBtLe5sbGRYj9tHknou3c4iGcbCD8vzFuaOYVj6IoryP4WeLtX1nxgdPOsf8JBpB0aC9uLzyYl+yXjEBoMxqo6ZO1ssMcng1zHxb+KGs6B4j1mHQr+W1fSpbYSWl69uEuFkAz5UXkmV1/vN5oxkY6gUcytcOV3se+X15bafaS3V/cQ21rEu6SaZwiIPUseAKjvdTsLHTW1C9vbW2sFUM1zNKqRAEgAlycYORjnvXn/7QDPdeDLPQYT+913U7XTgAcHaZAzEfgnJ968h8Zavca1aaqkWnx3Sap4pj022gtbaNZrm0tBkruVQz87Mbyce2KHKwKNz6oRldQyEMrDIIOQRVe71Czs5raG7u7eCa5fy4ElkVWlbGdqgn5jjnArwBfiR4mudK8NXJ1uytYddmuJZ7ucx2sGn+WSFtFlaGQK3ctIjE8Yx1qW3l8R+IvFfhmDUNTs9Q1jSNEv9UjvbJP3bSSkxQNtZFBIwCPlAPXBHU5g5T6Dory34ReIfEPjKHS9Vur4jSrbT447kCGMfbb1hlmzt+VUXbwuBuYj+EiuX+JPxO1a08Q31r4WvHgurC+t9PNldSwBbiRyDlYfJaVlIyN3moBwRnoXzaXC2tj2q81zSbKa4hvNUsbeW3h+0TJLcIjRRZxvYE8LnjJ4q9FIksSSROrxuAyspyGB6EHuK+Z/HHma/rXjbYcnWdd0/wxblTghYsPNj8QM+ma6DTPGXizVvFstra6zo+ipZ6v8AZP7GupAJGtU6nyvIaQkrz5glVBjoOtLmHynvVFfPMXjTxv8A8IBN42OvxnT729ktrS1fTowlrE0+xZ3kHJVArYBA5I3E9Kj1H4g+KbD/AISWXSteOqaRb6nZ6XBqVzFB5duHQtNOzxRY2g7VBKsAGzgnGTmQcp9FUV4OfFni9LbRbCHxNp17PrGvpa299Y+Xc+Xaqu6YF/JjjkIyvzKmOozmu4+Dev6r4h0nXLjVLtry3t9XuLSxnkiSOSSBCArPsAUnkjIA6GmpXE1Y9AooopiM74Wf8irP/wBhfVf/AE4XFFHws/5FWf8A7C+q/wDpwuKK5mboPin/AMirB/2F9K/9OFvWjWd8Uv8AkVYP+wvpX/pwt60a1p7EVD5/+FWraf4B0jxro/jiVLPV21Ge68u4+9fROihfKzzLkhuBk/N71wt7ousaJ8G/h7bamjWt3L4jWaCK4Qkwo2du5cg8nLYyPvdjX11RVcpPMeGeBrl7L4/a9H45MaeJrm1WLS5oVMdtPbDkiNSSQ525OWPRh256X9pX/kifiP8A7dv/AEpir06vMf2lf+SJ+I/+3b/0pioasmJO7R8LV6z8HPBFzrF/beLPEtybDwtpDrK13cvtEpjIKxpntkAEj6DmvJq9B0n4x+O9I0u007Ttd8mztYlhhj+xwNtRRgDJQk8eprxs1pYutQdPB8qb0bbasutrJ6/kdUHFO8iv8ZvGUPjnx3d6rZxtHZKi29uHGGZFz8x+pJOOwIFd5+x5/wAlM1P/ALBEv/o6GvK/GPjHXvGV3Bc+JL77ZPAnlxt5Mce1c5xhFAPNeqfsef8AJTNT/wCwRL/6Ohrpy+h9WoU6PKo8qtZO+3m0r/ciKjvdn2FRXKfFXTtb1bwBq9j4WmMWrTxqsRD+WxXeN6hsjaSu4Z9+3WvJdc+HHiG70/xInh/Qzotjq62Vgmmi4hDLGjhpbmXa5Qt8uOGZiGOa9Fuxglc+haZcTR28Ek8zBIolLux7ADJNchceD00DwFrWkeAU/s28uY5ZIHaeRyJ2QLu3uSwOFABzxgV5ZH8NPEF1Yag9hokWjO3h7+zJYLmeJ31K7Y5eaQozKcEsQzHdnHA7DbBJHqs3xF0LyPDM9m11ew+Ibn7NZNDCVzg4Z2V9rBBjk4J9Aa7CvA4/hvdS3Hh6P/hD4YtL0jQrhmtpzbf6VqTII/3gVyGZgiNvJx0yQRgU/wDhXHikaR4NsdXttR1HSrPTZY7yztZ7SSWK6d2bcRc5idQpVQRyu3II7q7HZH0RWX4g8QaZ4ehtJdXuTbpd3KWcGI3cvM+dqgKCecH2ryPRfhKt94ps4fE2nXc3hzTNFjtLRbm/3u07SmRwWiKkhdxTlQpAGAcCum+KvhO58R+KfBd02jw6to+nXE0l9CfKLkMqhPlkIDJkZYZ6DocCi7FZHpMjiONnYMQoJO1Sx/ADk/QVBp95Ff2cV1As6RSDIWeB4HHOOUcBh+IFeEXPwt1Cbw/421g6D/xVd7d3CaTAl2qrDauohXgOIsiNn68gdMHFcl410oWkus+HJILLW9RNjp+kaJHBcQTtYlVUTkw7vMjckFt4THqwzRzMajc+rKK+VfF2jJfatq/hUQ2msapdXtnpumz288Fw2n2cO0SDywxeAjadxKgHJyfXsL74aatqnjPVn1201We2k1CKTTr2xubNI7a2XG1cyKZ4yoHIjGHPX1o5gse7zyrDDJK4cqiliEQu2AM8KAST7AZNYHhPxlo/iqW9j0eWWVrOVopSYztBBx94ZAz2UkNjqBXGfDb4dRRajq/iPxdpQGv3upXc0ay3HmLHbyjYEKK5jOVLDkE4bFehaToGlaRLNLptjBbyysxd1X5uTkqCei552jgdhT1J0KGq+LbSw8V2HhyK0vb3VbuE3JjtgmIIA20yyF2UBc54GTxwOldFXiPir4f6/q/ij4ga9YWVvaanPa29roly7R7zhQJnVgcxuQCgY4OD1ArE1b4deJZtM8RHw9oP9kQ6hptrpaacbmENIwkVprmUq5QnaGXO4swYnrxSuyrI+ia4vUfiX4etfDtvrNrJc6hZ3GoLpkQtoSGeckjaBJtyBg89OOM1NZeCtO8N+CtX0jwtYxo91BKdlxI0izTGLYN5ct8p2qMdMdq8s8P/AAxvFs/AWlXvhWKCx0+aa61uRzbN9qmRG8nO1yZFLOwG7oDyAKG2JJH0DWXrXiDTNFutNttSuTDNqVwLW1QRu5kkPb5QcfU4A9a8Q03wZ4ztvB2j6LeaBbzWMtzd3t3bD7HcvZvkiCOITlolXHdQxAY8A9XeGvhlrMUnw7HinRY9VtNNhuY76GR4JTC8rnYGDthokXacKWwc4FF32HZH0DRXj3xhP9qfEHwLoKaY+rW8DT6pc2EZjzII1Cx8SMqY3Fs5PTPXoeaj8A+LrLw9aaO2h2l1pk8l5qL28KWc7WU7n91An2nKKgHVlU/ebHY0XFY9Q8Yab4Rk1/SU8TvdTXmoXKiytJbq5kt5JY1GD5AYxDA5yVA7nk11lnfRXc1zFElyrW7+W5lt5IlJ/wBgsoDj3XI968N8O/DfWIdT8BS+KNCTWbTTNMkgulleCZo5nkYqrh2AZEUgDaWweg71nWnw58XjSdC/tayuZ7ae/vdQ1fTrSW0eTz5DiNys+6GUAKODnGeOehd9h2Xc+jay9W8QaZpGoaXY6hc+VdanKYbSMRsxlcDJHyg4wO5wK8aX4Z6jFd+H7UaPPe6Ho+kX0sNvqN1BMTeTFgsBxtXptOduwetM8MfDPVLfVfALeJtCi1Sx07TZYLsSvDM0U8kjsPMDth0QNxt3YPQUXfYVkev+L/FFl4Xs7Sa9iuLia8uUtLa2tUDSzSueFUEgdMkkkAAVug5AJBGex7V5r8XGGmeIvAviC7z/AGTpupOl2xGVi86MokjegVsc+9cV8Sfh1r+uaz8Q9R03SUuLi+GmPo9wJ4lffFsErISwKEAMMnGR0zmhsEj3XU7+HTbN7m4S5eNSARbW0lw/Jxwkasx/Acd6tV87+Kvht4mltPiHY6NpCrY6pJps1jCk8SLJJHtM7YLDac5JJxuPrTvFfw18R3tz4zvrHR1bUbrW7W8024E8SyCJM72Vi2U7cHBPvii77Dsu59DVk6J4i0vXLrU7bS7rz5tNuDa3a+W6+XKOq5YAH6jIrxDxH8P/ABVJdeJbWz0drmG/8SwavDcrcwqnkgsWBDOGDDI4xzzS3nwz8QQw/EK00TSIbK71S7M+n38TQIr2xdWa2DBvMTd6bdp28mi77BZH0JQSACT0HNeCr8OLlvCuuWVvpXiqxXUJbWU2yz6YVMiBt22GNo4fL+6GBILnB28HPf8Awt0PU7TwPPpnirSdJtHmllU21paxRJJCwAzLHGTHvPOQpIxgc800xNHTeF/EOl+KNGh1bQrr7Vp8xYJL5bJkqSp4YA9Qe1atfOXh34a+INO8HeH9OufDau2nat9o1a3WW3xq8G9imDvw+wH7su0fNj1r074R+H9W8PeGNUt9Whe2juNQuLmx09JVdrK3Y/JCGB2gjk4BwM9etJNg0jv6K+c9L+HHjK1s9fsNEtksormxdYdS1SG1TUWlaQM0fn28jsykAgs5H3sdhVm1+FV5N4V1u3ttK1bTdSls4ZoRc3FisP22EgoYktgADwV8x8Ehjkd6OZ9h2Xc9v0vw/pmlarqmpWNt5d9qbo93MZHcylRhfvE4ABwAMCtSvn69+HnjDUPCT6heW6rr2p62NR1fTopoSZbdcqkKs+6Jto5CvlTu56YpknwpvLu58L2Y0jVhoEGqXU95Df31uskUMscYO0W5UIhYNhEJxz0zii/kFvM+hKwPCviqx8TTa1FYRXMbaTfyadP5yqA0iYyVwTleepwfavFfHPw+8VXfiCVtE0CGGKxurP8Asu6sfskTfZ4lCkyzOftDOAFAGduAeuBXpfwq8P6noV740k1W28hNR165vbU+YreZC+NrfKTjOOhwfai7bFZWN7wV4rsfGGmXF9pkVzFFBdSWjC4VVYuhAJG0njmugr558PfDbxHp1z4avRpCwX9t4mnu7qdZ4vMFk5HVg2SpGfkGT145qz4c+Hvim18Q6NJcWXlapa6vNd6h4i8+M/brVgMRcN5pyONrKFXHBoTY7I99rKuvD2l3XiOz12e13arZxPBBP5jDYjfeG0Hac+4NeCeG/h34us7fwLp9zojoug3GpfaLn7VAUdZh+7ZQH3YPTBAIq3o3wims/hJY2dzperW/ieeUfbRY3EE+VSSVo1kSaZYWjwwJVTySMg80Xb6BZdz2jxR4ns/DL6WdSiufs1/dLZi5jCmOCRvu+YSwIBPGQCM9cVu14J4nsdVtvgta+FtX07TLDxFrWox29lZ6dDHEBiZJDIyRkqCFUlipIGRzXqWj6Z5HxA8Qah/wj/2X7TDAv9rfbfM+2bVxt8nP7vZ0z3ppisdTRRRTEFFFFABRRS4oASilpKACoL+0hv7G4s7oM0E8bRSBHZCVIwQGUgjjuCDU9FAFHQ9JsdC0m10zSbZLWxtk8uKFM4UfU8k5ySTyScmr1FFABRRRigClrGl2+rWot7qS8jjDBwbS8ltnyAR9+JlbHPTOPyqLw/oWm+HrD7Fo9qttbl2lYbizO7fed2YlmY9ySTWmaSgAooooAKKKKAM74Wf8irP/ANhfVf8A04XFFHws/wCRVn/7C+q/+nC4ormZutg+KX/Iqwf9hfSv/Thb1o1k/Fy4htPBi3N3NHBbw6ppckssjBVRRf25LMTwAAMkms//AIWD4M/6G7w9/wCDKH/4qtabImdNRXM/8LB8Gf8AQ2+Hv/BlD/8AFUf8LB8Gf9Dd4e/8GUP/AMVV3M9TpqwvHHhiy8ZeFr3QdUluIrO72b3t2VZBsdXGCwI6qO3Sq3/CwfBn/Q2+Hv8AwZQ//FUf8LB8Gf8AQ3eHv/BlD/8AFUXQanmP/DMfgz/oJ+If/AiH/wCNUf8ADMfgz/oJ+If/AAIh/wDjVenf8LB8Gf8AQ3eHv/BnD/8AFUf8LB8Gf9Dd4e/8GUP/AMVStEq7PMf+GY/Bn/QT8Q/+BEP/AMarrPht8HvD/wAPtdn1XRbzVZ7ia2a1ZbuWNkCllYkBUU5yg7+tdF/wsHwZ/wBDb4e/8GUP/wAVSf8ACwfBn/Q2+Hv/AAZQ/wDxVFkK7Onormf+Fg+DP+hu8Pf+DKH/AOKo/wCFg+DP+hu8Pf8Agyh/+KqroVjpqK5n/hYPgz/obvD3/gyh/wDiqP8AhYPgz/obvD3/AIMof/iqLoLHTUVzP/CwfBn/AEN3h7/wZQ//ABVJ/wALB8Gf9Db4e/8ABlD/APFUXQWOnormf+Fg+DP+ht8O/wDgyh/+Ko/4WD4M/wChu8Pf+DKH/wCKpXCx01Fcz/wsHwZ/0N3h7/wZQ/8AxVH/AAsHwZ/0N3h7/wAGUP8A8VRdBY6aiuZ/4WD4M/6G7w9/4Mof/iqP+Fg+DP8AobvD3/gyh/8AiqLhY6aiuZ/4WD4M/wChu8Pf+DKH/wCKo/4WD4M/6G3w7/4Mof8A4qi4WOmpfyrmP+Fg+DP+hu8Pf+DKH/4qj/hYPgz/AKG7w9/4Mof/AIqndBY6ekrmf+Fg+DP+ht8O/wDgyh/+Ko/4WD4M/wChu8Pf+DKH/wCKpXA6alrmP+Fg+DP+hu8Pf+DKH/4qj/hYPgz/AKG7w9/4Mof/AIqndBY6eiuY/wCFg+DP+ht8O/8Agzh/+Ko/4WD4M/6G7w9/4Mof/iqVwsdPSVzP/CwfBn/Q3eHv/BlD/wDFUf8ACwfBn/Q3eHv/AAZQ/wDxVO6Cx01Fcz/wsHwZ/wBDd4e/8GUP/wAVR/wsHwZ/0N3h7/wZQ/8AxVF0FjpqWuY/4WD4M/6G7w9/4Mof/iqP+Fg+DP8AobfDv/gyh/8AiqVwsdNRXMf8LB8Gf9Db4e/8GUP/AMVS/wDCwfBn/Q3eHf8AwZQ//FU7oLHTUYrmf+Fg+DP+ht8O/wDgyh/+Ko/4WD4M/wChu8Pf+DKH/wCKpXCx01Fcz/wsHwZ/0N3h7/wZQ/8AxVH/AAsHwZ/0N3h7/wAGUP8A8VTugsdNRXM/8LB8Gf8AQ2+Hv/BlD/8AFUf8LB8Gf9Db4e/8GUP/AMVSuFjpqK5n/hYPgz/obvDv/gyh/wDiqP8AhYPgz/obvD3/AIMof/iqLoLHTUVzP/CwfBn/AEN3h7/wZQ//ABVH/CwfBn/Q3eHv/BlD/wDFU7oLHTUVzP8AwsHwZ/0N3h7/AMGUP/xVH/CwfBn/AEN3h7/wZQ//ABVF0FjpqK5n/hYPgz/obvD3/gyh/wDiqT/hYPgz/obvD3/gyh/+KpXQHT0VzP8AwsHwZ/0N3h7/AMGUP/xVH/CwfBn/AEN3h7/wZQ//ABVO6Cx01Fcz/wALB8Gf9Dd4e/8ABlD/APFUf8LB8Gf9Dd4e/wDBlD/8VRdBY6aiuZ/4WD4M/wChu8O/+DKH/wCKo/4WD4M/6G7w9/4Mof8A4qlcLHTUVzP/AAsHwZ/0N3h3/wAGUP8A8VR/wsHwZ/0N3h7/AMGUP/xVFwsdNS1zH/CwfBn/AEN3h7/wZQ//ABVH/CwfBn/Q3eHv/BlD/wDFUXQWOmormf8AhYPgz/obfDv/AIMof/iqP+Fg+DP+ht8Pf+DKH/4qi4WOmormf+Fg+DP+ht8O/wDgyh/+Ko/4WD4M/wChu8Pf+DOH/wCKouFjpqK5n/hYPgz/AKG7w9/4Mof/AIqj/hYPgz/obfDv/gyh/wDiqd0FjpqK5n/hYPgz/obvD3/gzh/+Ko/4WD4M/wCht8O/+DKH/wCKpXCx01Fcz/wsHwZ/0N3h7/wZQ/8AxVH/AAsHwZ/0N3h7/wAGcP8A8VRcDpqK5n/hYPgz/obvD3/gzh/+Ko/4WD4M/wChu8Pf+DKH/wCKouFjpqK5n/hYPgz/AKG7w9/4Mof/AIqj/hYPgz/obvDv/gyh/wDiqLhY1fhZ/wAirP8A9hfVf/ThcUVF8I7iG78GNc2k0c9vNqmqSRyxMGR1N/cEMpHBBByCKK52bosfEz/kXLT/ALDOk/8Apxt66rA9BXLfEv8A5Fyz/wCw1pP/AKcbeuqFAxNo9B+VG0eg/KlooATaPQflRtHoPypaKAE2j0H5UYHtS1m+ItasvD2h3urarN5NjZxGaZ8ZIA9B3J6AetAE2o31pplhPe6jPDa2kCl5ZpnCoijuSa8j1b9ovwTaStHp6apqeMgPb221G+jOV/lXzT8U/iXq3xH1lprx3ttHiY/ZNOVvkQdmf+859T06CuYtutRKVikrn1bB+0fo8rjd4c1ZVJ6iSEn8t1dt4N+LXhXxTO1tDcSafeKhcQ6gghLqOpVslWx3wc18Z2narWsBG0O5EieZnaEG3OGzwf581z+3kpJGvsla59/W00NzAk1vJHLE4yrowZWHqCOtS4HtXx38EviE3gjxdb6RfTsvhzUXWGSNmyttOcBZV9ATw2OOQe1fYgJ710xlzK5lJcrsG0eg/KjaPQUtFUSJtHoKNo9B+VLRQAm0eg/KjA9BS0UAcnqKj/hafh7p/wAgbU//AEfYV1eB6CuW1L/kqnh7/sC6n/6PsK6qgBMD0H5UbR6D8qWigBNo9B+VGB6ClooATA9BScelKTzXyF+0R8YrrW9VvfCvhq4kttHtpGhvLmJtr3bg4ZAR0jB4/wBr6UAe0eLfjt4K8O381iLi51S8hbZImnxCRUb+6XJC5+hNcp/w0rpryYg8L6i0f957iJT+WT/OvlS1AUAKAAOwrXtOorGdRrY0jBM+s9B+Pnhm/uY4dSstQ0pXIXz50V4l92ZCSo9yMeuK9T0/VdO1LzRp17aXflY3+RMsmzPTODxXwrYEBgT06n6VS8Ka5e+ELy11zQ91teQzu/ln5RLHu5idf7pHbtwRUU67k7SKlSS2P0FABHQUbR6D8qxfBniOx8WeGNO1zSmLWl5FvUHqh6Mh9wQQfpW3XSYibR6D8qNo9B+VLRQAm0eg/KjA9qWigBCBjtXK6iB/wtPw9wP+QLqf/o+wrq65XUf+Sp+Hf+wLqf8A6PsKAOpwPajaPQflS0UAJtHoPyowPQUtFACbR6D8qNo9B+VLRQAmB6ClwPQUUUAJgego2j0H5UtFACbR6D8qMD0FQ3NzFbKGmcLnoOpP0FJDLJL83llEPTd1P4Urj5Xa5PtHoPyo2j0H5UtFMQmB6CjaPQflS0UAJtHoPyo2j0H5UtFACbR6D8q5X4Tgf8Ks8G8D/kDWf/ohK6uuV+E//JLPBv8A2BbL/wBEJQB1OB7UYHtS0UAJge1G0eg/KlooATaPQflRge1LRQA04HUCuF8d/FXwl4IuRaazfl9QI3fY7SMzSgerAcL+JFc1+0p8Rr3wH4XtLfRSI9X1ZnhhnIz5CKAXcDu3zKB9c9sV8ZRPJNM808jyzSMXkkkYszseSzE8kn1pN2Glc+uf+GkfDrygQaFrTxn+NhCp/IvXVeF/jN4P12R4pbqTSZlUsF1JRCrgddr5Kk+2c+1fGtj1A7+lasun3GsaddWmnW73ckKfaZ1jXd5MSHc7t2GADweT2rn9tJSSNfZq1z75tbiC7t457WWKaGRQySRsGVh2II4IqbaPQflXyt+zH47ksPFsng+WQNpeoh7ixAPywSqNzKvorrk49R7mvqkV0Rd1cyas7BtHoPyowPQUtFMQm0ego2j0H5UtFACbR6D8qNo9B+VLRQByvw0/5Fy8/wCwzq3/AKcbiij4af8AIuXn/Ya1b/043FFAB8S/+Rcs/wDsNaT/AOnG3rqhXK/Ev/kXLP8A7DWk/wDpxt66oUAFFFFABRRRQAV43+1jfNafBy9hXj7ZdW9ucem/ef8A0CvZK8R/a9Uv8JVIGQmpQE+3DD+tAHhfw5+Ceq+MfC9vrv8Aa9npttcs4hjmheR3VTjdwRgEg/lXSWP7PHiD7Xtude0dLXP+sjjkdyPZeOfqa9U+Br/bPgx4Z8nOUgkjP1WV811sF5CkZjXUbLzieAbhD/WuSU5XaOiME43ueI2vwA1aOc+b4n05rfP3hZuHA+mcZ/GvQfBPwy8PeH5TPcPJrOobWTzbpQixqwKsEjHygkEjccnmu8nkaJFLKCP42zgAepNU7V7D7XiHULSSQ9I1nRmz9Ac1ne+pSStqz4w+Lfhi48G+Jb7R5TI9ug82ynfrNAeUOfUfdPutfdvgbUG1bwZoOouSXurCCZifVo1J/Wvl39sKPbqPhiXkM1rcR4Ps6n+tfRnwb/5JT4Rw27/iWQc/8AFddLWNznludlRRRWhIUUUUAFFFFAHK6l/yVTw9/wBgXU//AEfYV1VcrqX/ACVTw9/2BdT/APR9hXVUAFFFFABRRRQBV1S6Fjpt1dld3kRPLj12qTj9K+BvhT4Av/iZq+piC+hsIbdPtE9xJGX+Z2O1AoxyeT+FfePiNTJ4f1RAMlrWUDH+4a+V/wBjmVc+LYOjmK2kH0y4qKjai2ioq71En/Zz1eOdRYeJtLlg7tNbyIw/AZB/OtE/s9X8ckTQeK7Urj94kliw59iG6fWvbnkh0+cm9vLa3BBYCaZUJHrgnp71asblbm08+3ngu1JOx4HDq3tkVyucmbuCWzPLvD3wZ0HTbpG17UbjWiP+XUxiGAn/AGgDucexOPXNcT+034SNhfw+KLCM/Y77bBeKoG2GZVAjYAdAyjH1Uete8fbtLuZSDqdik6na8X2lMqc9CM8H2rk/2hod/wAGtfHOY/s8g/CVf8aIO0kE7W0epT/Y71E3Pw51Gyck/Y9SkC+yuqsP13V7zXzn+xaf+KV8S+v29P8A0WK+jK7TmCiiigAooooAK5XUf+Sp+Hf+wLqf/o+wrqq5XUf+Sp+Hf+wLqf8A6PsKAOqooooAKCQBk02R1jjZ3IVFBJPoBXJ+ItJvNZ0SS5iLm9BEttbFwqbR/A2eCSOST3x6UAdcelRNPEsywtKglYZCFhuI+lc3FIbi2s5bT7XE7iTzY5pWV4yo5Q9QDn2PFWbfTfttrZSNG1qWYTy/OWlZsfL8/wCNAHQCiuZ01tdW4MDovlWu5WluDn7Rk5Uqw5GB1yK3LG6F1CWKNG6sUdGOdrDqM96ALR6Vh3usvJevp2jotxep/rXP+rg/3j6+1Z2q6tdaxqkuieHpDGYSBfX4GRbg/wAC+sh/St/SNNtdJs1tbKPZEvJJ5Zj3LHufeovzaI6fZqiuapu9l+r/AEX9Nmnaatu3nXEjXN2fvSv/ACUdhWjiiiqSsYSk5O7CiiimSFFFFABRRRQAVyvwn/5JZ4N/7Atl/wCiErqq5X4T/wDJLPBv/YFsv/RCUAdVRRRQAUUUUAFFFFAHy1+1lbDVPiT4C0ueRltrn902DjAeZFY/XFegah8Lfh+1wto3hayjEbYV4mdGOOOWDc1zv7SGipq3jjwveJM0X9jxpd3RC5xC1zGoI9CCG/St74p+L9a8NazGlhol7e2j4bz7SFW5JIKszAgEdegwDnNYVbtpI0puK+JF2P4Z+AiI2Xwtpf7r5M7G/Xnn8a6HR7S10lWstM020s7POfKgiCK3+8B1/Gs3w3eXdx4Qkv8AVGuGkdXkAnijWQL/AA8L8p56HvXCW3j3xPB4hh0ePRtYvn3hHmltotn3sYYIAVx9enNY2k76mnNFdNzzFNFi8H/tQ6RpmmswtF1SGSAEfcjmXOz6DcQPavtUV8zeL/DRuP2jdK15LkLaWdxpy3HGQsjBgig++0fma+mR3rqg7xRhLcWiiirEFFFFABRRRQByvw0/5Fy8/wCw1q3/AKcbiij4af8AIuXn/Ya1b/043FFAB8S/+Rcs/wDsNaT/AOnG3rqhXK/Ev/kXLP8A7DWk/wDpxt66oUAFFFFABRRRQAV5x8bbCLXdD0nw9dQ+ZBquoxwtnOPlDSAEjkZ29QRwCO9ej1yXxM065v8Aww8livmXVjMl6kXP7wIfmXjnJUtjHfFJ7aAcJ4Bsoo/hTBp9lZwTw20lxb2ySyN5UxSZtruy8lCeenIFZuk6X4tmvHj8R6f4OutKdwfs8VmUkxnswGMgZx/Sug8HXcS+H3trC6W6tbe8nhhuFx88e4MCccZ+fGPbpWx9v+xWtxdyLLMsKbmSMbmIzzgd8dfwrku1c7I0k4c8kP8AEARdKgtxAksE88Ns0EwJVkbI2n8h/wDXrgV0vxnFqKRx6f4J/sVV2C0js2Rgp6rvxkY55HPtXc+I72NvD32yGSZfmSaBvs7sSytkBlA3KDjGccZq3dXTq67U8slQ209Vz2P0qYtoUIKbtY87+L3hTT/Fd54P0e6jaKNFu5oyzHLKkanyd2c5PUd+K9V+GEsc3w88ONBCYYRYxIiHsqqFH5gZrzvxtPJf6hp9nFIBfpbSPZw5wZp5XWJenOFG5yR0A5IFevaLYrpmkWNhGxZLWCOAMe4VQuf0roo3sYVVaTReooorYzCiiigAooooA5XUv+SqeHv+wLqf/o+wrqq5TUf+SqeHv+wNqf8A6PsK6ugAooooAKKKKAM3xHdvp+ganexf6y3tZZV4zyqkjj8K8V+DOgWHhvXNTg02FAL3SrO+uJI2JwzO+1eScHad3HqDgdK94uIlngkik5SRSjD2IxXi/hISaN4gutNuZg1/DZvDPCFKAeXMojlUHna6FTnJGcgYxisqyfKXTV5WOf13wv48stcFxpuoaeuktMxk2QJNOUY8Y3Izs+MhiWx6cV6f4dspdN0KKKdLcXIQvIsEQjTd2GABz+FR28jvdJlzkmrem6ml2s7G1u4Wt3IkSWJhnBP3Tj5s47etc0m2jedL2btc8s8R6F40vprX/hFrnToILnZO+6yiWNkK8ncUYeYDkc9sc81s+I9Ku9N+CniKy114rq4lhbzTB9xFZ1AYDoCo+Y7RjIOBXT6DNJ/wjUa7JVWGR4Y2liMTOgY7WKHkcHH4VQ8U3Cr4Zuori5W2hupoLWS4bGIleRdzc8cAGq5m2JUrwc7h8CNAs/Cf/CS6Dp6BorW5hcz8kzF4VO7PoQAePWvWK4v4WafLaeH57qdWRtQuXuo0dSrLFgJEGB5yURSfdugrtK647anMFFFFMAooooAK5XUf+Sp+Hf8AsC6n/wCj7CuqrlNR/wCSp+Hv+wNqf/o+woA6uiiigDO1vLWqQAkCeVIiR6E8/oDWhjjAxVDWsraLOAW+zyLMQOpA6/oTV5WDAFSCDyCKAMy+insnmvbTDqTvlgP8WAASp7HA/GtJHVlV1OVYAgjvWd4lhup9GuI7AEzMMbQ2CR3APriuVsbfU2uG86DUntFVQZZ0VXjwQQI0U89Dz2z3oA7qUuI2MShnwdoJwCe3NYQWWzsJrDULh4GnDbb+IbfmbOSf7rDPGeDW5BMk0KSxsGjcblPqDT2UMCGAIPBBpbjTad0Zfh/TLHQ9LgsrBlEKDJdmBaRj1dj3J9a1QwIyCCPUVV/s6yGf9Et+f+mY/wAKjfSrXJaFXt3/AL0DFD+Q4/ShJLRDlOU25S1bLwINLWW011pxJuibm07yqnzx/wC8B1HuPyrQilSaNZImV0YZDKcg0ySSigdKKACiiigAooooAK5X4T/8ks8G/wDYFsv/AEQldVXK/Cf/AJJZ4N/7Atl/6ISgDqqKKKACiiigAooooA8n+OVh5UMGqlYkt/LEU85QsQY5FmhQ4/hZ1YZPAJU1uXd488zjgROfmjxkEHsR3rs9RtIr+xubO5BMFxE0MgHGVYYP6GvN/CMovbKW3adHv9MlfT7kYJAmi+UMR1II2t75rCsup04eUY35jSurqG70zWLZre6gEEbwMPs7HPy4DR4++OQflpsF3KdNspTCbae4iV5kC7WLYA+bv+fPNc89h8QCzB9csW3fxQQpGi8/wBgSv4k1tWMWoWuhyTeLdSsZntt00lzbRGJUhUZO7J5YeoAB9Kxsl1HTaUk5GHY2h1j4ryeWIpVtzatdxlCREsMZkjkJ6FzJIAo7BWNeyCuV+HCGTwzDqUgKy6sx1FlP8IkA2L7YQIPqDXVV1wjyqxzyd3cKK5mx8a6Nd+J9S0AXBh1CykWIiXCrKzIrYQ9yNwBHXNdMORTTTCUJRtzK1wooopkhRRRQByvw0/5Fy8/7DWrf+nG4oo+Gn/IuXn/Ya1b/ANONxRQAfEv/AJFyz/7DWk/+nG3rqhXK/Ev/AJFyz/7DWk/+nG3rqhQAUUUUAFFFFABSYpaKAPOdRsv7P8XahbIirDqCf2hBgYBcAJMvuf8AVt+JrnviD4i1fwnptudF0S91C4uN2+4gTctsBj72Ocn1xW/8SrRtS8Q6MljcG21HTLee+jlKllQttjVXHdGy4I64GRyKqrcab4rtI9O1AzadrUGGa2WfZPC+PvRN/wAtEI6MMgjrg5rlqq0jto1LRSltc8hb4meIlKi21Czu7oEH7HbyTG4Qn+8DGB+ter+GNXv/ABBoMF9quk3Ol3uTFJBMBlyMfOo6gHPej/hAbgO7P4k1nYw+YgKrMPdxUqXsKwLo/hKRWWA7bjUifNitc9SG6Sznso4Xq3TBzunsjpq1oK3K7v0sbfgK2F5q2q6qyqY4iNOt3xknyyTKQfQuxX/gFdxjmuO+FcMFh4Zk0m237dMvJ7b52yzAuXVie5ZXDZ75rsq7I7aHlzblJthRRRVEhRRRQAUUUUAcpqP/ACVTw9/2BtT/APR9hXV1yuo/8lU8Pf8AYF1P/wBH2FdVQAUUUUAFFFFAAa4v4iQC2bTNZOBFaSmC5Y/wwzYQt/wF9jfQGu0rk/icIp/B17p8qq51IpYJETjzDKwUj8txz2xmk0mrMabi7ozXgurWC4mgtRdXUSny7cyiISMP4d5BC/WuWbxL4xGFn0WGGV8hY/JlbyTnruGQ4/KtTStXGiTNpuu3G23DlbPUpTiOZO0crdElA7nAYcjnIrrYwZIg8PzxsOGQ7gR7EcGuK/LurnVUk3LU5fw/qHiLUfOi1/R0toFXMd75gRpT/dMPJX65/Cp47L7f4k0nTSAyQP8A2pcA/wAIjysQ/FyT9ENT6vr0FlN9jtEGo6sw/d2MLjcP9qVukSDqWb8ATxVbwTC1h42uJNQuVudR1axVpJgNib4XP7qJeoRVkGM8nknk1pT1lchyag0tj0gDjmloHSiuo5wooooAKKKKACuU1H/kqfh7/sDan/6PsK6uuV1H/kqfh3/sC6n/AOj7CgDqqKKKAEZQwIIyD1B71lwx3WnARxL9qtB91QQJIx6c8MB26H61q0YFAFD+0gPv2t4h94Sf5ZqGea9vVEdlE9shOHnmGCq99i/3vrgfWtWsTxnq/wDYXhjUNQAzLFEREv8AekPCD8WIpNpK7KpwlUkoR3ehnaLf2Ml3KNGjlSG0u/sExI+SZgvJU9yp6n611g6VymiaT/wj3hLSbZyDJbMkty56s7H52P4sa6sUo3srl1lBVGqe3T/P5hRRVK8uJLae2bg27t5b8cqT90/TPH41RkXcVnzabHvaSzd7WYnJaP7pPuvQ1fFLjNAGbFfSW7rDqKrEzHakyf6tz6f7J9j+BNaNNlijmiaOVFdGGGVhkEVlq76U2yZ2ewJwsjHJg9mPdfQ9u/rQBr0UgOaWgAooooAK5X4T/wDJLPBv/YFsv/RCV1Vcr8J/+SWeDf8AsC2X/ohKAOqooooAKKKrX95b6fZzXV7PFb20S75JZWCqg9STQBZpCcVxs3inUNRjDeH9N8u2f7l/qWYkI/vLEP3jAjoTtB9azp7KW7GNZ1vUb4Yw0UbC1iPsVj5I+rGs5VYouMJS2R0uu+KdL0ljA8/2nUCP3djbDzZ5G7AKOmfU4A7muDt9Hv4bq3v7S4t7bxA6t9sJUvb3G92kMUgHJClsK45GOMgkV0+mWtjYwtFptrBaow+YQoF3fU9W/HNKlskUhkb1zWE6vMbU4qN+YwbjxRqFnNFbXXh52uJDhTBfxlG9wWAIH1FOms73UpYLzXktzZxuJItLgYvEGHR5nOPNYdlACDrycEU9ZmhuPF9hAuQFI/XJrsSqhdq4IA44rK50VacKag7bmd4Q1+20WxttD16dbO6twY4J7g7IrqLPyMjn5d2MAqTkEHjGDXcKwcKwIIPIIOciuHRXlmkiuoVmhk4eOVQyEe6ng1mX1jZaRY393o9xeaS1rBLdFLOXETFELcxtlMcdgK6Y1ujOWpRcXoeVeFoU8T/GG1fG+C41y71Pnn93ASE/8eEdfUYr5i+AhvLTWbjVIdNfUEtNOht5VjlVZFeY+c5QNgMSAvGRX0PoOvWOuQSPYSsZIWCTwSqY5YH/ALroeVP8+2aqk1Y3zB/vVD+VKP3LX8bmtRRRWpwhRRRQByvw0/5Fy8/7DWrf+nG4oo+Gn/IuXn/Ya1b/ANONxRQAfEv/AJFyz/7DWk/+nG3rqhXK/Ev/AJFyz/7DWk/+nG3rqhQAUUUE4FABkUhZQCSQABk5rlNY8Uytez6b4cto72+gbZcTzMUtrVsZw7Dln6fIvPqVrHvNNk1DDeI9Rl1SMHItVXyLbPvGpy//AANiPas5VFEqMHLY6G+8ZaFbTeQl+l3cnpBZKbiQ+2Ezj8az7jXdevvl0zTItNhP/Lxqb7nx7QoSc/7zD6VFDcQWkXk2kUVvDjHlwoET8hgVNDc7xWMq0uiNvYNK7MxbI2KztJcT3t7dsHubuYANIVGFUKOFUZOFHAyepJNS3Ol22o6cIb20huUU7lWVA236HqPwrUeNZME9ahuLlYBtRcmsuZs1i7xUIo5UeF9I3hW05XA6I8sjL/3yWxXUNaJ9ihghSOKOIYWONQqqPQAcCmW9ysjjegBq8KG31KqScWrKxhyWk1rqCXejX32PUXQRzB4/MguFX7okXIIIyQHUg445FasHifUbMBda0SYqMZuNNb7Sh9SU4kUfgfrVSeyl89mUcE5z6VPcXDWyIBkn1rSNSUdFqROlGTXK9WbWk+KNE1ZxHYanayTE7fJL7Jc+mxsN+lbORXEX9lbatGn9oWttdxYwwuIwxH+63UfUGobeDV9MTGh6v50Cfds9UBlT/dEw/eL7Z34rWNZPfQ55U2jvqKwfDviOLVZpbK6t5tP1aBQ8tnOQTtJxvRhw6Z43D8QDxW9WydzMKKKKAOU1H/kqnh7/ALA2p/8Ao+wrq65TUf8Akqnh7/sDan/6PsK6ugAooNYXiLxFBpDQ20UE17qdyGNvZwY3uB1ZieEQZGWPAz3PFD0A3cj1rE1fxToelSGK+1S2jnBx5IbfJn/cXLfpXN3EesalGx1rVjBC3Wz0r92o/wBkzH529yNmadp6WWkw+Vplpb2aDr5SBS3+83VvqSaxlWS21NY0ZS2L0/ifUbtSui6JMFOR9p1JvsyD0ITmRh+A+tZz2d212mpazei+vYQ32eOOPyre2LDBKLklmxkbmJOCcAZNWo7wMetPubhQioqeZNIPljzgY/vE9hWLqTloaey5GnIrWMJmEqugZHUqysuVYe4PWvPPG2h2FrrWnpFZRwI/LJDmNT8+OVUgV3V/GscBa6kaVyOxKqv+6P6nmuJ8Q6g11f6OXYPKiiNyeuRJ3/DFa0FeV0bSk5Nux6FpGnW1hYyW1law2sTHJWJAuT6nHX8aq3+mQSQL50ssNxFIJbeeBtssEgGNynoeCQQcgg4IxTHuZbvVLpTLIkEUhjWNG2jjucdTUl1BcriSJ3uEA+ZHOXH0Pf6GsbWe+pMZczaezLdnq3iKwRftdva61bcfvrYi3uAP9qNjsY/7rD6VoW/jXRDMsN9cSaXct/yx1GJrc/gW+U/gTWfayCGwWRXDq3KkU6OV7y1kiO0gnlXG5T9QeDVqtJbmTo3u4vQ7KKaOaJJYZEkjcZV1YEMPUHvT8155Foy2MjSaDez6PK/Lx26q1u59TC3yg+67a0rDxPdWFzDaeKIYIhM4jg1G2z9nkYnCo4PMTngDJKk9GzxW0asZGMouO52NFIpzS1oSFcrqP/JU/Dv/AGBdT/8AR9hXVVyuo/8AJU/Dv/YF1P8A9H2FAHVUUUUAFFFFAAa4vxzjUtf8MaJkGOW6N7OvqkIyAfYsV/Ku0PSuMsv9N+KuoSsMrp2mxQL7NIxcn8lrOpqku514T3ZSqfypv9F+LR100azQvHIu5HG1h6g1nwXjWKrb6kSgX5Y7k/ckHbJ/hb1z+Fao6U1lDAhlBBGCCOtaHIKCCAQQR14qK7t47q2kglBKOMHBwR7j3rOI/siYEHGnSHBHaBj6ein9D7dNY0AUbG4kWZrS8x9oUbkkAwJk/vD0I7j+hq/VLU7Z54FaAhbqI+ZE3+0Ox9iOD9alsrlbq1jmQEBxyp6qehB9weKALFI6hkZWAZSMEEcEUtIxABJIA96AMG8d9H8hLK4R/OcRw2k7dT6I3UY9DkYrRsL+O4klt2/d3cOPMhJ5XPQj1B7Gsa9hivVl1aY7URPKtlK7hIpI6qeu44A6HpzV3StI2aZEmokS3m5pGlRjlGJ6K3XAGB+FAG1Rms/7HdRgCDUJcDtKiv8Arwf1ozqcfLJazqP7paMn88igDQzXK/Cf/klng3/sC2X/AKIStn+0HiH+k2dzH3JVRIo/Fef0rG+E/wDySzwb/wBgWy/9EJQB1VFFFABXn/iy5XUPF0NnKqy2mlQrctG3KtcyEiMsO+xVZh7sD2FegV5ejGfXfENw/wB978xE/wCzHGiqP5/nUVH7pth4Kc0mXpLqSTO4/Me/c1Ccnkk5qW2j82UJgkmrDWDA8ZIrlukek5Qg7C2BYtVu6KeUUZsE02JFt1y3BFQTKt04ZHwe4qN2cztKfN0OIkV1+JNvC/Q7SD7bDXocLB4wVzjpz61wOtOlp8UtEB/ijUMffDAV6BLIsaFmIC55xSNcTJzUfQY06LKqZGWOK+eb/wAeSeR4502acPHrbzjTOSWhZpfK8v2V1Ule2VYd69iu9a094vEMtldLJPocbteRdGiPlF1OO4I6H1BHavEPDfgyfVPhtqHiHT7fz9b0+5AhhxkzxRxr5kY9/MYuv+0vvWkdBU40krzemifld/5JnpfwZtzB4cmu0XK6hfSzIcf8skIiT9EP511GtXi6brOn63HhXtZUt7qT/npbSMFYNjrtYqw9MH1NXvC+kro3hXSNOjAJtbKOLcB1YKCx/MmsvXYPP0bU4pBkNbS5/wC+Cc/mAaINKV10FKSxDlNrV3+96nqdFUNBne60TTriU5klto5GPuVBNX67TzQooooA5X4af8i5ef8AYa1b/wBONxRR8NP+RcvP+w1q3/pxuKKAD4l/8i5Z/wDYa0n/ANONvXVCuV+Jf/IuWf8A2GtJ/wDTjb11QoAKyPFmqHRvDeoX6DdLDEfKXGd0h+VB+LEVr1xvxIcvb6LaA/6/Uo2YdisatIf1QUm7K5UY8zSMfT4TpunW1hE25YFw795JCcu59SzEn8aleRnHJpg6e1SwwmTNcfmeuoxgiICp7XPme1IbeQHBFXLS328tSbJqTjylxDhATVG7iWZi0Rywq1MVZdisATVK0glWbnjFSu5zU9LyuNt4GUGSQEBeTWnG4dAy5wR3FIJULmPdzT+AM9AKG7k1JuW5FLMsa89aiLRXIAbqOhqG/hZjuU5FR2kD7snii2hcYR5ea+pcuv3dviMcCqdjIzP3IHetMgEYPPbFQTosVuxQc0Jkwmrcvc5/xFdvayWmrRZ8zS5xNxyTCx2zJ9Cp3fVBXp64wCORXms8AuoJLaQZWdGiI9mBB/nXW+Bbs3vg/RpnyX+yoj56llG0/qDXVReliMVTUGmjeooorY5TldS/5Kp4e/7Aup/+j7CuqrldS/5Kp4e/7Aup/wDo+wrqqAA9K8wsL0395qmrAhjezmKFvS2iJRAPYsHf6tXoGv3TWOh6jdocPBbSSqfQqpIrzrRYBa6NYQAY8u3jU/XaCf1zWVV6WOrC01KTb6GgZnKkE8VGepPU05F3sAKme1cdOlc+iPQvGOhWeYW8bSv91R09T2FW9OBWF5pj+9f5pG/oPYVm6hGTd2tufeUj6cD+ta4YwwNsALgZAJxmieiS7nNVkpOyMue9t9Rst0TBWO4BSeeDjNcHqkRTUrTIwQwYn1G6tS7+1jULq7sbWJ7dUaSVTIVVHIyQDjk8ZwO9Z+n295rdvPeERosa7lDHG8DstdlGChd9DObasonc2U8VxqN5JF/q/M6nvgYz+NaEd5HvuI3OxoWC8sPmBGQR9a5fwRqcV5CbacCO6j+Vo243j/PWh3z4iubbTYUvXhgCxt5gxFznBz129OK550/eafQULPVnQxXkcV/5RwILk4Yf3X7H8ehrWjjWOM+WOozXGahDP5A8wFZQAT04b8Peuu0yf7TYQTY+Zl+Yeh71E4+6mOolF2iUfMcz4wevSl1hI7yymsbgboLiNo5F/wBkjH5jqPcVp+UgbdjmseckzPkc5qVqzaDVR7bHR+A9Tm1PwxayXjbr6Ata3PPPmRsUYn643fjXQ1xXw/Yx6n4htQPk86G6H1kiG79UNdrXandXPOnHlk0FcrqP/JU/Dv8A2BdT/wDR9hXVVyuo/wDJU/Dv/YF1P/0fYUyTqqKKQmgBaKz9Z1W10fT5ry/lEcMQye7MeyqO7E8ADqTXEXXxA1XTZL1b/wAOvObSOK7nSynDvBbuSDlTy7pgkheDzjpym0twPQrt5I7eR4YvOkVSVj3bdx9M9q80+H3iRNU8beIjbWN3vu5Y2cyqE+zpGm3D/wC1uyABWhovj26199Sn0HSI9S0qGfybW8hvVRbnCgttDAcgnHGRnuDmug8K2umMl1rOlRso1ZluJdwwQwG0gjtgg5Hrms5JykrPY66FWnTpVIzjdyWn3pm+OaXNYOqeJ9P065ezUzXmoKAxtLSPzJFz03dk45+Yiscajr+pfOLqy0uLPEUMf2mX6MzEJ+QP1q5TUdzlUW9js3VXRldVZWGCCMgisxVl0s5TfPp/9zlnh+ndl9uo965+eTV4o2Ztenx7WcWf5VVgsobyIm9vdTu8n5lnu2VT/wABTaP0qHWii1Sk1ex3ysHUMpBUjII5BrKvI7vT5JbnT4PtUUjb5bcNtYHuyHpn1B6+tc7HFDo8ara2u+yHBt1yTH7pk/mv5Vt2nkXFss9i5Ct/FG5AH1B7+xFONVPUTptGjpmo22pW5ltWJ2na6MMMjd1YdjWTruok3yWLQubMgG4lQ889I8ep798dKi1LTbrzWvtLuFTUlXADqAJsdFcjr9cVnjW86fHZ28MX2ucsLlZXw8LfxM6kdc9Ox4xxVxfNsZvTc6C1dNTu1liZWsrZsR46PIOCfovTHrn0rXXiuZ0vVrSysYrezsZY4kBCruU9+STnknrmpW1+4LfJbRAejSHP6CtPZy7C549zoqK50a/cA/NbREe0h/wqRfEDfxWbfUSCj2cuwc8e5u45zXLfCf8A5JZ4N/7Atl/6IStAeIIAPnt5x9AD/Ws/4T/8ks8G/wDYFsv/AEQlS4tbjTT2OqooopDCvOYrTGt+IogMEah5n4PDGa9GrzQ3Jm8R+I54jhDerD9THCin9SfyrOr8Jvh03P3SXWbKVvDmrLbs8c32WRkZTghlUsMH8K1LW4S9tbK9jlwk0KTDB4YMob+tN8xm0q5c/wDPGTr/ALhrmPh/aTweFdO0y5WQQ2ltE1pcnlZYHUFVz/fQ5Uj02nvXJuaNtz946u7g85OOtQWdo6OWbgelXlXaoHUgdaCQOpA+tK/QFUklyo858co8fjKyukAJiSNvyau/SOGeHC/MjnJ9QTXK+MbYz6hbyhMqU2Z+nNdhphXyrZhgIArH+tStDeq2qcGfLvieS9bxN4x1HTXaDTUu5rXUrtRkCCaTYsbjuh8o8/wkg9Ca93+E9r9i+HmiIU8uZ4jdS9jukYvn8mH5VyvwL0u31PwPr95fxJcW2u6hcI6MPllgUsmPxJevSrl/7K0pmsLF7k28apBaRdXIAVFyeg6ZPYAmtZPoZ1K3PG1u3zskv69Spo0jXGs+IJfMZoluo7ZBnIVo4l34Hb5n5+lL4lYQ6Fq8nljaLGc7vQ7GA/Ws74fWj6dpGpw3UyzXI1W5kuJuzyttLke2SQPYCrnihnn0LVrWNc77OXBA6kIT/Sp6mUU2nY7fRIfs+j2EJ48q3jT8lAq7VTSbhbzS7O6j+5NCkg+hUH+tW67zmCiiigDlfhp/yLl5/wBhrVv/AE43FFHw0/5Fy8/7DWrf+nG4ooAPiX/yLln/ANhrSf8A0429dUK5X4l/8i5Z/wDYa0n/ANONvXVCgArjviCmZ/DsnYX7R/8AfUEgrsa5T4gKotdFkJ/1erWx/Niv/s1TLZlQdpJmIEYnGKkmuW04ae3lhxc3sNo5P8AkyNw98gfnVxDCzYB5rL+IDtaeB9XvIIzJNZxLdRKvUvG6sMe/GK473djurVW1Y3ZHIkRRGWDHlh2ouNwiO2opdQiaGG5t8PBcIJUI7qwyP0NTwuJIlcDg9qgys0lKxjtI/md81q2pJUFvShoIy241KOMYBFNu5dSopKyRSFupupGjfLj+GpZUmltiHIEntUxQAO6KN5HX3oh3iNfNxvxzjpRclzb1IrON44ishB+tPkhWRl+bbt5wtS1SWCZbkvuypNIE+Zt3sXGZUR3Y4jRSxPsBVLSLp9S0Wyu541ikuYElMY5C7hnH5EVmfEHUzo/gvV7tF8yVovs8MYPLySfIAPfkn8K3YIEtreG3i/1cUaxr9AAB/Kn0M1uVo7VI5g5IwvzEZ9Oav/DeMx+CNG3DBaAP/wB9Et/WqOpKsdleXAyJEt5CPwQ4re8JII/CujIOi2UI/wDHBXRQ6k1puVrmtRRRXQYnK6l/yVTw9/2BdT/9H2FdVXK6l/yVTw9/2BdT/wDR9hXVUAZPi2MTeFtYjPRrOYf+OGuKsg0lhZyAf6y3jf8ANAf616HqMQnsLqEnh4mU/iCK4Hw5PHL4d0lmPzm0iB/BAP6VhW6HThpuLdiWKORIpZI1DSqjFFPQsBwD+NWtOvWvdEsr5YgWuII5SingEgEgfjV20VVdGX1rlvAGoLJ4cubbaUl0u9uLIoTzsWVjG30KEY+hrn31LnNzmiS7uEbxBMHITYioM8DOMkZ+pqWdmDAMwAPTnrVDTZxd6xqLMM75iSCMjHT+lX9Ss7d02ppxkf8Ahbd5a/n6etbTSUkn5DoycXsc74ru3WxaztpYA1wdrovzOQfvMfTp1rW0W1gzHah1Vfs+xR7ZAzWMmm2vnztCv7nySBOvAkYnBKj+4BwPWul8NW8Mc0SRIg/ck4H+8MVpJqMLIUp+9zGGvh2PUoyJW8i5iBjEq9dw4+Yd6l0Ozs2t2tLpILO7tJMPsk2Nv/vhs5IPpT4Lye21fUJotrxNMx8s8Buf0NOvkWLX4ZobWC6S+h3sLgDBbPygHHB7c9aU3La4oSLGqtbvbGOCXzFB2lg24/n3rV8NEC1uIlJIilA59SoJrmdTIlTEVpJZrEfnjcAYPoMGuk8Mx+XBP5zBSSrOx6Alck/gP5VEo2pin01LVhevc6nq1sUXyrKSKJHHV2aMO2fpkCpJ7RC24kLk9TWJ8Pb3+1NEvdU2MgvtSuplDddgfYh/FUU10UsSTLtcZHWsHowhJxdyLwegTxP4kVfuoton/kIn/wBmrsR0rlPBChr/AMSzHG7+0fK/4CkMYH866uu6Hwo55athXKaj/wAlT8Pf9gbU/wD0fYV1dcpqP/JU/D3/AGBtT/8AR9hVEnVHPbrXzL8UPi5rFj8Snt7Ca4j0DSpvs0sdqwEsr8eZJz8rbclVU8ZGTnjH02a+FPHMbDxJrQcHeL+5Bz1z5rVlVm4JWNKcea573owsPFUMWreEtQuGt7iKeA3joJLm3ugMo0jSAtG3UcDHTHBrs4obu1tbV2ctdiJBcSjBZ5AvLFsAnnOM18WaZ4g1rw5czTaBqt5p0k23zTbybRJt6bh0OK92+GfxkmuPB9x/wksM17rlvN5Vs0SHdqAPJ4VTtKZAZsYwV71jKLeq1NIyUZXsey2lyLeGPzY1jAbIVFCjGcngfjVPR28RWejCyg/sq1DSSutzueUxq8jMMR4ALAEfxYzVTw9fnxFbyS/abWUCQrbvF8plXALfIST8rZUkcEqTWpFbXUE4EgdU6ZIxmpUnHY0cYVFfZkVl9m0q2+ywB3DMZJZHO55pG5aRz3Yn/DoKsSKJIF+ykJuPT1NUbpCkzg4zVyCSJ7ZoFd42KlQ6cMuR1U+oqX3NXBQinEsxYMflyMrsPvYpUVld1MaiMcr3zWL5fiC2txGDpF2w480tJDJKP7zDBUN9OKdbX2rQxEXmi3O3+/a3EcxH/ATtNFjHdXNlhI0oGFMXcd6pXNw9rcmWzKxznhwR8ko9GH9eo96jh1/TXnWCa4+x3TdIbxDA30G7AP4E1cu7MSN0KsfWhOzCDi372xc0rVor1/KbMVx/zyc8n/dP8QrM8W6cLi9trm0YW9+sbASFQVdQRhXHce/apks4vKKTIHHXnsfUHsawbrxDbQ+LP7Gu7yJ5EgTY8kq71ZySI2Hc4HX3rqw8lKokYYhJJ8o3TdThhAt79TZ3DMT+8H7t+f4W6VtqCwBX5gehHOarJFFPYpFPGksTDlGGQa5bVdNXT5iLeRmgY427jmMnoD6g9jXqRV9Dz5O2p1F1fWtpn7RcRJ/sk5b8hVI6/Y/9PB9xEa5bYI2xtCsePQmlIIOCCD6Gt1Q7swdbsjqTr9gVJ3TLx3iIro/hP/ySzwb/ANgWy/8ARCV5jJ/q2+lenfCf/klng3/sC2X/AKISuTFQ5bHThpuVzqqKKK5DqCvMPDED3dk11IMfarme4bHctK/9AK9Prz7wgQPC9jk4CeaCfpK9Y13aJtRm4ttGlIYthts/fUoB65GKwfD8sn/CK6JtGV+yRjP0GP6VvA2xuoXf7xbII6cVz3w5vFvvA+huYGTMToVPPllZGGCfwrmWiubJqMk7G79q8pIxICd3f0qtfmTeM/d7VfuXiih8yYDatZserW8kzif93EBkBqSdi6e/MkSQW/2u3MUuQOqk9jXJ+ItWubDS72JGZjbQylVUcsQhwK7CDVbF4ZHjnRFTkhuD+FecXmoG4vLiU5CtIWWk31OmgpSk20S/C2eTw/4S0LTX4jhtY/MQ9mYbm/HLGvTmZ98flgbGGSc9PSvJVuW3KsYyzsF/OvW7NMxwRt1wqmi99TPFU4ws0jH8NKDb6tuK7ZdVujg+zAf0raijRnRGUbT8pHtXM+B7mHU/Dq34DASX146g9f8Aj4cf0rf86VbyJUQNGWFOS1OWMea1i18OXZ/BWkhzloozDn2Rig/Ra6WuZ+G//Im2B9TKR/39eumr0DlCiiigDlfhp/yLl5/2GtW/9ONxRR8NP+RcvP8AsNat/wCnG4ooAPiX/wAi5Z/9hrSf/Tjb11QrlfiX/wAi5Z/9hrSf/Tjb11QoAK4v4jTb5fD9kCQ0t955x/dijZz+u2u0NcH4u3XHjLTo9uVt7CaUexeSNf5LUzdkzSkk5q5XtwTKoTqTT/GLFfCOqsOqwg/k61es7YRDc3XFZ/ix0uPCmsRow3C1c4+gz/SuK92jqrS53p0JtN0w6W93amSOTTPNMlmmMPArEloz2KhiSp64OD0FaaYCgL0FZ19M7eWx6Oobj3Galin8q3LsDSs9xeyfKrF0nAyelQPcIwKB8GopZTcQbo8jHUVmDO7kfNmmkXTo33NSySVJD5hyp6c1bZgvJOKitd3ljdVfUSVXApbsza552LqkMMg0tZVlKxcDORWoc4OOuOKGrCnDkdjlPHVhLdWF9eXMkf2KytHa2gUHJnYbTK/b5VO1QP7xPXFdTPKsIBkHGQKxPGHmHwZqgmAV2REGPQyIP610E4HnSDg4Y8UPZEKyepnSRzT3BiY5ilBjP0Ix/WtX4f3L3PgvSGkXDxwCBh/tRkxn9VqEHGMdaTwCDHba1bjhINVuVQeikh/5sa3oPVomrLmtodTRRRXSYnK6l/yVTw9/2BdT/wDR9hXVVyupf8lU8Pf9gXU//R9hXVUAY/i+9GneF9WuyceVayMPrtIH64riNPga00+ztjkPDDHEfqqgH9RXSfEweZ4Va27XV1bW5x6NMmf0qlbW2+UySZ5OawrO1jswslBSky5YgiKPd6iuX8Kac63C6layRosl1dwX0Lj/AFyLcSGNge0ikkZ6FSQegrqfPjSQKSAR0Fc/obFNP1FI+keqXa/+RCf61zLYnlcpepQ01Ct1PNCu51kfeo6uu7kfXvWrNZjUPKY3Mslk7EvHu2qQP4MDnr1zWXardWV9Oy2c88buWUxgEc+tS/bL6adzbWcls7D5wF37/qOmffrXTOLk7odnEXXzbwv55faUj8oAcAL6YpnhPzbnUJ7lSfLCogH90ZzWNf6Tqd9L++DKSfvTNjH4Cut8NWB06z8sMWZjudumTRK0Kdr3Zbi17xzS7ozOCMOHYc9juNdGunRrIjMwmQR+TIr9PLx0Hp83OaTWtH85pLm1ZVkfmSJ/uufUHsa5w2+ooyqY52C9FDb1H4d6NKmqdiKcXa5auwzvHH5rSwo/yu3JbHQZ749a1XsJ9T0+eziuBBbzzLHdvg72hCjckfoW+6SegJxzWU6atNJETp8kgXvs2f1xXU6NDcRIi3CKhdy5UHOCT0zSqe7Ej4myl4TCx6Tc7FCoL66wqjgASsAAPQACrd00k0avBkLnp0qn4PJOgRyFhmW5uZM+uZ3ra6DFc70ZUJcupX8HlofEmv2zfKsot7xR6loyjH8467EVxumjb46gYHiTTJEI/wB2VSP/AEM12VdlN3ijnluFcrqP/JU/D3/YF1P/ANH2FdVXK6j/AMlT8O/9gXU//R9hWhJ1J9q+Rvjz4fm0Xx7qEjxEWmpsby3kx8rkgCRc/wB4MM49GBr66rC8Y+F9L8XaLLpetQGW3ch0ZDtkicdHRuzDP9DkHFZ1Ic6sVCXK7nwBfpgmk0vxJrehQXMGi6lPYpcKUkMOA5U9QGxlQcDOCK971j9m7XWncad4g0yaHPytcwvG5HvtyM/TH4Vp+G/2YbJXjl8Ua9PdYOWt7GMQofbe2W/LFKEWtypST2PFPgH4WvfEvxP0k2kcv2Syl+0XtwN21YwDlCw6F/u4z3NfYGuaRZ+GDBq2mwG3sUby9QRGZl8pukpBJ+42CSOdpb0rpPDXh7SfDGkxaZoFhBY2MfIiiHUnqSerH3OTWo6hhggEdMGtJRUlZkI4K8jbztwG9GAKsvIYeoPce9JbQu0gIBFas3hH7M5fQL06ehO42jxiW2z32oSCmf8AZIHtTE0fxCwIe60aH0aO3lc/kz1zulJaI61ivdtYp6hDIpEgB24xx2qXT53ddjgkjoattoWtgArrNm57q+n4H5h81F/ZfiRW4fQ2TPXy5lP/AKFip9lK1iXXTjytDboR3UT2zpDcDPzRTKGQj3ByKzjolraKBp1zqOnRsceVaznygT/sNuA/DAq8LTXrdmeTS7C5cjJNteFM+2HT+tKx1YoyNoN2rEdUuIWH57hU+zmuhPNBsq/2SAw8zWdbyewvAg/ILXNa18P/AA/c3899JcazFqFxjzbmK+PmOQMAnIxkD2rqmh1Zwjf2DcM0fTfeQrn8iac9prdztzo1rEfWW/BA/BUqoxqRd0L92/i1M+HT20/TooY7qae3RVVZp2Bcf9dSByD3bt3qvrOmwPYGNxNKG2osckmGK7wGiYjqVOCCD0Nb8Wj+IZV2SXek2aYx+5geY+4+dgP0qFPCGoW8glg1W2mYHcI7iyGwMeCw2sCpIAH4VvGVW1mzK0L6IwU0Tw9FFNjRbXaqnpC0rfXGST9K4rU0bSyZdFEN9HEC02n2/mxSNH1Z4oJudy9SEYgjsK9SPh7XJ4nhnl0eKJxy0KThj+O8EfgaytR8B61qkYs7zVrcae+5Zg4kuSVIIBQSEmN+eHVuPQ0qTq05cyf4jrKnU0S0MGHQPEF5biS00ZjDIuY2muo49wPQ4G413/wn/wCSWeDf+wLZf+iEro7O2jtLSC3hBEUKLGgPoBgVznwn/wCSWeDf+wLZf+iErpqVZVPiMKdKNP4TqqKKKzNBGYKCWIAHJJrz7whiXwvZM4AMwkmK+zyMw/Qj866rxal7L4a1OLTIvNvZbd44l3BcMw25yfTJP4VgrFBpkECQKWSKJIF/3VAUfyrnrvRI1pRu9CS922+l3boABDbyuPbCE/0rE8BRfZNJns/+eUqSY9BLBFJj82arviq5EPhLVpsY3WrxKD3ZxsA/NhTtIgFtrniCFTlIpLaIHtlbdAf5iskvcbG2+azG+JyfsKJu2gvk1V/s+K60RBGQs7KCZPSp9XQzhon4B6H3qn4eluoLo2k8f7kAsrHt7CosejCLVJNPbU4vUEmtJHiulKOPXv7isO4uWMqxxhnkY4VFGSfwr2zULWO7jSOW2inQ9Q46D2qCy0zS9LnH2Szhhlf+ILlvzNS43KWLVr21OT8C+HplnF9qqCN4+Yrc9Qf7zf4V2OsTy2um3l1EwAt7aWUk9cqhIx+IqK8n2MVjAU55qlrTyTeFdaXPP2GYg/RCapROes5T/eMzvCdnJZaA1nGCBBdOmB6lUc/q1dZp4ZBG0nUEday9EmR9W1qKPhTJb3Sr6iS3QZ/ONq1J1ZoWEbFGPf0qqnxNGEZ80VEl+HI8vwlZ25+/bvNA49CkrDn8q6euZ8HWl1ZXespJH/oc9yLqCUnli6DzBjthlJ/4FXTV2Rd1c5no7BRRRVCOV+Gn/IuXn/Ya1b/043FFHw0/5Fy8/wCw1q3/AKcbiigA+Jf/ACLln/2GtJ/9ONvWx4i1mz8O6FfavqkhjsbKJppWVSx2j0A6msf4l/8AIuWf/Ya0n/0429bmu2MmpaRdWUU6QNOmze8KzLg9QUbhgRkEH1oA57QPH+mappy6heW9xo1g6I8VzqMkCwyByAoEkcjqGJONjEN7VoXuu+F4Ptl7e6rosZsnFpczzXEQ8hiciJ2J+U552nFeYT/AW3nttcK6rZ6fdaj5GxNL0029pE0Ugk3GAytuJIxwygDoKvH4OXTX1xqbeIoDqz67Hr0b/wBnHyFlVSpRo/O3MpzkHeCPegDV8O/E7QdT8FXfiHUl0zS4o7q5tbeO4vY9t00WcbHIGS3oAfxq54a8a+F9X8H6Nq2uPouivrMG9LO8uYgWBJUqCwXePw71zFh8FbjTzp9xa+I4ft9rNfsXl04tEyXYw6hBKCrDs24+4NUz8AYktdPjXXVnMOlrpdzHcwXAhuEWQuDshuYiOT90sy8ZxnmlZDuz1Ftf8KLqaaU2raGNREn2dbM3MXm7+PkCZzu5HGM1Z1zUvD+hW8cmu3ulabBI21HvZY4VY+gLEAmvOn+DKs0xGtqok1601tVFmSE8hNvlDMhPP94nI9DXSfEzwLN4xfTpbPUbfTLyxWUQXohnNxA0ihS0TxTxbeByGDg8cdiWQXZW0Lx/oN94m8SaXOul2Njpb2SQag91H5d6bmIyJsyAOg4wW3dRWpb+LfC32eSfUrrSdLC3M1sv2y8tRvaL7+CkjDjOSCQw/iAriYvgrNB40HilPFE02sRzWUscl1aeaG8mDyZPMXeA7SDneNpQ5xnOav6b8Ils9c0rUH1kTLY6tqGqGE2mBJ9qUL5ed/G3HXBz6CiyC7PRbW50q601dQtZ7KbT2QyrcxujRFB1YOOMcdc1lw+J/B91YPew65oE1kkiwvcJdwtGsjfdQtnAY9h1Nc/o3wxgsvg1/wAK/u9TlnhMEsLXsUXlMd8rSAhct0LAYzzjtmub1L4IPrAu5dY1+Ca8uWsVfydN8uAw23RDEZWyWHBYtgdlxxRZBdnpz6l4dg0Yaw97pMekkAi+MsYgIJ2g+ZnbySB161WtvFPhK7nggtdd0GaaeUwxRx3kLNJIOqKAeW5HA5qh8QPAdp4o+Hd14S06SDRrSXyhGYLYFIQkqyYWMFRg7ccEdc1zmp/CL7bquoXo1vy2u/EFrrwX7JnZ5CkeVnfznP3u3oaLILs7cav4Y1D7PajUNFuvtsjxQw+dE/nvGQXVVz8xU4JAyRxnFQJ4p8Hy/bZE13QH+x83TC8hPkfNtzIc/LzxzjmuAsfgk1vqelvN4h8zTdPu9QuIoEsikxW7TaymXzCMr1DBB9Kur8KdQPgzS/DUniG0Nno11Dd6ZIumFXV4nLKJx522VSGIIATJ5zRZBdnby+JfCkWkxapLrWhppkreXHdtdxCF2/uh87SfbNRxeK/CFrcxQRa/oENxfbZ441vIVa43gbXAzltwAwec1wN58GZZ7OZk1y2TV59RudUbUBaTxtbzzKq5txFcoYwAvRi+eM9Kj8W/BvWPEkEdtfeO9QuLOOG2RI7qF5NskWN0gCTIjF8HO9XIzwaLJCO/8C+K/wDhKv8AhIf9C+yf2TrFxpP+t8zzfK2/vOg253fd5xjqa6euY8C+FP8AhFf+Eh/037X/AGtrFxq3+q8vyvN2/u+p3Y2/e4znoK6emByupf8AJU/D3/YF1P8A9H2FSeOfGmm+DYLB9SSeaa/uBa20EGwNI5GfvSMqKAByWYCo9S/5Kn4e/wCwLqf/AKPsKk8eeGG8U6dFZmTTTCpLPBqOnC8hkJGASu5GUgZwVYHJoAfB4h0fUIIU1dYtOuTvnSy1RoklAi+ZpFG4qyr13oSvfNY/jr4geGvC3hKbWo7vR72RrdriytlvIkN6AcfuzzuHuAa5Gy+Bv9m2ulrpfiHyri1jvoZfNsjJCyXS7WWNPMBjCj7oLNz1zzUUnwLmTSRZWXiWOMy6ENCupJtOMm+MSbw8YEq7DnGQSwNKyYHQ+M/iPoPh3RNLu2ttLutXvja40s3UaTokxHz42liBnrtGcdq6yPWPCkOp3Olx6joceoKXnntFniEoIGXdkznoMkkdua871H4KTXEt+lt4ijitL+awuZ0k08ySeZaqFXa4lACsAflKnGeD6rD8EIbfWLy5j1ZJraa8ub2JLqO5eS3kmUqxQrcrETz1aIkjgk8YLId2ej6NrnhnWp5LfRNU0bUJkQSPFaXEUrKh6MQpJxyOaJta8M2mqtp02paNBqS43WrzxLMMqWGUJzyoJ6dATXJeCPhcPC+vaBqf9ri6OlaGdG2fZdnm/vTJ5md5x1xtwfXNN134RaVr3iTxdq2qzRTPrtnFawn7Kvm2G2Mxs8chJ5YHkADgYORRZBdnUweI/CN3YXd9BrOgz2VoQLi4S6haOEnpvYHC596ibxh4KjtYrlvEXhxLaUN5cpvoAj7SA2DuwcEgHHTIrgLP4JLBpVzaXF9pV7NNFbw/aLm1vnfbD9zP+ncEYGNmwDkAY4FDUfhh4tXxF4ajg119RjgsdQt7rWNQj8/yfPGAgjaYSMMEgEs2O+RxRZBdnptx4p8PW9/NBez6db2sdpHeG9mu7ZYTHI21DjzN4BJGGKhTnAYnikl8V+CIWgEuveG42uATDuvIAZAGKHbzz8ysvHcEdRXnmqfASC60SfTLbxBJFDJo9rpIaW0EjDybkTmQ4cZ3EFdvGPU1p/ED4Pv4mgk07SteGieHmtfIXSLe1ZbeKTzPMMqpFLGrEns6uOpGDggsgu0dJpHj/wAKaj4k8Q6Glza213oZAuGnkiRGGMuyfNkhD8rEgbTwa1YvFHhR9NXUYtc0NrBphAt0t3EYjKeiB843e2c1w2q/B5tQ/wCEsgOvFLHxDFaedH9kzJFNbqoRlfzMFCVyUKnP94dah1L4LjWJ7671nWoLi81DVrPUrxU0/bbSJbIyCEQmRsbgx3MWbPpRyoVzu7bXfB4sZHttV0AWduY97R3EPlxGX5o8kHC785H97PGa6D7PB/zxj/74FeQa18LEu/jJompafp6WPhe1tIpryOExpDNcQMwt0EYORtBB+6FwoHWvZKLId2QC0t1nWYW8ImVSiyBBuCnGQD6HA/IVPRRTEFcrqX/JU/D3/YF1P/0fYV1VcrqX/JU/D3/YF1P/ANH2FAEnjnxppvg2CwbUknmmv7gWttBBsDSORn70jKigAclmAqxYeKtNnij+3yf2Tdusji01CSOOUpGMu4AYh0A5LqSuOc1X8eeGG8U6dFZmTTTCpLPBqOnC8hkJGASu5GUgZwVYHJrzyy+Bv9m2ulrpfiHyri1jvoZfNsjJCyXS7WWNPMBjCj7oLNz1zzQB2fjr4kaD4W8JTa1HqOl3sjW7XFlbLfxob0A4/dnncPdQaoeMvinpfhvQtLuibK51W+a1P9l/blSdEmI+fGCxAz12jPtXLSfAuZNJFlZeJY4zLoQ0K6km04yb4xJvDxgSrsOcZBLA1Z1H4KTXEt+lt4ijitL+awuZ0k08ySeZaqFXa4lACsAflKnGeD6gHpp8T6ANUl0w65pY1GFWeS0+1x+aiqMsSmcgAcnI4FLo/ibQdbuHg0XW9L1GdEEjR2l3HKyoejEKSQORz715lD8EIbfWLy5j1ZJraa8ub2JLqO5eS3kmUqxQrcrETz1aIkjgk8Y2vBHwuHhfXtA1P+1xdHStDOjbPsuzzf3pk8zO846424PrmgDtLjxLoVtqbabca1pkWorjdayXUayjKlhlCc8qCenQE1Fa+LfDd3YXl9a+INInsrPH2m4jvY2jgz03sGwv41x2u/CLSte8SeLtW1WaKZ9ds4rWE/ZV82w2xmNnjkJPLA8gAcDByK59PgUh0ae0n1m3a7K2qxXgtrl3P2dgUEiy3Tqy4GNqCPGeMDigDsPBXxL0jxPe6vD59hbQ2upnTbOb7cjrfttDBo+BkkH7oLdOtb1x4x8MW9hHfXPiPRYrKSRoUuJL6JY2kX7yBi2Cw7jqK8+HwfvPtramfEcH9rHX115ZBpx8kPs2tGY/N3FT2O8Ee/WmeGPg3d+GLvStR0jxHAdWsWuh5l1pplgeOdtxHliZWVgf4g/I4IoA9KbxPoC6nb6a2uaUNRuFV4bU3cfmyqwypVM5II5GBzXPap8RtMt/iD4e8KadJZajc6lJcxXLQXil7FoY94DxgE5bkYJXGD1rnbj4NpN4wuNbfVYp47m/g1OW1uIrnalxH/HH5dyijvt3o5XOMkcUvhf4QS6Dr/hu7XXo57DQbq+ubaA2O2WQXSkMJJfMIYrxghBnGMegBt+MvijpfhTXL7TLrS9Xu5LGwXU7qW1WHZFAX2bjvlViQeygnmoNb+LekaVfXsA0nWruOysItTuri3jhCQ28nRiHkVyR3AUkVR8f/CY+LPF93rg1DTENxpY0zyr7SvtZg+Zm86JvNXZIN3DYOKW0+DWmNrjXmt6je6raHS7bTWtZZZY/N8nHzzMkgEobGSjKR9aAPQptc0u30WPV7u/trXTJI0lFzcSCKPawBUktgDOR1qnP4y8MW9pa3U/iPRorW6V2t5nvolSYJ94oxbDAZGcdM1R8d+D08TadpENpdLp9xpN/DqFm3k+ZCHiztV4wy7lwTwCCOMEVxWnfA/T49Z0i/wBYvrbVUtr7UNQvLS4sFMFzLdKgwqMxEaoUUgHfz3FAHsAORkdKKAMDA6UUAFcr8J/+SWeDf+wLZf8AohK6quV+E/8AySzwb/2BbL/0QlAFHQPiTpevaldW+mWOpTWdrcvay34WIwq6nBJUSeaqcH52QLx1rorbxLoV01utrrWmTNcQtcwiO7jYyRKSGkXB5UEHLDgYrz26+D0OoeL7LXNQv7BJLaV5mlsNMFrdXJYEYmlVyjj5jnEYJGATWTYfAl47W1tL7xL59pa6PdaNEIbDypPLmZmDMxkYEqWPQAEelAHX6P8AFDRNV8X61pdtdaa+k6ZYx3r6vHfo8B3NgqSPlXb3O78BUXhn4jeHten8TS3T6TaaVo92lqupSXkbQ3IZdwYMQFHpjJ+tcvd/A6fUbO+i1LxJC0s+nWenxNb6b5aILZwyMyGVt2QoBXKj0x0qfUPgrPqU99fXviQDVbjV4tXSS2tZIIkkSPYV2rPvwc5BWRWHY0rXC53154m8GRWdvLea34eS1uE86F5buEJKitjepJwQGAGR0NazyaTb2Mupu9hFZyKLiS7JRY2BAw5foRgDnPTFeX2XwUitnVo9UtoFGm32ntFBaTFGNznMn724kbIzkjcc+1bPib4f/aPgiPBQuLu6a3soLdJbWNFklaIqQQjyKuCV5VnAx36UWQG+PFngmaxmvRr/AIcks4XVJJ/tkBjRmBKhm3YBODgHrg0+48S+DbOxtb+41rw9BZ3Wfs9xJdQrHNjrsYnDY9q8x8OfDzxlqc/ijUdQ1WTwzd6pqNpOq26bTNDBEUKOsNwTGrZHCTbht61Ja/Au5sdJtbXT/EsdpeW8k7xalDa3Ed1CJX3MqOl0BjAx84fPJ70WQ+Z9zs9M+JXgu/1vXtMOo6favoxQTz3M8KRSBhy0bb+QpIViQMMQK2J/FPg+GG3uJ9d0COKZ2jhke7hAkZThlUk8kHggdK4nxB8ILnVI/GUEXiQJbeJ4rUXBnsfNljkgCgOHEightpyu3qeCMYM3iL4P2t3PM/h28stEiutHfRbqBdOEkRhd97PGqugjkJJ5+Yd8Z5o5UF2dZc+IvDtvquoWeptp1kLMQlri6ubZUcyglABvLqTjjeq5/h3VkeIviL4H0W10l5r7Tbux1e7OnpNaywSQocfO0jbgAiggMecbhkc1z2o/BKK4lm+za7JFAy6Wkay23mMq2QIGW3jcXHfAx71YuvhBIbi5u7PXUhvW8THxLA0ljvjR8Y8p1Eilx/tBlPtRZBzPud3Bq3hg6wumW+oaKdVaNQtok0XnFAMrhAd20AkjjGDXO+K/if4G8OaTc30mq6ZqBt5UhkttPuIJZwzNt+5vHTkn0APpWFb/AAZS38UT6sNUguopdSfVRBeQ3T+VO4+YoEukjx/vRsccEkVSf4H3Evh7VdGbxTJb6ddRxLbWNrbzfZLR0mEu9YpriQ5JBBCso56UWTEehW/jjw+094ralp8NlaxwSC9a/tvIkEv3NuJCwzjALKob+HdVp/GPhhNM/tJ/Eeirpwm+z/ajfRCLzcZ8vfuxuwCcZzXCeJvhHc+I7rXbvUNfhS61YaeZTDp5CI1qxJwplJw2ehPHqamvPhZqIutdn0fxZcaYdW1ZdTlSCB0DKFwYWaOVJCCedyun0NMDoR47tJ/HGh6FpqW9/Z6rYzXseo29yHjxGwXAABDZ9Q3GK7KvKPh78IB4P1fQ71db+1rpcF3CIvspTeJ5N/UyMRt6d89eK9XoA5X4af8AIuXn/Ya1b/043FFHw0/5Fy8/7DWrf+nG4ooAPiX/AMi5Z/8AYa0n/wBONvV/xrqtxofhPVNSsvsRuraBniF9cLBCX6KHdiAoyR1I9MjrVD4l/wDIuWf/AGGtJ/8ATjb1u61qdto2j32p37lLSyge4mYDJCIpY4H0FAHh8Xxl1yDwmniS4hsb3TbDU47PWBb2JQRRuo+eCVLmWOUByBuB7jgUmp/FPxvZWtuLi00G2vG8Ly+IpI5LWZwpWU7Yv9aMfJtyezZ47V6Tr9z4e1zw1pun/EM6dpr6l5c39mXOo7C7hgypnKGQg7crgjPHNb6+JdCbXBoq61ph1g5H2EXUfn8KWP7vO77oJ6dBmgDxLWPjR4j0yz1F5LbRjJHaaZfQOYZAkaXRG9HHmfMV3cMCo45FZviX4i+JdUGk3UOs6dZaXp/iuOwfWbSKVLG7hKZDv++wYlIYMu8hsr8y45988W6Jo+vaLLa+JIkl02NluJN8rRKpjO4MWUjABGeuPWoE8beFX06TUE8TaG1hFIIpLkX8RiRyMhS27AJA6ZoA8ztvivrknjO30v7Npkok106SdMjjf7aLbaD9v3eYV8o9fuYx/GaxtD+LvjDU4dDcx+H4/wC1rXU5U/0OY+S1oWIz+++YMFxjjBOcnpXtU3i3w5DdWttN4g0iO4ulRreJ72MPMH+4UG7LBsHGOvanzeKNAhv7qxm1zSo720iae4t3u4xJDGoyzuucqoHJJ4AoA8Yt/jVrFxceGHkTRra11S2tmkjt1W9uvPkbDDyPtEciJjkMFk49a7H40/EK68Erp8Oly2y393FPJHFdWfmRylFBA81riFU9MDexyML2PXy+NPC0U8UEviXREmlcxRxtfxBncHBUDdyc8Y9az7Dx3p7zXa6oYNNit7m8gM895EiBbd0QudzK3JkXoGC/xEZXIB5TefGfxPLpl1f6daaLFHa+HLbW3inhlkLu8gR0DCRcDnIOD05z1rG+Lnjy/wDEf2nSLo6dptrZ3+lTQWcisbu7EhDtKjFwPLUkDhG9yOle+/8ACb+FBYR3x8T6H9iklMCXH2+Ly2kABKBt2CwBBx15FVtf8b6TpWt6Ro8V3Y3WqX93Hbm0W7QTRI6M3m7OWI+UdgPmHNAHPfGfx5qPghNLk099ISCbznumu5Y2nVEUEeTA88JlJJwQr5HHBzXE6r8UdX0q68SX1laRzOlppEgluhcxxQfaFO+WS3aVliVf7qbTz8zNjNes61400zQ/FVvpGs3Nlp8E9m10l3d3SwqWEioIwGwCTknr26VZvL7S9auL3Qrq6eCZZViCwaiIJpSI0m+QwyCVcBhkHaSOcFSCQDyKw+LniS91KDT7aXw9ded4kGipfQ2sphkiMW8SqomOSTyPnwR+dUp/jf4gi8P6de3MegW7+ddQ3pQrLMxjk2IYbV7mJ2Dd8O54PFeseGJ/BPhvytM0TVdKhm1SZrpI21ETT3kjHBfc7l5CSuM5PTHat3S/EWi6vd3FppOsadfXVt/r4ba6SV4ucfMqkleeOaALthMbixtpmyWkjVzmMxnkA/dOSv0PIqeiigAooooA5XUv+Sp+Hv8AsC6n/wCj7Csn4xeM9Q8GaTp9zpjaQhmnKztfzxqyxKuWMUbzRCVunyhweehzWtqX/JU/D3/YF1P/ANH2FaHijXDo0enx29sLu/1C7SztoDJ5YZiCzMzYOAsaOx4P3cd6APIdU+LPiq1vdBtLLTrK6bxLZQPo80tjLb4uDKqyrNGZWwqoS/DdMfMQc0+T4peKj4kazjTQxanxW3htd1rKXClMrMT5uCQeq4GfVetemXTeEtQ8bWk09/p03ibSYZRDD9uBltkcDzG8ndxlcZYrnHetXRPEWia8bgaFrGm6kbfaJhZ3STeVnON20nGdpxn0PpQB4SPjfrpt9LF1L4c0x5o9S8+5uoZDEZLZsIEXzlI39MbmOTxnpTdL+IHilvH0WrX8gtVu/Ca6hb6DKsirdTKSTHCGkA81ipbcFY7Dt2kjcfZ/EsPhfTtY07xL4jubGxvbJZLe1vLy78hVEg+ZQCwUkgdwT6VW8O+PdG1nXNT0o32nwXtvefZrWH7YjSXieRFKJUTglcSEcZHy5z6AHk03xr8Qw+HNbvreLQ9Taz0a21MXNpDIILWeSZEa0mHmEmQBieCp+XlRV+9+K/inTdS1iG6i0SeHStW0+yk8u2lRporpd3BMp2svqQwOegxz6/B4q8PXD3aQa9pMr2bBLlUvI2MDFtoDgH5SW4578VkWHxK8I32sajp0Ov6Z5liiSSSm8h8twQc7SH524+bgYyKAOU8AfEnU/EHxCvNB1B9K8tPPkhXTFS7TykbCl7lLhtjH+68KfWszx18X77QPiGmi6cLO6to7+0tLq3ntPJlRJsAskhuNz885EGwZALZxn1E+MPDQ0ptUPiLRv7NWXyGu/t0XkiT+4X3Y3e2c1K/inw+l5Z2j67pS3V6qvawm8jDzq33Si5ywPYjOaAPI9G+LHiW41fSvtVnpU1he65faP5EEMiTDyVyjhzIQSehG3tx14w/APi288a/GLwdq2pT6YLp9Mv1exs0ZXsSHwIpizsS+AD91OvTvXvui+ING11rhdE1fTtRa3IEws7lJjETnAbaTjOD19DWP4k8f+HNE0nXbo6tp91c6PA81zZw3cZmUrwEK5ypLEKM9yBQBx3iD4lanpnxXg8OF9KGmTXVtbRC2VL27dnG5/NjW4SSADs3lOACCfSuN0v4s63Y+HtFSIaZYJcx6lO17qb3FykjwSuEt0Mk+8u2B1c/eG1eMV61e+N107wZpev30emNFeXdvbSPaaiJraJJZxH5gn2KGChtx4AyCM/xUeJZfBfifTLV9W1+2fTrhJFjNvrj20NyhKo4PlSqsoBZFOc4LY43cgHlUvxm8WSaPc31tbaEhtPDltrciSW8reY7ybXQESjaMHIJz07546PSfipqd98SbPQ5/7KisLx0WCOzCX02PK3v5xW4V4MHjLQke/evQ9M8QeEtP0+ay07WtEhs9HiWOaKO8iC2aL8oD/N8gGMc4qpcfEbwpFqOj2q65p0q6r5ot7iK7iaEshUFS27qSwAAzkgigDrqK5bwH420vxhpkMtpdWS6iY/MuNPiu0lltxnHzgYI7dQOtdTQAVyupf8lT8Pf9gXU//R9hXVVyupf8lT8Pf9gXU/8A0fYUAZPxi8Z6h4M0nT7nTG0hDNOVna/njVliVcsYo3miErdPlDg89DmuH1T4s+KrW90G0stOsrpvEtlA+jzS2Mtvi4MqrKs0ZlbCqhL8N0x8xBzXtWsavpuiWf2vWdQs9PtNwTzrudYk3HoNzEDNee+CfFXhbx0+meKtTSxsNbsVvBZxS6jvaKBWKSTKuVG0heW28DjNAHNSfFLxUfEjWcaaGLU+K28NrutZS4UplZifNwSD1XAz6r1rKHxv102+li6l8OaY80epefc3UMhiMls2ECL5ykb+mNzHJ4z0r2uXxp4WimtopfEuiJLcoskCNfxBpVb7rKN3zA9iOtcT4I8W+GPHmvw+IrhNLtb6yuJtN0hzqu+4mByHzCMKNwUMoy5IOeO4BxGl/EDxS3j6LVr+QWq3fhNdQt9BlWRVuplJJjhDSAeaxUtuCsdh27SRuMs3xr8Qw+HNbvreLQ9Taz0a21MXNpDIILWeSZEa0mHmEmQBieCp+XlRXssnjjwnFbxXEvijQkgmVnjkbUIgrqrbWIO7BAbg46HirGo+K/DumG0Gpa9pNmbtBJb/AGi8jj85T0ZMkbhyORQB5De/FfxTpupaxDdRaJPDpWrafZSeXbSo00V0u7gmU7WX1IYHPQY53fAHxJ1PxB8QrzQdQfSvLTz5IV0xUu08pGwpe5S4bYx/uvCn1rc8OfFfw54is4bjSpfN36mumGJ7q2jkR2LBJCrSjcjbW2hdztg4U4OOnh8UaBPqFzYQ65pUl9ahmnt0u4zJCF+8XUHK4756UAeW+LfirrukeM9T0y2s9OP2O+tLW30qWNze6lHL9+WFg4AVf9x+nJFWPgPbXNx4k+I2q6i9lcXg8QXNiZ1tis22PZ8okLsRFjGI+xBOTnj0vR/E2g63cPBout6XqM6IJGjtLuOVlQ9GIUkgcjn3rXoA+fNH+NHii/1HUkn0vR7RLeDUHaynnijurZ4IneMNGbjzZQdnzYiTA5BI5p8Hxj8U29hdT3mmaXfyN4Uh8RW8dnDLGUZ5VjZHy77lXJfIxwPxr6AooA8C+FGravqPxH+Iuo6VJoOuX1xFpLPLFcPaWrD7O+djBZzlThcHqQTx0q/40+K3iPQNf1Kx/s/SY7mwNisOlN5ktxqpnx5n2WTKZVDkZ8tunIXpXt1FAHgl58VPG8Gj+Ndbj03QJdH0XVLjSYMLP5yuk0aiWUbseWEZixBBJxwoyaP+FyajDZ639o1HRZjaatDp9nfWWnmS3uVeMtuJe7SNOcEM0oGAeD1HuWpWUWo2MtpcPcJFKAGa3uJIJBg54eNlZenYis/wz4Z0nwzBcxaNatD9qmNxcSSTPNLNIerPJIzMx+pNAHi2i/GLxVrdloAtrTRbW8vbLUp7gywSSoJLUnaFCyjAbGDy2OoJ6H174ceIJvFfgXRNcuoY4Li+tllkjjJKq3fGecZH/wCuukooAK5X4T/8ks8G/wDYFsv/AEQldVXK/Cf/AJJZ4N/7Atl/6ISgDzbT/ij4p1XWtf0rTV0KbU7a3ubmwt7SIXsMixn5BJcRXWVdhkbWiTnHPaqdj8ZPEmr+HLPXtO0/TLfTr3WbDR7f7TBIzl5I83DnEgyFc7V+hznt6ta+K7C8sNavNTlttN0O1upLFL64uxEJmQ7JGycBAJAyA7iSVJ44qHSdV8D+DPDWlWVlrOiaZorRk2PmaggSRSSSyO7fPySScnrQB5rpnxb8TG7sE1CDRpYpNZv9FlEFvLGS0CbllUmVsA5AKEHp97njn/8AhbfirxV4QvoLCbTHu7nw7c6hJJpMMyzaZKjEBWIlbDMoO0/KVLKcMBg/S08KXEEkMq7o5FKMM4yCMGuV8Pal4L8NWkfhrR9Y0i1TTsQ/YTqCvJCWcKFYMxbJdwOecsB3FAHkq/FnW9J8L6Msep6DdbfDw1EX91HI4v7hSF+xIRN/rx/ESSSxzsFT+I/jF4qsH1yeDTdLtYdKg0md7O7glabN2q742cSAKVLcHaenIr2Sy8X+Gr+/hsbHxDo9zezKHit4b2J5JFK7gVUNkgjnI7c1VX4geDWXK+LfDxG5VyNSh6tnA+91ODj6UAeWa18XPEWlprdtL/wji3Olaw1lJcSusO+3EYfdHBLcJ5kgzjaJR1HFeveCdXfXvCelarIWL3cCzEtbG2PP/TMu5X6bm9iRTpvFXh6HUpNOm17SY9QjzvtWvIxKuF3HKZyMLyeOnNX7fUrG5mjitr22mlkhW5RI5VZmibgSAA8qezdKALVFc1q/jTQ7KHWI7XVNNvNV022muJNOjvE8792pYgqCWXpjOOM0uk+NvDuoaC2qjW9JS2hRDdOL6NktXYfckbOFOeOcUAdJRXGaD8RdA1DSP7Rv9T0vTbaW/urK0kmv4wl0IZWjDxscBgwAbAzjcOT1rUvvGfhewvZbO/8AEmi213FnzIJr+JHTA3HKlsjgg/SgDforCPizRcxyf2lY/YHtvta332yHySm8JnO/JBZgNwG3PGc4FI/jPwumlR6o/iTRV02SUwpdm+iELSAZ2B92C2ATjOaAN6isDRvEsOreJtU0u1SOSCzs7S8ju45g6zrOZcYAGMARZzk53dsc79ABRRRQByvw0/5Fy8/7DWrf+nG4oo+Gn/IuXn/Ya1b/ANONxRQAfEv/AJFyz/7DWk/+nG3rR8ZaMfEXhPWNHWUQvfWklukhGQjMpAY/Q4NZ3xL/AORcs/8AsNaT/wCnG3p3xR1KXR/h14j1G3G6a1sZZUHmSR5IUn70bK4+qsD6GgDlPEnw7u/Gs9trOoTHS72502Ox1DTrh55ImCuzEf6NcxAjLt94sCMcA5qlZeE/Elp8QbRrK3/4kVjqd/qyS3cUUfmS3EMq7fMSZ3cb5j96JCFHU4FU18a6xoeoeJ4LjX9GZ118W+29icnTLdwhE8g87Pk4woGEXc2dwBIEMniPV9P8T+JvEGk6poOq28Wm6S11LDbuYrtWnuU/clZiI8AtyTJyBxQB6Jr/AIevtV+GV1omr3kuoanJY7Jp4Yow00wG75UJRMFhgKSoxwSOTXA2Xw78R+Jby91rXrptG1YXyTWoRHhBjFuIjuS2uty+22c9DkYO2tr4rJ4g1PSrPT7u20a0sbnW7OBd0kl6t1EZTxNFtiAGQhKhmB5GR1rl/DHjM+CLfUtPuDplnpnm69NbPIhiV7uG9IjgjG7GCrN8gy3AweKAOttvhTDBpOp2Ud/BGL2xsrJfLtnKw/Z5ZJCy+ZK7EMZBwWONvU9qOofBxbq81pl1n/RdQN/JEsy3Mj20t3HIjsoFyITjzW/5ZZI4Jz81YutfEPUdSj1TR7650dYbvRZpUt7NFnmybEyHzCLjfDht33oSuAo35YY6fwZ4uu9JhuLHxZPY/ZbHS9OuoriztpVIFwzxLEU3OXbcigMuM7vuigBfHvwzv/FFvDZW3iSTT9Kjso7T7GsMvlhkOfMVY5o1JI2jbIrgbRjFWbn4eX6X8t/pHiBbG/Lak8UzWXm+UbuSFs4LjJQRED1LZ4xg2/iv4svPCWl2V1Z3OlWySTMsz3zRlgoUn93G88Ic5xkB846BjxXOXfxXvNJOqf2hpTXUNpbQ6h9ohieHbayxRiNmjYsdxmaRSuRtVCT93kAdefCS6urXT92t2kV3aJcQM0Ftdwx3EU2wv5oS8EjyFlJLGQhgcFeAav6V8M7jS72yS11i2TSLbUY9TFqLFjKZEhEWzzmlJ2dxuVmHQsazX+Iev2niK20vUTosN8txYWsml+TILq889IzNPAfMIWOMu/BV/wDVNlgcVw3h/wAS3vhOwj1LTrZJ5v8AhH9NhZ5QpjgR768Bkfc8a4Hu6DJGWAoA9o8V+DE8QX+oXL3iwm60W40cAwb9nmkHzM7hnGPu8Z9RWHqXwva6s9TFtrclnqFxdW91a3sdsC9q0drHbMAC3zb0V/TG/vjnn7H4jeK9UtYvsJ8PRyLpuoai8xUXUcy28kSoFEFyyoWEmCPMfaR36H1zQr46nomn37II2ureOcoDkKWUNj9aAPPbr4SWo1+G706+WHTB9j36fL9p2f6MFEezyriNAcKpG9Hwwz7Vb0rwT4g0SK9XSPEFvAty8SxwQwSrBap5oaV445pZhvKblCrsTJzivRaKACiiigAooooA5XUv+Sp+Hv8AsC6n/wCj7CpPGmm3txc+H9U0uA3NzpV+J2twyqZYnjeGQKWIGQsm8ZIzsx3qPUv+Sp+Hv+wLqf8A6PsKj+IXii78KLpF1BZreWlzdGzmjUHzDI8beSFPQbpQiEkHG8HtQByd78II5L7WJn1OW4sr1r+ZLcm4M0Ml1HIj+WTciAH94wBMWccE5+ak8FeH/GwvtXvr14dKmuhptnG7W0Mbrb27SGTbEks6Assm0ZbuThcAVm614l1jxXqWgvZw2umtZeKI7GH7VA8uy4SwuTPuAZfMVWbapG3O0nPPFHU/jB4ktoNNCWOkRzSW8jtLcyRQQXUsdzLC0cbTXMfl8RBuPNI3jK4AJAPUvH3hi58S2lolhfW+n3dtIzx3TxTNJESpXMbRTxMpweckgjgg1kWPw5NumbjV3urhtZg1d7iS3AkcxW8cOwkN1bYW3DGN5GO9csPipq58Y6rpt3/Y+lWFpLeRO140Xm28cKOUuDH9qEsqttBKLEvytkOcZOVP8YNfj0mxuYbzwzdx3ss+27hESx26IqGNJ1kvVSOSTcx2mXIVfuk5CgHTJ8IpX0230681yCWzsbIadZKmnBGEPnxSnzj5h81j5KrkBRyxxkmtvxP4CudZvPEHkarb21hrVpDb3ED2RkdGi3bWRxIoAw3KlT06it3wn4kh1u1topfLTVhY295dwQt5scXnKSAsq5RwSrYwxyMHoRXD6p8RNStZvFLJeaHHc6U88cGhyxOb2VEAxcEiUEx4JkIWM/KPvZzgAueJvhadW1671iz1l7K8kvEuogiTIsYFssDKTDNE5yFyCHXHQgijTvhndabe6VJpmrWlhbWkcUdxFa21yDdqhY7H33TKyHcRh1dgCQGGcjMsPijcw6rZLqWo+H7vw/8A2ibO4160RorUg2jyqqs0jKrCRVUncwO7HB6Yt58YdYGkreC48P6c4sUu4YbyCRn1FnnkjKwDzVxtVAW++ct0AoA9K+H3hO98KpdxXOrLd2kixpb2cMc0cFqFzxGss0rKCCBtDBQFGFHOeXv/AIST3uk3GlS69Cunpb31vZBNPxLF9qYljK/mfvduTwAmepyRVfwhrOr6T4ne33WEmj6r4o1Cy8ryXE8bBJZfM8zftIzHjbs753dq7nVfE8UvgO68ReH7izkj+ztNbTXzG3gbBwCxfbhT2JIB45wc0AS+OfD03iXRobS2vIrOeC8tr2OSa3M6boZVkCsgZSQSuD8w61h+H/h6dO8RWet3upR3d9HJfzzBLXykaS68kExjexjCrDjGWJ3Ek9c8VpPjrVNZ8V+D7t/EemWthcNfWcu+08q3uJVa22xqUu5I5JCGYIyuwBD4DcgTjx/4jXw14c8R3lrY3U99o93qMdnZrPGFZIkbDfvCJASc8oSoyBk8kAu6P8H7vRrGa303xNLBKlp9is7vbdNPBF5qOyHN1swwTafKSI85BXHN/wAN/DLUNAurS9tvEMMt9Ff3N5I1xZyyo6TxxI6fPcGTP7rIdnbryDXI6b43vLPXte1GDXfDd4t7c6baza1FA40+0QxTsWZfOJPzKEyZFG5xnGMV0OhfEnU714ZtQk0u00uGzN5c3aWk8v2hBdyQAwoG3ASKisudxG4cPmgDVtvh9f6Pp+lnQNWgj1PTdKu9Ogmkttql55I384jLfcKE7SCGJ5I5r0SFWSJEeRpGVQC7AAsfU4AHPtTxyKKACuV1L/kqfh7/ALAup/8Ao+wrqq5XUv8Akqfh7/sC6n/6PsKAIvH3g6TxPdeH76z1COyv9FvftkDTW/nxOdpBVkDofTBDDGK8r8U/BG+Hhvwvo2lXct1cxancC91KJUt/Lsbnd56lC5LcEAAZ79M16h8Q1W71Hwjpl2AdMvtWC3SsMrL5cEsscbexkjQ4PXbjvXDzfFfxBH4q1uyXSrB47A34WwaaGO7cQRyPG6j7QZXEhQcCAAB8hmA5AOgn+GEqeNrfXNG1hNFt0ltzLBp8M8cl1FCgRYZSZzE64GM+TnGBnuaOn/CGXTtI8N29nr6C90TVZ9TimlsS0cnmliUZBIDxnqG7dKn8D/EkX95rI1nWdE1CxtItOMV1pFtLtM108ieSR5khYhlQcAHk5Axxo/ExL6TxV4AXSZraC9Op3HlyXMLSxr/oVxklFZSeM4G4c4oA5fQPgYNJsLO1bxAJxb6Vf6YSbHbv+1Mx348w427sY746itnwr8ML3wnqljqGh69bG4TS7fS7sXunGZZUhwA0e2VTESByCWHftVPSfiJ4ivP7EtZLCw+3a4kf2GSOKTyg0crLdl/mzhY1DqMj7wUk4ycyH4sa3i8kt00bV54l1PfplhG4ubMWzusbzHzG4favGxSdwK56AA2LP4ST2ttZWQ1+NtPsvEkfiK3Q2J83IZ2aFn8zBB3DDBRjB4OeK2mfBYWb6dC2vmTTtLN+1hGLTbMDdKwbzpfM/ehd3GFXPesbWvHus3dxpUkHijw+mnWesW6Ta3awSLYyLLa3BMcg+0YIRlUEeZgs8f3Su03r34q6zbx6vLG2izXFtBqch0xYZPtFj9ljkaKS4PmYKSFF4Cp/rF2s3WgDofBHwuHhfXtA1P8AtcXR0rQzo2z7Ls8396ZPMzvOOuNuD65r0qvJX8Ya4upLp2sfYJpYr/SmEtkk9uPLuS+VKiUliuzudrZ5TtS/C74m3fi7xndaUz2VxYfYXvIZoYFhkUrKqbHQXExBw4OHEbDutAHrNFeSXl6nhzVPiX4kstPspNWi1Oztftc0WTDC9rZBmdl+YxJuMhUH+E9Oora/8S9Q0yEG18Q+Er2NbKS7ivI7d/J1GVX2/ZIAs7YlAAz8zn51wnWgD2SivAI9Z/srxRdaxcK9ube81m4ZTCZjGRa2p5RSpbB6gEZx1HWprD4w6tdWmJr3w5Zp/bEFg2p3KL9mSGS1ll3ER3TpuDxbeJiDnBAPQA95orxS1+KesNc+GxfS6Law6hhZBHEJp7gm5eJXigNwkixOqoysqzY3HIwuTb8BeOb/AMda/d6H4g0vSH06WCcz2ErW5mtykgUJJF9okdwQTktFHg44INAHsFFcD8HtUsk8D+FNHEhF9/Y8VyIljbAiGFyWxtHPABOTg4HBrvqACuV+E/8AySzwb/2BbL/0QldVXK/Cf/klng3/ALAtl/6ISgDmLjwBe6pokmiz3Eun/wBl63Lqem3ySPtmSUyvtYRSxyAr57ocMh+VSCQSK5nxd8NdestIm0vwtGtxJqelvpl5MIAYEDXEsu8PPdmZCTM5bAmzjoDgC5ZfFjUDNcPdXejTxx/2n59rY2kktzpy2zuscsyiY7g+1flwmdwIOM4raH8UNU1uW1WdbGYwa1HbrPavsSRGsbiXlYbmVGIaPGDI6+qhgNoB7DpEGpx3uqy6ndxywzXGbOCNQBBCEUYJ2glmYMxznG4AcCuLi+HV6NKh0SXWLKXQbfUYtQhhbTT552XSzlJJPN2uCAy58sHkE5wQafhD4g6l9ms7zxjLpiWV3oNvrSvY2kytCZGC+WV3yGQ5ZcbQDnjB611vj7xDceF9Ht9ZWON9Mt7mP+0iyMzx2zfK0iAHqrFWPB+UNxnmgDA1f4e6jqnje01u58SzPZWt/HfQ2LxzER7E2+WoEwiwcsdxiL/MfmI4qvb/AAoii8Nx6V/aaMyeGpvDwm+yDOZMfvsbux5255z96sS/+JniOxSE6hFo2n3bWUF9DptxDIZ9RM0rgQQESDEiIEDHD/M2cKtXrXxf4y1HXILWyn8PQW95q2padB5thNI0K2ruA7ETgOWEZBAC4JzntQBLo3w/1WXxBqT6ndW9voya7DqcMS2wae6MVtCit5okIRNysChTd8p5w1bXwp8JzeG7LUJr6N47iedoLaGR1draxiZhbw7lyCApLdT9/HavN7vx7rWsWNjqsV/aaGrJoN5dTyPM8EazvcBwy+cqrHlVz0LDhmOFK9LZeLvEFzrB03RbnSN9xf3qm7uIp7mNlhggdWRPPG0MZDwG2gYIGc7gC1qnwr1HVPEdxqWoeKpriJherDFJDMxiS4heMJgz+UAgcY2RoTt5JzmnJ8L79riDULnXrNtXsxZJZvFprJbIlt5mwPD5xLk+a2TvXGFxjFc+Pi7q09vp1z5mhac88elOmn3MbyT3oumjErwnzF2pHvI+6/KHOOM9/wCDVW08aeM9PtflsUnt7pYx92OaWPMoHpnarkerk96AOeX4W6hDFcvb+IbT7dex30N5LNpfmRvHdTmZvLTzRsYEkZJYEYyvFalj8NbezePbfCRY9bg1dfMtwzYitkgWMndyfk3bvfGO9egUUAeXv8J0ewe1bVlMbRzxkG04xJqAvOm/tjZjv19qua38Pb+8vNUn03xHLYJqGo/b5oUjlRXX7PHD5bNDNG5wY9+QwGTgg16JRQBw/wANfAR8FKwOpfbs6dZ6fnyPL/49zMd/3j97zunbb1OeO4oooAKKKKAOV+Gn/IuXn/Ya1b/043FFHw0/5Fy8/wCw1q3/AKcbiigA+Jf/ACLln/2GtJ/9ONvV/wAba7/wjHhHWNc+zfav7PtnufI37PM2jON2Dj64NUPiX/yLln/2GtJ/9ONvV/xtoX/CT+EdX0P7T9l/tC2e38/Zv8vcMZ25GfpkUAR3PjDQrEXDavqun6YkNw9tuvL2BA7KFJx85x99eGwwyMgZGbDeJ9BXUrbT21vSxqF0qvBbG7j82VWGVKJnLAjkEDmuF1bwNrcXi2zvtBvbNBLd393Nc3Vn5yW3nRQoqeX5qFj+7b5gceo9Z9C+GMmiX+k/YNYWLTrO3htp4Vhl8y+SOPZiY+d5LA/9ccgYAIoA6nXvGOi6Br2k6Tq17Da3OpiQwNLKiL8m3g7mByxYAYByc1Mni3w5J9t8vxBpDfYTi623sZ+zndtxJ83y/Nxzjnisi68DW1rqOjXXhNdM0JdPkmZ7eLTx5Uyyqqv8sbx7Xwi4bJ6cg1zMfwjlbTbfT7vXIJbSxshp1kqacEZYfPilPnHzD5rHyVXICjljjJNAHdt4x8MrpK6o3iLRhpjSeSt4b6LyS/8AdD7tufbOae+s+HdRtTM+paTdW1uIbsuZ43SMMf3Umc4GSDtbuRx0rhfFHg7VdL8QS+JfDYmvtVl1CW6jgS0hkSFZLWKFgwkuIsn9yCHDZG4jaRms/R/hNqkPhi0sv7bt7F7nSrCy1OE2ZuCXtizDy38xQoy5ByrZxkYoA9Rtdf0a71afSrXVtPn1SAEzWcdyjTRjj7yA7h1HUd6nutTsLSWWK6vrWCSKBrqRJJlUpCv3pCCeEHdulef6H8KbfTvEM13eXkWp6W0t1KlndrcyFftG7zFIa4MBB3sD+5yR155qx4m+GqXfmJ4XurDw/bTaXcaTNbx6cHj8qVtxaNVdAjZ3c4IO48Z5oA7I69o4t3nOq2AgSYW7SfaU2rKQCEJzgMQynHXBHrWZ4l8X2GkaCdRtJrXUGMcE8UMVyuZYZZUjEqkZynzgggYPrzWKfhraP4mg1Ka+ka0W1RJbERAJLcpE0K3Oc8MInZcYP8JzxWVafCu+XTorO+8RQzxW2m22l23lacYykUEySKWzK25iI8EjA5zjsQDu4vEmk3t7e6dpGq6Ve6zbK+6xS9TzFdeMOF3MgzgE7Tj07U/wprUXiLw/Z6pDE0InUh4XILRSKxV0JHBKsrL+FcZYeANT0/xpH4nvdfudYaz+1tBaMkgdxKOIwXnMK4wqjZHGDgbs9a6f4f6TdaL4UtLXUdovnkmu7hUbcqSzTPM6g9wGkIz7UAdFRRRQAUUUUAFFFFAHK6l/yVPw9/2BdT/9H2FTeLvFtn4Xv9Cj1N7eCz1K5kt5Lu4uFhjtwsEkoYluDkoF6j734GHUv+Sp+Hv+wLqf/o+wq7r2gLq2t+HdQecINIupLryjHu80tBJEBnPy4Mm7OD938QAWU8Q6LJbS3Eesac1vFEk8kq3KFUjfOxyc4Ctg4PQ44plt4n0C61ObTbbXNLm1CHf5trHdxtLHsOH3IDkbSCDkcEc15+nw1kt9Y8KWiO8umWMUv9ozgIkd0qTia3hMe4txIS2fu4DA/eAqtYfDHUNYXU4vEV5Haae2o6xNbW9tABOVuzNGJHm8xgR5cpIXYpBxuzjFAHo2neK/DupeV/Z2vaTd+bL5EfkXkcm+TaW2DB5bAJx1wCaH8WeHY3sUfX9JV77/AI9A15GDcc7f3fPz88cZ5riL34WXWsW97Druu28q3sdrbzmy00W5ENvvMYjzI+yTc+S/PA2qF4Ii1T4Tzajd21xPrULH7DBY3kIguYIJ0hZihWOC5jC8N91t6gjIC8igDrT4y8E2N3ek+I/DdvdF83RN9Aj7lwn7z5s5GAvPTGKuXPizRLNrptQ1KxsrWAQsbq4vIUibzQSmDvyMhTjcBn+HPOOd034dQ2baWWvo5WsX1N8m1ALm8kL/AN7jaDt77gO3SsyL4X6hZ6TDZ6V4pltJEttPtpHSCSMTJawvHhjFMkgDFg3yupG3GWBNAHYS+KbVdW0KGAwXOmaysiWuoQTh0aZVLhOBghkVyGDHlMY5zVjXfDGma7cQy6ol3MsW3EAvZ0gfa24b4VcRvzj7ynoK5HQfBN9o0HgzQ1mN1p2i3NxqM98QE8yRvNEcQUuz/wDLdiSSeE65OK9IzQA2RFkRkkUMjAhlYZBB7Gm28MVtbxQW8SRQRKEjjjUKqKBgAAcAAdqkzRmgAoozRQAVDdW0F3GI7qCKeNXWQLIgYBlYMrYPcMAQexANTZooAKKKKACuV1L/AJKn4e/7Aup/+j7CuqrldS/5Kn4e/wCwLqf/AKPsKALnis6VOun2GtRhobm43xyfaVgMTxKZg4ber5Hl/wAGSOpAXcQJ4r8M32nX1xD4i0mWytlAup4b+PbAG4BZ1b5M9jke1QeMPC//AAkVzpM32z7N9ge4fHlb/M822lgx1GMebu75244zkcxefC3zTps1pq0cFzp1hYWkBayDxmS1kZw7pvG5W3kbQQR1DUAaWiP4A0x7aW01jSrifVJFlt57zVvtkty0ZKKY5JZGZtpLABTwSe5NbN3418NWx1BP7d0uW5sIpZri2jvImljWLO/K7sjBBBzjB64rmdb+H2qa1NfS3mvWStqtrDZ6n5WmEb0ikdkMG6ZjCcOQc+ZyNwCmp1+HEYkgLalxHqOp37bbfBb7YJRszu42CX73OdvQdgCfTPFng/Wbq18SJfWS+Vp4K3s1/DstkmkUGJl8w7HLhATt64XcTxV/Sdb8HaH4ajubDW9Ht9Ce4lKXJ1BDC0skjSOBIzEElmY4zx0GAK5o/DC7ubC3t9T1y2maCzsbFGh08xgx2tyk67lMrZZgm08gc5x2p2u/C19Qvpr611t7W8bUri/QhZ0RVmhijaNvJnicn90CGDgckEGgDtJfFPh+G+trKXXdKS8udhgga8jEku/lNq5y2e2OtNfxb4cS5vrZ/EGkLcWCGS7iN7GGt1BAJkG7KAEgEnHJFchD8LIIdHvbCK+hiW4i02NfLtnKxC0kD4XfIzENjABYlfVqbc/DS+n8L3Phw69Amkrcfa7Ix2UkdxFKJxMvmSpMvmDOQdqoxyCGBGaAOnvfF9jGmiXdhLa6jo+pXYsjfWtyrpHI2RHjGQwLjYcHIJXg846WvNYfBF9YaZpWjwtHcpLrUWraheo0oA8lkkXInmmkZ2eOMcNjG4nHf0rNAGVZaBp9lruoaxapcJe3+03P+lSmKQqqIG8ot5YbbGg3BQcDr1rVpM/WjPTg0ALVLUtKstSm0+W9h82SwuPtVsdzL5cux03cEZ+WRxg5HP0q6DRQAYqvf2kd/ZzWs7TrFKu1mgneFwPZ0IZT7gg1YooAzdD0LTNCtILbSrOO3jhgS1RuWfykzsQu2WYDc2Mk/ePqa0qKKACuV+E//JLPBv8A2BbL/wBEJXVVyvwn/wCSWeDf+wLZ/wDohKAN3R9KstGsRZ6bD5Nt5ss2zczfPJI0jnJJPLOx9s8cVdoooAhuraC7jEd1BFPGHWQLIgYBlYMrYPcMAQexANTUUUAFFFFABRRRQBiar4X0vVtTt77UUu55YHSSOE3s4t9yNuRjAH8tmBwQSpOQD2FXdL0qy0v7V9hh8trqdrmdi7O0kjYBYliT0AAHQAADAAFXqKACiiigAooooAKKKKACiiigDlfhp/yLl5/2GtW/9ONxRR8NP+RcvP8AsNat/wCnG4ooArfFyFbnwYsEjSKkuq6WjGKRo3AN/bjKspDKfQggjsaof8IVpn/P54j/APChv/8A49Wp8Uv+RWt/+wxpX/pwt60a0ppGc2zmv+EL0z/n88R/+FDf/wDx6j/hC9M/5/PEf/hQ3/8A8erpaK0siLs5r/hC9M/5/PEf/hQ3/wD8eo/4QvTP+fzxH/4UN/8A/Hq6WsLxx4nsvBvha917VIriWztNnmJbqrSHe6oMBiB1Yd+lFkF2V/8AhC9M/wCfzxH/AOFDf/8Ax6j/AIQvTP8An88R/wDhQ3//AMerzD/hpzwZ/wBAzxD/AOA8P/x2j/hpzwZ/0DPEP/gPD/8AHam8R2ken/8ACF6Z/wA/niP/AMKG/wD/AI9R/wAIXpn/AD+eI/8Awob/AP8Aj1eYf8NOeDP+gZ4h/wDAeH/47XWfDb4w+H/iDrs+laLZ6rBcQ2zXTNdxRqhUMqkAq7HOXHb1p3iFpHR/8IXpn/P54j/8KG//APj1H/CF6Z/z+eI//Chv/wD49XS0U7IV2c1/whemf8/niP8A8KG//wDj1H/CF6Z/z+eI/wDwob//AOPV0tFFkF2c1/whemf8/niP/wAKG/8A/j1H/CF6Z/z+eI//AAob/wD+PV0tLRZBdnM/8IXpn/P54j/8KG//APj1H/CF6Z/z+eI//Chv/wD49XS0UWQXZzX/AAhemf8AP54j/wDChv8A/wCPUf8ACF6Z/wA/niL/AMKHUP8A49XS0UWQXZyreAtFa6juWm143MaNGkp1+/LqjFSyg+dkAlFJHfaPQVL/AMIXpn/P54j/APChv/8A49XS0UWQXZzX/CF6Z/z+eIv/AAob/wD+PUf8IXpn/P54i/8ACh1D/wCPV0tFFkF2c1/whWmf8/niL/wodQ/+PUf8IXpn/P54i/8ACh1D/wCPV0tFFkF2c1/whemf8/niP/wob/8A+PUf8IXpn/P54j/8KG//APj1dLRRZBdnNf8ACF6Z/wA/niP/AMKHUP8A49R/whemf8/niL/wodQ/+PV0tFFkF2c1/wAIXpn/AD+eIv8AwodQ/wDj1H/CF6Z/z+eIv/Chv/8A49XS0UWQXZzX/CF6Z/z++Iv/AAob/wD+PUf8IXpn/P54i/8AChv/AP49XS0UWQXZzQ8F6Z/z+eI//Chv/wD49R/whemf8/niP/wob/8A+PV0tFFkF2c1/wAIXpn/AD+eI/8Awob/AP8Aj1H/AAhemf8AP54j/wDChv8A/wCPV0tFFkF2c1/whemf8/viL/wodQ/+PVE3gLRWuo7lpteNzGjRpKdfv96qxUsoPnZAJRSR32j0FdVRRZBdnNf8IXpn/P54i/8AChv/AP49R/whemf8/niL/wAKG/8A/j1dLRRZBdnNf8IXpn/P54j/APChv/8A49R/whemf8/niP8A8KG//wDj1dLRRZBdnNf8IXpn/P54j/8AChv/AP49R/whemf8/niP/wAKG/8A/j1dLRRZBdnNf8IXpn/P54i/8KHUP/j1H/CF6Z/z+eIv/Ch1D/49XS0UWQXZzX/CF6Z/z+eI/wDwob//AOPUf8IXpn/P54j/APChv/8A49XS0UWQXZzX/CF6Z/z+eIv/AAob/wD+PUf8IXpn/P54i/8AChv/AP49XS0UWQXZzX/CF6Z/z+eIv/Ch1D/49R/whemf8/niP/wob/8A+PV0tFFkF2c1/wAIXpn/AD+eIv8AwodQ/wDj1H/CF6Z/z+eI/wDwob//AOPV0tFFkF2c1/whemf8/niP/wAKG/8A/j1H/CF6Z/z+eI//AAob/wD+PV0tFFkF2c1/whemf8/niP8A8KG//wDj1RWngLRbO1htrSbXoLaFFjiii1+/VEUDAVQJsAADAArqqKLILs5r/hC9M/5/PEf/AIUN/wD/AB6j/hC9M/5/PEf/AIUN/wD/AB6uloosguzmv+EL0z/n88R/+FDf/wDx6j/hC9M/5/PEf/hQ3/8A8erpaKLILs5r/hC9M/5/PEf/AIUN/wD/AB6j/hC9M/5/PEf/AIUN/wD/AB6uloosguzmv+EL0z/n88R/+FDf/wDx6j/hC9M/5/PEf/hQ3/8A8erpaKLILs5r/hC9M/5/PEf/AIUN/wD/AB6j/hC9M/5/PEf/AIUN/wD/AB6uloosguzmv+EL0z/n88R/+FDf/wDx6j/hC9M/5/PEf/hQ3/8A8erpaKLILs5r/hC9M/5/PEX/AIUOof8Ax6j/AIQrTP8An88R/wDhQ3//AMerpaKLILs5r/hC9M/5/PEX/hQ6h/8AHqP+EL0z/n88R/8AhQ3/AP8AHq6WiiyC7Oa/4QvTP+fzxH/4UN//APHqP+EL0z/n88R/+FDf/wDx6uloosguzJ+EcC23gxoI2kZItV1RFMsjSOQL+4HzMxLMfUkknuaKl+Fv/Iqz/wDYX1X/ANOFxRXOzZB8Uv8AkVrf/sL6V/6cLetGs74pf8itb/8AYX0r/wBOFvWjWtPYzqHK6r8QfDOmX15Z3Oou89kN139ntZrhbYesrxoyx/8AAiKl1vx14b0XSdO1O/1NfsOoyLFaS28T3AmYgkBRGrE5wa8k+FWraf4B0jxro/jiVLPV21Ge68u4+9fROihfKzzLkhuBk/N71wt7ousaJ8G/h7bamjWt3L4jWaCK4Qkwo2du5cg8nLYyPvdjT5mLlR9M6B4y0LXtVutM067k/tK1UPNZ3NtLbTIpxhtkqq2PmHOO4rk/2lv+SJ+I/wDt2/8ASmKuZ8DXL2Xx+16PxyY08TXNqsWlzQqY7ae2HJEakkhztycsejDtz0v7Sv8AyRPxH/27f+lMVO90wtZo+Fq7vQfhJ4417TYdQ0vQJZLOZQ8ckk8UW9SMggOwJBB61wlepfDrWdHPibSf+Fg3Pib7dYSW0WmR2xVYoYwBtDg4YL9w/JyRk85rx8yrYijSc8Pa611Tk/kk4/N30OmCTdmed61pV/omoy2Gr2k1neRY3wzLtYZGRx7g5r2f9jz/AJKZqf8A2CJf/R0NYv7T9vqcPxRlfVXtnE1rG9qYFK4hyygMCT825Wzz/hW1+x5/yUzU/wDsES/+joa2yzFPF4aniHa8knpsRVjyto+lvixq99oPw517VNJn+z31rb+ZDLsV9rZAzhgQevcV5t4Z+Jd9aahrl5e6re6xoWk6LFd3iXdrFbXMd45GI0URxkoQfvFccjk8Z9n17SLHXtIutL1aD7RY3SbJot7LuX0ypBH4GuctfCngvXZl1eytrK/zaHTTPb3JkjlhA2mNwrbXx0+bJGB6DHpNO5grWOVj+MUttoGq6vrXhXUrK0tLOO7hmCTeTcF2VVi3ywx4bLr0DDGSCQK5O9+JWueFvG3jPU9as2njtrSw2aTHqTvBCZdoyrGMAHnJwnXIyetetwfDvwxFp9xYmwmms57f7I0NzezzosOQ2xA7nyxkA/LjoPQVX/4Vf4QaDUYZdLknTUIY7e6NxeTytIkZBQbmckbdowQQRgUWY7ow9c+LcOj6l4ts59IkkbQ57O2iMdwM3UlwCVByoEYGOTlv6Va8U/ELUvDE2j2Gp6Dbyazqssi21vZ3c9xGI41DMzMluXzzjasbeuQK2I/hx4USDVYm0szrqoiF4bi5mmabyv8AVks7khhn7wIPvUtz4C8P3dpbwXcF7cfZpvtFvNNqVzJPA+AMxzGQyIOBwrAcdKNRaHF3vxR1HULG20y08NXmna9eaddXc0N/M9r9jjjDDereWWckj5flXtkil8N6tqM37M02qS6hdyamNFu5RdtMxmDgSYbfndkYGDntXYXXw78MXS2vnWM5ltxKEnF7OszCT/WB5A+9w2TkMTnJrStfC2jWnhNvDVvZ7NEMD2ptvNc/u3zuXcTu53HnOaLMLo8QvfiNq8Hwwj0e9W4g1O48MJqVpq0N+zzSEbQxf5QyP1OQzZ9c100PxXn0/SblLfSH1KPQNMsrjVbma88uQmaNT+7Uo3mNgkksy9Dz69hb/DDwjBa3FuulvJHPaCwbzryeVltwciJGZyUXPZSKm1D4ceFNQkV7rSskQRWzqlxKizRx42LKqsBKBtGN4bpSsx3Ry2q/GGK3/ty703RmvNH0NLV7+5e58qTE+NvlR7DvIB5yy+2a5j4o/Ei/1fRtRXwws1lYabq1rZy6il48M0rscsixqv3OxJcZ9DXqmq/D/wAMarqEl5faUjzSiMTKk0kcc4j+4JY1YJIFwMbgcVDqvw28KarfXV3e6Y7S3UqTzrHdzRRySJ912jVwpYeuM9fU02mCaD4keMZPBtno0sOnLfy6lqUWmojXHkhDIGwxO1s429Md6425+Ml3DdJp0fhc3GtDV5NIe1h1BdnmKoKskjIoIPT5guK7L4keCl8bWmjW7372S6fqUWoEohLSBAw2AhlKE7vvA5GKktPh54XtGsnh0zEtneNqEUjXErObhusjsWJcnA+8TRqJWscfefF6/i1K6sLTwdqF9e6etuNRt7UyzvDLIoLIhjhZG2cjLOm7B25rSHxRQ+P5/DUthb2JjmWGN9QuZIJbrIzmGPySr54ABkUnI6Zro9W8CeHtV1W41K6spVvLqMRXElvdzW/2hBwFkEbqJBjjDA8cVXvfDfhW48UWrahM8+sqzXlra3OqTSGM9DJFA0hVcdiqjb2xRqGhxNp8bUuNG1m/fSrO3m063ec6ZPfyR3p2soG6NoAqghs5V2xx74s678ZP7K/tP/iReb9i0W21f/j827/OeNfL+4cY8zO7nOOgzXSx+EPBb6ze2U4S/wBXnsTDNDfalLd3AtSecCWRmRCT1GOTR/wq3weYLmF9LlkjubRLGXzL24ctAjKyJkuSACq4x2GOnFGo7o5u++LOp2b6ZaT+D7mPVtRSW5gtBctPm3VQVcmCKRssSRt28YyxArsB4qmf4bXXiebS7vT7iGwmumsbyMrLG0asdrAgHGV4OBkEGrWr+DtD1b+zmvLNxNpy7LSeC4lgmhXGMLJGyvjA9avWmh6fa6EdHhgP9nGN4mjeRnLK+d2WYliTuOSTnmnqLQ8d1fWfEXhz4W+Abiy1nUbjVNd1O0+2Tho55pFuEZ2ji84GNMfKF6KMDsTWfqPxB8T2PhDxBHPq1zDrGneIIbP97aQPdQ2sh+UOEQxM5AP3AenevQ4fA2j6d4E0/SfGOore6dok4uLS9kmexa2VMiItIkg+ZAxAbIHTgEZrTh8A+E59Ia3jsBcWl1cpqDzNdSyyTyrykjTFy7+2WI5qbMd0chZN4o1zQPHMF9qGtQadbqr6LqdxAbC8ZljLMWRUjJQMFHKjIz+HYeE/FJ1D4X6f4m1BreGR9PFzM00nlxBwvzEsAdqkg9AcA9DWp4x0m717w1f6XYagNOlu4zC1z5PmlEbhto3LyRkA54znFPi8O6XH4Wj8OtarJpC2oszA/wDFGF24JHfHfrnmnYVzxzxL8YL7UvDfimx0yxWx1K20oX8F7DcSmNoWdULxmSCNsjeCpC7T1DcU/wAN+KPFGl+M/CmkSPE2lXGhDUbqO41GS6dxklpjK8Rk3gDIjB29sjrXoEPwt8IRR3KDTJnW5shp0nm31xITbgqRGC0hIAKrjGMAYHHFas3gzQptQ0q/NpIl5pcK29rLFdSxskQxhG2sN68chsg85zk0WY7o4PR/jHc6rbG/tvCWoto72t1cxXoE2xfJVmCysYRGu/YQCjvg8HB4rrfhn4t1Lxlow1W98PtpFnNHHJau14k/2gEHccKAVAIA5wTnoKda/DnwvarKltp8sVvIJc2y3k4gXzUKOVi37FJVmGVUEZ4xXQaHpNloWkWumaVD5Fjap5cMW9m2r6ZYkn8TQr9RO3Q848NfFm58Satbx6R4Wv59JubiW2jv1WfahXhXlPk+WqM3GRIxUckdqk0z4qz6hJqsMegBLnRrK5udVRr4Yt5ImdViQhD5m7yydwwAOuTxXUQeAPDlteyXNrZT27PObkxQXs8cPmkY8wRK4QN/tBcjrVSf4a+HU0trXS7Q2E62Fxp8E6SyMUjm3Ft4L/vPmYth889xRqGhyEfxuS1srK81zQTa2t/pUmp2jW1557PsODG4MabT6HJHT8NKP4rXFu17b6p4cmTUI9GTXLa3sbn7T58DELtJ2LtYE88MMAkE4GdPwh8LPD+haPb2t9ANWvFsf7PlubppHDREklUjd2WNTnouK1dM8A+HdLS5Fha3UElxCls0639x5yxIQVjSUvvjQYHyqQOKNQuji7f4yxzaTpV7HY6bctfarbaW8FpqMjvbGUMd0geBCCNpG3GDz83FM1H4zT295c2tp4aa7uI/ELaBHGt8qGVh0cFkwMnjaTgf3q7GT4beFJbG5tZtMeVbm5ju5ZpLudp3mTOxzMX8zIycfNxk+tEHw28KQTxzR6Yxmj1AaqrvdzO32of8tCS5yfY8e1FmF0clffF3UrfU7rTLfwZf3eqafDA+oWlvJJO8TygHYhihdGKqc5dowcEDNafxu8T634e8FWOpeHGW2nmvII3aYAOqufu7GRhz0PQj3rpdX8D6Bq2qzald2cq300XkTzW13NbmeP8AuSeW6iQcAYbPHFXvEHhzSfEGinSdXs1uLDKkRb2TaVOVIZSCCMdQaLMLo4PXfipd6Vd6/ANAhuP+Edggm1ZkvyoQy4IWHMX73AOcts6H2rrPFHi220XwjFrqvZiGZY2iF7M8IfeMgDZHIxbHRQpJxUGo/DnwvqM3m32nzTytEkMzPezk3KIQVE3z/vsED/Wbula3iPw1pHiPS49O1izE9nHIksaK7RGN1+6yshBUj2Io1DQw/hp45HjW31YSadJp93pl21pPEzMQSOhG9EcfRkUj0rz7wj8Q7u6+KXiixtDPqlzdal9ktrOW7MVvZW1uu2WfowG5iOAuWIPNes+GfC2j+GTfHRrZ4XvpfPuXknkmaWTpuJdmOaybP4aeEbKa3mtNIEM8Ek0qTJcSiQtMMSbm3ZYEcYYkDtiizC6OX0H4wnUptAluNDW30vWri6gtbhLzzH2wfelZPLGExnoxIx0qbTvixJfXOgSJoDrpevvcR6bMbsGd/KH3ni2YRSe4diOpFdZpvgLw1psujyWWlrG2kRSwWWZZGESS58wYLENuyclsnml8P+A/Dfh++ivNK07yp4UaOAyTySrbqxJZYldiIwSTkIB1oswujz3Sfj1YX0WmyyaS0MM9ncXV3ILnctq8aSusOdg3syxE9sbh1qze/F/ULOPUTceF4Yn0vS4dSv0k1LBhMrDbCP3XzPtKnnHOR7nqbf4V+C7fT7Wxh0ONbW2uzfRp58p/fEAFiS2WGABtOVx2q9qfgHw1qn9ufbtN8062YTqB8+UGfyseX0b5QMDhcA980e8O8SbVvFVtpvg6HXbo29r58MbxRXkxjBdwCIyyq5zz/CrHjpXlvi34nXuu+APEVrp1rdaPrsWoW2kxSxSSr+8lccoXSORWChwQUUjj1r1zxJ4a0nxJp0FjrFp51tBMlxCEleFopE+6yshDKRk9DWba/D7wzaiMRaa2Y9SGrgvcyuTdgYEpLMSxHocjrxQ0xKx5pYeP7jQvFHimed9S1YS6pDoWl2JeV0DwRfvpMKrnkkFiqMxOODW5J8VtYWHSYB4Ivv7Z1K/uLOCxmuDb+akSK5mRpo0JUhhjcq9D6V18vw98MSactkdMKwretqCOlxKkqXDHLSLKGDqT7MKs2fgzQrTVNP1GKzka/sFlW3nmuZZXXzPvklmO5j03Nk+9FmF0cDqvxf1Gz0zUbyHwtFJ/ZtzBp91E+pbW+2SBd0MW2Jg+wtgsSo44zV2b4r3E2v3dlonhfUdVs7PUBp1xc26TNhwQJGXbC0ZVSed0ik9cY5qWb4Uw3niwatfX0CWn9ojVHsrKCaJZ51+40u+d0JHcqilv0rqYfA/h+DW59Vt7KWG7nuBdTCK6mSKWYciRog/ls2eclc5560aj0OMsvi5LdahZBNAB0y9119Et7hL3MjlSB53lmMDZ1z82RjvWp8N/C/i/QvEniG88UeJP7V0+8k3WcHmO/lDcTnDABOCBtXI/KtrTvh/4Y05dHWz0wRjSJpZ7LM8reXJJ99jljuJ/2s47YrqaaT6iv2PD9U8YX+k/FrxleawbiXRvD2nxTxWtvfyoo3rwfKACSMxcA7+F6gnArS1X4yTaNZX51bw6kV9DpMGs28EN/wCYk0Ekix4Z/LGxwW6bWHBwa9Am8IaDPqerahPp0ct1q0C2160jMyzRqMBSpO0cDsBWWvwy8JCwvbJ9LeWC8gjtZvOu55H8lCGSNXZyyICo+VSBwOKVmO6J9J17WtU8F32q3GiDSb4RSSWlvNeJKJE2BkdnQELnPTBIxXjemeM/F+reHfhbqN5dhrrUNWkjdorowi9UOy7ZkSMKoGMYAfIGepxX0VBbQwWcdrGgFukYiVDyNoGAOevHrXLaf8OPC2nrpqWunzLHptybuzja9ndLeQ5JKKzkAEknbjGe1DTEmjlrX4vC68OQ3yaZaRai9/Pp/wDZ8t5MzyyRYz5PlW7tJ95f4FxnmsJPinr3iLXfhxceHLaC10/XPti3Flczj948XBUyeUxVVxkMvLZwQuMn0L/hWXhEJCqaW8bQ3Ut5HJFdzpIksoAkIdXDAMFAK5xx0p8Hw28K2+naTZW2myQQaTJJLZGG8njkgaQ5ciRXD89wTiizHdCePfGM/hjUPDtjaabHfXGs3n2OPzLkwLG2MhiQjEjn0/PpXNRfFwTaGtymm2keqLqNxpj6fLdyu8ksWC3k+VBI0gwy/wAC4zzXS+PvBCeL7/w9PLfy2kelXZuWWIMrygjG1ZFdWjP+0ORQfhr4T+x6fbJpRiWwkkmt5IbmaOVHk4djIrh2LYAO4nOBRqLQ870v4pa94n8YeAX0G2gttK1mC7aexuJx87xbw2ZBEzKF27l2/e6EL1q1pnxgeGxtYPsF9qOqX+qXlpBHM+/akGCxzb25bHzDCiNm65bAzXd2fw28K2VvpENlpslsNJaR7J4bydJITIcuN4cMQe4JI5xTj8OfCv2KO1XSzGkV299FJHcypLFO5BZ0lDh1zgcAgcdKLMd0cmnxY1KS60my/wCERuLTUL2yubx7fUbhrYw+TuJXmIlgwXhsDqOOtZdt8Stf1/xj8PG0K3t4NK120uZprK4nA3vGHDAuImZdpXK7fvdCFr0aHwF4civLe7FhI11BFNCk0l1M7lZc+ZuLOSxbJ+Zsn3qKH4eeGILfRYbbT5LcaN5n2B4bueOSEOcuN6uGIOTkMSOcdKLMV0dZRRRVCCiiigDO+Fn/ACKs/wD2F9V/9OFxRR8LP+RVn/7C+q/+nC4ormZutg+KX/IrQf8AYX0r/wBOFvWlxWd8Uf8AkVrf/sMaV/6cLetCtaZFQKKKK0MwrzH9pX/kifiP/t2/9KYq9OrmfiX4V/4TbwTqPh/7Z9h+2eX/AKR5Xm7NkiP93Iznbjr3pPYa3Pzur1DTvjNrVpbaetxofhnULrT40itb280/fPEqgBdrBhjGM9Otemf8Mrf9Tj/5S/8A7dR/wyt/1OP/AJS//t1cGJwFLFpKvDmsbRq8uzPnzxZ4k1TxZrc2q65cm4vJQFztCqqjoqgcAD/PNeufsef8lM1P/sES/wDo6Gun/wCGVv8Aqcf/ACl//bq7r4O/BX/hXHia61f+3/7S86za08r7H5O3Lo27PmN/cxjHeuijRVKKhBWS2S6Eymmdp8XJ7u3+GPiiXTtwuV0+bBXqo2ncR7hcmuN1TUrvRLT4V6L4Xv20/TNUUQSNBDEzNH5KspG9WAOTnPcnnNeuzRpNE8UyLJG6lWRhkMD1BHcVQ8PaJYeHdJh0zSIWgsYc+XE0rybATnALkkDnpnA7Vu0ZpngvhX4i+KrpPBc+oap9qj1W7vrC6ga2hVHESjY/CAhstzg7Tgcdcw+BPFfiC4074baXZakmmW+q2WpyXAsrG2jG6JpShVPL2rgqOAADznOa+kaKXL5jufOvhn4oeJLiy8GXusapHBa6lpuoedK8MaJNdRNIsfO3hvlX5RgEnpziszw3rGo6x4w+GXiLxFr00E97p90humW3hRpFldREMx7cuNoI688YNfTtFHL5hc+fPBvj3xjqeoRXGpa/oFhN5t1Fd6LfybJLfarFD5SwCSNVxku8rKQeqniul+CvjHVte1rUNN16+uNQvLa3Er3FrNaT6ecsMBHhQMrYP3WZjgE+levUtFmJtHz5qN3f6B8avH95Y3ssmqHSo57CxkEQ+3sIifLC7dzhME4Qhjs5J5rofhZ4x1rWfFVjZNq39vafPosd7fS+TEn9n3ZbBhzGq47jY2WGM5617DRRYLni/jvxvrOi/ExLE6oJNHkkggisdHuLR71JGALedDKjSEHJI2bcDHPORleHvG3jDVfF3kXuvaTpTf2s9lJo9ywFx5JOFMUXkFywGWEhkKHHIAzXvtFFn3C54F4Y8c+OdR1HUdLy1zqPheyvX1JBboBqFwGYW6DC8AgBvkxnB5OayLX4h+MP+ER1HVv+Ep0i4m/slpzZoUlurO4V1BJjFugjXnbskL9Mhmr6Uoo5X3HddjwjX/FniTQNC8Oxal4mnl1TW4pLyC8ENrY2sKiFGELs8U25s5xtALFsemKHw28Q33iv4h+AdZ1do3vrnQLsSsi7QxS4dM46AkKCcd6+hqKOUVz59+IV3qGnfF/xfqOkahLYXtj4QNzHLHHG+SkqnaQ6sMHvxn3pmsfEjxGbSOe51hdDU+GINUsdtvERqV46qTGDIrZ5JGxMNznPFfQ1JRyjufO3iL4meLNMTxP/AGleLpN6uhWN9YWjwRgpO4j87YGUlsEuCGzjB9K2fDfiTxhrnjbxFCnie1stN0azsrsw3NlEY5DJah2DyDBRN+WJ5IHTA6+4UUW8xXPGfhJ4rvvE93rGjeK7yXUmjsy1zNDNaT6ayMcEK8KBlbafuuzcBiai+FurzW3gT4fwS+IW02O4vbi3ggaz886hCsjiOPfj93hQMNxwBXsGr6dbavplzp9+jvaXMZilRJGjLKeCNykEZHoadplja6Zp9tY6fAkFpbRrFFEg4RQMACiwXLNFFFUIKKKU0AJRRRQAUUUUAFFFFABRRS0AGKSiigAooooAKKKKACiilFAB2pKKKACiiigAooooAKKKKACiiigApcUlFACmkoooAKKKKACiiigAooooAKKKKACiiigAooooAzvhb/yKs/8A2F9V/wDThcUUfC3/AJFWf/sL6r/6cLiiudm62Ivi5cQ2ngxbm6mjgt4dU0uSSWRgqoov7clmJ4AABJJrP/4WD4M/6G7w9/4Mof8A4qtj4mDPhy0H/UZ0n/0429dTsX+6PypxlYUo3PPv+Fg+DP8AobfD3/gyh/8AiqP+Fg+DP+ht8Pf+DKH/AOKr0LYv90flRsX+6PyqvaE8h57/AMLB8Gf9Db4e/wDBlD/8VR/wsHwZ/wBDb4e/8GUP/wAVXoWxf7o/KjYv90flR7QOQ89/4WD4M/6G3w9/4Mof/iqP+Fg+DP8AobfD3/gyh/8Aiq9C2L/dH5UbF/uj8qPaByHnv/CwfBn/AENvh7/wZQ//ABVH/CwfBn/Q2+Hv/BlD/wDFV6FsX+6Pyo2L/dH5Ue0DkPPf+Fg+DP8AobfD3/gyh/8AiqP+Fg+DP+ht8Pf+DKH/AOKr0LYv90flRsX+6Pyo9oHIee/8LB8Gf9Db4e/8GUP/AMVR/wALB8Gf9Db4e/8ABlD/APFV6FsX+6Pyo2L/AHR+VHtA5Dz3/hYPgz/obfD3/gyh/wDiqP8AhYPgz/obfD3/AIMof/iq9C2L/dH5UbF/uj8qPaByHnv/AAsHwZ/0Nvh7/wAGUP8A8VR/wsHwZ/0Nvh7/AMGUP/xVehbF/uj8qNi/3R+VHtA5Dz3/AIWD4M/6G3w9/wCDKH/4qj/hYPgz/obfD3/gyh/+Kr0LYv8AdH5UbF/uj8qPaByHnv8AwsHwZ/0Nvh7/AMGUP/xVH/CwfBn/AENvh7/wZQ//ABVehbF/uj8qNi/3R+VHtA5Dz3/hYPgz/obfD3/gyh/+Ko/4WD4M/wCht8Pf+DKH/wCKr0LYv90flRsX+6Pyo9oHIee/8LB8Gf8AQ2+Hv/BlD/8AFUf8LB8Gf9Db4e/8GUP/AMVXoWxf7o/KjYv90flR7QOQ89/4WD4M/wCht8Pf+DKH/wCKo/4WD4M/6G3w9/4Mof8A4qvQti/3R+VGxf7o/Kj2gch57/wsHwZ/0Nvh7/wZQ/8AxVH/AAsHwZ/0Nvh7/wAGUP8A8VXoWxf7o/KjYv8AdH5Ue0DkPPf+Fg+DP+ht8Pf+DKH/AOKo/wCFg+DP+ht8Pf8Agyh/+Kr0LYv90flRsX+6Pyo9oHIee/8ACwfBn/Q2+Hv/AAZQ/wDxVH/CwfBn/Q2+Hv8AwZQ//FV6FsX+6Pyo2L/dH5Ue0DkPPf8AhYPgz/obfD3/AIMof/iqP+Fg+DP+ht8Pf+DKH/4qvQti/wB0flRsX+6Pyo9oHIee/wDCwfBn/Q2+Hv8AwZQ//FUf8LB8Gf8AQ2+Hv/BlD/8AFV6FsX+6Pyo2L/dH5Ue0DkPPf+Fg+DP+ht8Pf+DKH/4qj/hYPgz/AKG3w9/4Mof/AIqvQdi/3R+VcrqKr/wtLw8MD/kDan2/6b2FHtA9mZH/AAsHwZ/0Nvh7/wAGUP8A8VR/wsHwZ/0Nvh7/AMGUP/xVehbF/uj8qQqv90flR7QPZnn3/CwfBn/Q2+Hv/BlD/wDFUf8ACwfBn/Q2+Hv/AAZQ/wDxVeGeNv2mtYj8TXEPhTTdMGk20xjWS7Rne4CnBbhhtBxwOv8AKvavgh8Tbb4l6DcztYiz1OxdY7qFTuT5hlXQ9dpweDyMd+tHOw5EWf8AhYPgz/obfD3/AIMof/iqP+Fg+DP+ht8Pf+DKH/4qvQdi/wB0flS7F/uj8qPaByHnv/CwfBn/AENvh7/wZQ//ABVH/CwfBn/Q2+Hv/BlD/wDFV6FsX+6Pyo2L/dH5Ue0DkPPf+Fg+DP8AobfD3/gyh/8AiqP+Fg+DP+ht8Pf+DKH/AOKr0LYv90flRsX+6Pyo9oHIee/8LB8Gf9Db4e/8GUP/AMVR/wALB8Gf9Db4e/8ABlD/APFV6FsX+6Pyo2L/AHR+VHtA5Dz3/hYPgz/obfD3/gyh/wDiqP8AhYPgz/obfD3/AIMof/iq9C2L/dH5UbF/uj8qPaByHnv/AAsHwZ/0Nvh7/wAGUP8A8VR/wsHwZ/0Nvh7/AMGUP/xVehbF/uj8qNi/3R+VHtA5Dz3/AIWD4M/6G3w9/wCDKH/4qj/hYPgz/obfD3/gyh/+Kr0LYv8AdH5UbF/uj8qPaByHnv8AwsHwZ/0Nvh7/AMGUP/xVH/CwfBn/AENvh7/wZQ//ABVehbF/uj8qNi/3R+VHtA5Dz3/hYPgz/obfD3/gyh/+Ko/4WD4M/wCht8Pf+DKH/wCKr0LYv90flRsX+6Pyo9oHIee/8LB8Gf8AQ2+Hv/BlD/8AFUf8LB8Gf9Db4e/8GUP/AMVXoWxf7o/KjYv90flR7QOQ89/4WD4M/wCht8Pf+DKH/wCKo/4WD4M/6G3w9/4Mof8A4qvQti/3R+VGxf7o/Kj2gch57/wsHwZ/0Nvh7/wZQ/8AxVH/AAsHwZ/0Nvh7/wAGUP8A8VXoWxf7o/KjYv8AdH5Ue0DkPPf+Fg+DP+ht8Pf+DKH/AOKo/wCFg+DP+ht8Pf8Agyh/+Kr0LYv90flRsX+6Pyo9oHIee/8ACwfBn/Q2+Hv/AAZQ/wDxVH/CwfBn/Q2+Hv8AwZQ//FV6FsX+6Pyo2L/dH5Ue0DkPPf8AhYPgz/obfD3/AIMof/iqP+Fg+DP+ht8Pf+DKH/4qvQti/wB0flRsX+6Pyo9oHIee/wDCwfBn/Q2+Hv8AwZQ//FUf8LB8Gf8AQ2+Hv/BlD/8AFV6FsX+6Pyo2L/dH5Ue0DkPPf+Fg+DP+ht8Pf+DKH/4qj/hYPgz/AKG7w9/4Mof/AIqvQti/3R+VGxf7o/Kj2gchxvwjuIbvwY1zazRz282qapJHLEwZXU39wQykcEEHIIoqz8NP+Rcu/wDsM6t/6cbiiszQPiX/AMi5Z/8AYa0n/wBONvXVCuV+Jf8AyLln/wBhrSf/AE429dVQAUUV5n8f/H1z8PvAbX+mxo+pXc62lszjKxMysS5HfAU4HrjtQB6ZRX5wf8LA8Y/2h9u/4SrXPtO7fu+2yYz/ALucY9sYr7B/Zs+IWoePPB1ydcKyarps4t5bhV2idSuVcgcBuoOPTPenYVz16igdOaKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArldR/5Kn4d/7Aup/wDo+wrqq5XUf+Sp+Hf+wLqf/o+woA6qmsMgg9D1p1eJfH/4zTfDq/stJ0ewt7zVLmA3DPcsfLhTJVeFwWJIPcYx70AfJfxH8MX3g/xnqmkalD5TRzNJCwB2SxMxKupPUY/IgjtX1F+x94XvtG8G6nq+oWzW/wDa06NbrIpV2hRTh8HsSxx9M9CK+VfGfizWvGmstqniO8N3dbPLT5QixpkkIqjgDJNej/Dv9oPxR4StLXT9Qjg1nSbdVjVJvkmjjHAVZB1wOm4GqZKtc+4qKoaHqVvrOjWOp2RJtb2BLiIsMHa6hhn3wav1JQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr8NP+RcvP+w1q3/pxuKKPhp/yLl5/wBhrVv/AE43FFAB8S/+Rcs/+w1pP/pxt6T4leMrTwH4Vuddv4Jp442EaRRA/M5ztBOMKCRjJ4yR60vxL/5Fyz/7DWk/+nG3rX8R6LZeItCvtI1WLzbG9iMMqZwcHuD2IPIPqKAOR+FPxO0n4iWBexBt9QiTzLi0J3eSu9lXLYA525x6VkftL+ELzxf8M54tKga41CwuEvYoV+9IFBVlUdztYnHfFeD/ALP/AI20v4V+MfEuh+LI3tlmm8hr3YSYXhLja464bPBAPOOxyMf4kfHrxX4subq30q6k0XRHyiW9vxK6dP3knXJHULgduetO3YV9NTyEHIyDmvrf9iqOVfCniSRoCsL3yBJiOHITlR9OP++q+SMDoK9e+EPxw1rwK9rp2pBtS8NRqUFoqqskAyTujbAzyTkMefUdabEj6F/aD+Klx8PbG1ttISI6xdYlj+0ws0RiBIbBBGWB25Ho2a7j4YeIrzxb4H0rXb+1jtJb2MyCNG3DbkgH8cZx2zXyb+0d8VNL+I39jWXh62uDaWe6Vpp49sjSOAPLUc8DHPPJ6dMn7I8K2R07wzpFkY1ia3tIoiirgKVQAjH1qSrmrRXkH7RmqRaXp/hNjrdzpUs2tQQyeRqUloZLUn98W2OuVA2ZY/dzwRnnK1j4q6/pmr6yljFpFxo2laxY6aqukrzTwzpnf5vmEbh6lTnP5gHulFfMvhHxRdeFNK8V+ILy60z+1tQ8V3GnC6bSd7Nt6q0r3MSpH90qHkAQK33s5XY0X4xeKtbstAFtaaLa3l7ZalPcGWCSVBJak7QoWUYDYweWx1BPQgH0FRXzn4X+Ievaj8QLPV9Q1bT9Osb/AMKrfQ6deSPFayyqzblRmkCq+VLGTa2E4IOC1d58F/H+o+NJNVg1drI3VksRkWwgVrdGcE4W5S4mSXjHZCPT0APUKK8Dh+NWpy+O/wCybRbC706T+0Y1d7M280MtvE0ihl+0O5Hy4JeOLPVe+KsHxp8U2+lpeXWmaXftc+GTrkMVpBLE0UgmERVsu+5AMuSNpwCPegD6GorxH4H6jJq3xS+I1/Nf6dqMlxBpTtc6cpWBz5D8IC7nj7p+Y8g9OgyfG3jq+8ReCvH9jqWoaHpclsl7ax6HJE39oSJGvyy7jKBg/e4jIwOvcAH0JRXzZqnxD1zSfAmu6VcRWUw0nRdJvLSa2e4tWKyvEpR2jlDkjPVWUHHIwSKlg8YX3hPxv4xSxNhaxal4ojtZ9S1FWa3s18gHc4DJycYGXUcUAfR1FfL3wl8W+KrHSfDHhvwnFocs2qz6nPJLqSyhR5cxOV2HIyCeCD25FdLpXxi8TXvii9s5tL0i0gge8jezubiKK7h8qMtG2xrjzJdxHIEK4ByGPNAHvlFeCaH8XPElxBG+pf2BCt14Wk16Gb7NOkdtIjlCsgV3Z04z8oDdsHHO98e7t7/9nXU7yV4ZJLi2spWeAMI2LTwklQ3zBeeM8460Aeu0V4pqHxU16HxvPpMNrpgMeux6SmlPE5vpLdlz9tDeYB5ffGzGOrCuWu/j14n0+yuGvdD08z2DTadfFI5Qq6iWn8hFBYnYVhUt1JLjBFAH0pRXA/EDxRrvhbwBY6iF0NdckaCK4F5dJb26uy5k8vzJUDEYbCGQZA68V59qnxm8QWGheH9XttPt9RstcguLa0Y6fJbP9vDkRKV86QGNgR91jnBIYdAAe/0V4jq3xJ8R23jgeGJp9DSaYR2sTafCL6QzmLLtJGt0ksCh8YzG3HVu9c74B+JOu6f8OfByXmuaXNLfXdxbX2raqsko0zZuZY7k+cC0j/wklABgYPUgH0hRXy7eeM9T1jVYvFN9YfY9RXwVqE3lLJLErmO5wrqyMsiq20EYYHng9DXoPgv4h6jqviOLSdQv9D0KGGGy8m21BZJLrUhLErMYXaZe52g4kOevPFAHsNFeCfHnWL2z+IWh2MWt/wBmWc+k3bnztbm0yDzR9xy8edzA9FI+bpXKWWseJ/Emq6BZW0viu7vbjwUZo4Y9RNiy3guHjW6lHmoGXgf3yylflbsAfU1FZnhe31G18N6Vb63cLc6pFaxJdTL0klCgO34nNadABRRRQAGuV1H/AJKn4d/7Aup/+j7CuqrldS/5Kn4e/wCwLqf/AKPsKAOpNfDX7V16Lv4y30Wc/ZLS3gH4rv8A/Z6+5SM18MyXdt4z+MHjnxJq8ajSLC0vZpM/3VjMEAH+2WKYHrmmhPY8hpCMgjtSJwoz1xXY+AbG21bTfF2mtGX1SXSjPYd8vDIssij/AGjGr4+hqibH2l+z1fHUPgx4VlJyUtTB/wB+3ZB/6DXoleD/ALHmvtqfw3uNJkA3aTdMiEd45PnGffcX/SveKgsKK8H/AGgdZ8T6p4i0/wAJ+AbjU49RtbOXVr1tNmWOQKBtiRiXX5Sx5XJJBBCtwK5f4jfFe58WeBLmxhk03T7C+8N/bXe6RjJd3Ak2SQQfOoBQqxPDnA6DrQB9QUV87X3xg1fw1aajpccOkrNpyaPHp8dwjiS4hniXznxvG7axABUADPOa5+91bVdG8aX9zp+tR6PYN45uI7y4uA/2fBgj2+diRAU4b5SRk4ORjkA+qaK8U0v4rarc+MdY0i6m0REt47yW2NnGL2IRwoSrzzxXBaM5ByhgBOMA5rsbzxbfw/CBPFFvJotzqT2EVwjyTm1spJH2gYaYqVUluA5UngEjNAHdUV4EfjRrNn4TtfE1xb2d9pNvqb2GqGGyMWz92NjQyLcTRyLvyC4JByOB1M2sfFXxRoc/h+DXE0K2lvLOGa6itIhdXSTSvxGLU3McqqEIywEnIPGOAAe70V84eGfiB4k8PeH/ABS19qtlqN/B4naykW9SUnTIHkA+0yKZSwtx0VBtwf4z2dL4tv8AxV4x8E3N/HbOLHWtUtIL6yDJBfRpa8TR/OxAOezHpwfQA+jaK+fvAnxR1W7s/Dtle32h+HLW40sXn2/WDPcLdSGZkMUTyXCnIAyd0jN7YroP2hNWutLu/BKw6k1jaXGptHdZ1WXTYpE8snEk8fzKue+DQB7DRXyto3iDXdQPw70+4vfEuqpLf6xbTpY6m8DagsaK0bRzmWMyRrnId2BO1v8Adr2HS7vxV4L+Csl7rsUmteJbC1llaESGVn+clVZxkuVUjJHXafrQB6RRXy78RfiFrvib4deKdPF1pF5ZQjTi+p6ZBIsMgmdN9vzK2HBIydxyu5Sqk5Ho3xjsE0vwZ4Kso4rOJYPEOmpss7fyIQRJzsjydi5zhcnHqaAPXKK8B074yeJ7vxJf2kmmaFaQ273sbWd/fQ2lxB5UZaNmLz72U7SWPkqFXkEgE1HZ/GXX5/DN5ciTw6dTtru1t5vNMMNrGro7SeTMb0x3LAKMKJIiOcjsAD6CoryLxJ4n1bxD+ztqPiHRrq4g1KWzkmSaKzktZAqyHJRBK5Q7Rwwdh/F04rz6+8S6tbeK9M8SaVquj6pqFn4Enu2uTC8kEwjmJZCBKTv+XaW3n5gTgdAAfT1FfPetfHTUbW80f7FFYyefFp0t5ZTWvltGtyisTHK1wGkwW6rCVHG5umdXTfip4jm8S28NxBpDaZL4suvDZjSCRZgkYBSXeZCueeRt5xxjPAB7fRXiPx91TU9K1uxkOqXdvpD6bcrBbabqa2t0b3gRybPMR50GVGxd3P8ACc88X418SeKbWOQeJdX1TSdXi8MWc+mQQXD2/wBp1AuolGxCBLJngxkMACflHWgD6iorzv4geLdb8MeE/C11bRWn9p6lqNlp9wLuJmWMyg7yFVl5BHriuK0z4t+Jjd2CahBo0sUms3+iyiC3ljJaBNyyqTK2AcgFCD0+9zwAe80V862fxi8Y3Gi214YvD6yXPhy511R9jmwhgdgYz+++YMF4PGCehxzTvfGnirUpvHmoaZJtt38JWmoeW+pSwiwaS1Ll7dVRgXyc9U5A+b0APpaivmu5+L/iLw/4T0+OOXS0ltPDFjqKSausk02qzSKocRkSp93JLH5jwfqPovTZ2utOtbiQKHliSRgvTJAPFAFmiiigDlfhp/yLl5/2GtW/9ONxRR8NP+RcvP8AsNat/wCnG4ooAPiX/wAi5Z/9hrSf/Tjb11XauV+Jf/IuWf8A2GtJ/wDTjb11QoA8S+KX7P2keN/Ec2uWuqT6TfXAX7QEhEscrDjdgkYbGM84OOmc58S/aG+Gmi/DjRvCsGjCee4unuDdXs7ZaYgR7RjooGTgD8c19tEV8x/tq6hZf2b4Y0zk6l50lyuOiRbdpz9Wxj/dNCBnytX0D+zf8PPCvxD8Ka3b+IdPka/sbxSl5BM0cgjdOF4OCAVY8jvXz7X1F+xRqFqo8U6blxeuYbkDb8pjAK9fXJ6e/wBapko73wV+zt4Q8Ma7Dqry3+qT28gkt47x1McbDoxVVG4j3446V7PQOlFSUcz428Unw4dHt7ay+36nq16lla25l8pSSCzuzYbCqoJOAT0GOaut4p8Pprf9jPrulLq+4J9hN5GJ9xGQPLzuzjnp0rA+I+h6le6p4T1zRbb7ZdaJqHmyWodUaWCRDHJtLELuAbcASM4PNYPib4U6j4g8ZWus3ni25e0tNVt9TtrOSKQiARdYkxMIwG5+fy949TzkA7u08W+G7zU20608QaRPqClgbWK9jaUFRlvkDZ4AJPHFWNG8QaNrhnGi6vp+omA7ZRaXKTeWfRtpOPxrwbw38Jdbk1rSdIvoLq18L6XZanaJdTLDFcSC7DLx5U8u8jdncQnAwVrufBHwf07QnlXW/wCzdehazjsgLq1ndmSMgoGE1xLHgY4CxoB2wOKAO81XxNoOkX0Nlq2t6ZY3k+DFBc3ccUkmTgbVYgnnjim2Xirw9f6n/Z1jr2k3OoZYfZYbyN5crnd8gOeMHPHGDXF618LPP8UWmqeHtSt/DcUAhjK6XbSwyvDG27ymKziEoT2MJ49a5Pwh8ItWvpGbxVdfYLG11nUL63s7eNTNKJxtDmcSMAuOQuwH1PTAB6/Z+K/Dt614tlr2k3DWQLXQivI3MABwS+D8oyD1xWfJ4+8OFrN7TVtOvbO4eZGvLfULYxQGOPzH3EyAnCnJCBiBycDmvNrX9n+2XR7jTbrWhMhs/sVvdCK4+0RRiZZVU77loigZeVWJQeo212uoeB9V1jU/Dd/ret2Mk+izTugs9NaBJUkh8sKQ0z4IOTkcHgYGM0AVfh58U7Xxfa6ZcG1tLWLU5bhLcR6nDJJGIRubzo2KOrlSrbYxJgMCxUEGtXxD4+0628Maxq/hibTfEb6SgmvLWz1BC8cYyWPyhsMArEA4ztPNcpb/AAVhXw/4S0i51yWSDQrTUbN3it/La4W7RkJB3nYV3Z/iz7VqX/h/xTonwt1Dw9p0llrlx9hXTdPWC1FmYlKmMySs8zK2FIPyhTkHg54AO6i1rTn0KHWWvIItLlgW5FzM4RBGwDBix4AwR1qkPGHhk6bHqI8RaMdPkm+zpdC+i8p5cZ2B92C2ATjOawdd+HcGr/C2w8HG+kgFlb2scVyEDjfBt2lkJAZSV5XI/CucvfgvHqtw11rOrwXdzc69b61exiwxbTrEjJ5AiaRtoYMcsWbPpQB6bda7pFppEerXWqWEOlyKrpeSXCLCytypDk7SD2Oeazz438KC0juv+En0P7LIzok32+LYzIAXAbdglQQSOwIzWB8UvCR1Tw1okGh2kqy6LqFte2drZwQtGPKyFRonlhQxgHoHBHGK4nwX8Hru/i0u/wDGyWayQa1qGqzaXNbpcJMtwqqEf52VSCm7jeOgzxmgD2CPxLoUurLpUWtaY+psu5bNbqMzEYzkJndjHPSsLWvid4Q0zQNT1aLXtN1KHT4hLNDp95DNLgsFAC7xySQBkjk1y9p8GYLHxZLqtrqim1bU31WKCeO4Z7aZupjK3CxcY4LxPxwdw4rLb4GXl7cXtxrvjG61G5utMn01p5IJDIRI+9WO+Z1G0/wIEUjsDkkA9Lt/HPheXSNO1OTX9Kt7TUF3W7T3kSeYehUHdgsDkEAnBBFaEPiLRJ9WOlw6xpsmpglTaJdIZgQu4jZnd93np05ryfxx8L4Tp8GueIfEduo07R/7Nvi1pdLbT2ytuX91DcrJu6ArvYMf4c4x0Hws8B6Hp1/deLLCex1QatFbzWNyLMq9tEIAmEd2Z8MOoJB7HJ5oAk8UfF3QdFvfFOmw4udX0Kz+1tbvPHGtydpYxxnLNuUD5vl4q1/bXgjxVpukeItY1HSA+kGK8+fUlCWE8ijAkwwXdzgbx16AGqPiz4YT63rnim+tdbjtIPEWmpp91DJZGVkKKQrowkXHUZBBzg8jPFG4+Ed8l1e3Wj+LJ9LurnT7KwMlvalTttwASWWQNhwMfKVI4wxoA7w+MvDA0+G/PiPRRYzMyRXBvovLkZRlgrbsEgdQOlXk1ezn0R9W06VdSsxE00bWJE/nBQeI9pwxOMAA9eK8w8N/BhtGvdNuG18z/Y9en1zZ9mf5zLGqGPc8rtxtzvYsTnnnk9X4D8FT+Dfh9/wjdhq+blDO0N8LUDy2kdnB8ssQdu7pnnHagClL8VtGsYfEDa5YarpE2h28V1dQXccTOUkOI9pikdSSSBgkHJ571t+EPGVl4mvNUsI7O+07U9MaIXdleogkjEib42yjMpDD0btziuHm+C8OoWXiqHU9Utojr0EUTxaTp/2O3jkjfesxiMj7pNw5ORkEjvmut8D+DZ9A1zX9c1XVF1PWNaMH2iWK2+zxKsKbECpuc5wSSSxz7UAbFl4q8PX+p/2dY69pNzqGWH2WG8jeXK53fIDnjBzxxg1FH4z8LyJevH4k0VksebplvoiLf5tv7w7vl+bjnHPFeSeEPhFq19IzeKrr7BY2us6hfW9nbxqZpRONocziRgFxyF2A+p6Yev7PyDw/e6UddhYyWP8AZ8F49tcvPFF5yyhSGujEVyvRY0GTkY5BAPV7nxp4WtbWK6ufEuiQ20rMkcsl/EqOynDAMWwSDwR2qw3iXQk1VtLbWtMXU1UubQ3cYmCgZzsznGOelcl/wrYaT4ms9c8G3Wm6PcQ6edOe2k0zzbdkL7y6okkZRyxOSDz3HesX/hS0K+JrvU01VJre41GTVFhukuXeCaQfMUKXKR/QtGxxwSRQB2d98QvCtto+pajDr2l30dhateSxWd5FLIY1HYBupOFGSASQM81peEPEmneLfDtlrOjTLLaXUauBvVmiJAJR9pIDrnBGeDXnGm/BOK0sdKtZNbMiWWhXeiOyWgRpVnLHzAd527d5+XnPqK9B8CaHdeGvCWmaLe30N81hAltHPFbmDdGihVypd/mwOTnB9BQBv1yuo/8AJU/Dv/YF1P8A9H2FdUa5TUv+Sp+Hf+wNqf8A6PsKANTxZrNvoHhrU9VupooYrS3eXfIwA3BTgc9ycADuTXxTHp50P9m2+1S5fZe+KtXijA7vBCWb8t4Y/lXt/wC1T4dv9f0/SIbJb6Ub2OFJNujgcfKOrtk8nIVUbAyefL/jHpV3o/wC+GVneQSW8sTzGWKQYZWYFhn8zTQjwiuv+D2ox6T8U/C13M22IXyRSHHG2TKNn2w1clGFbfu3cIWG319/atDwurP4n0ZE++19AF+vmLVEo+of2fLSPwN8ZPHngyaZIo3KXFlG7AGRASVx6nZIOPY+lfSOfyr5O+Nvg/Vbz47PrFpZXzW6paSI1uzI8zj5cROPut8uAezY7V9T2KtHY26vJLKwiVfMlAEj8dWwAMnvwOahlorax4h0XRGgXWtY07TmnOIhd3KQmQ/7O4jPXtSL4j0RtY/sldZ006rkL9iF0nnZKbwNmd33Ru6dOelcd4/+G0nifWrvUrHWEsZL7SH0W6Se0+0qYGfcWj+ddj5J5+Ye2ad4G+Fel+FfFWo62Xh1CaWCzt7J7i1UzWawW/kErKSSS6gZwF9OaAOr1rxV4e0O4W31vXtJ06dl3rHd3kcLFfUBiDj3p3/CT6B9tns/7c0v7XAHMsH2uPfGEGW3LnIwCCc9Aa8a+Mfw68Qa5rXiUeGbSeYeJLezt7qa5WHyIRDIpBSQziReFBKiJgex9Olv/gtpOpReNPt9zHJdeIpfMjvEtFWezXC/IrkkspKgkfKCMj3oA7f/AITbwr/Zp1H/AISbQ/7PEogN19vi8rzCCQm/djdgE4zng1lah8TfC1l4j0DR21O2lfWonltbqK4ia32qcDc+/wDiYFVwDlgR2rk7P4QanY2lwun+KjY3lzPbyXVzax3ga7SFWUJKzXjSYwwwY3jwBg5GNrvDPwbm8OP4Vm0/xAjXGhS3hBlsmKTRXJ+ZMCUMrAZw2488kdqAOv8AEVz4J8VW9zpes6ppN7Fpri8urYagq+R5RzulCuCFU8kN8vHNac/i3Ql8O6jrltqlleabYRs88trcRyKNqhtu4NjcQVwCR94eteYaZ8B4dPsbqyj1lJoWsryxtZp4bl57dLhXBx/pPkkAvkgRLux2PNeg+HfBGm6H4BHhizjt4I5LL7Lc3FrbrCZ5DEI2mZRn52xnJJPuaAOZj+M+gXF54Pa3e3TSdfjunlvbm8ji+wGGNX2SgZUMd4BBYYyOua7O78Z+F7N7RbzxJosDXcazW4lvolM0bEhWTLfMpIIBHBxXD6X8Jrm2Hg5b3XoLhfDVreWcQj08x+fHPCIhuzK2GXBJI4bOMDqcPUPgXqN34RsvDZ8bXI0q3sPshtzayLEX80yeaESdQT0GJPMHGRjjAB6zL4q8PQ6p/ZsuvaSmo+aIfsrXkYl8w8hNmc7jkcYzzTfFGvvoMMUkejapqm8O7CxWP90qLks7SOij2GcnsDXnt/8ABkXn9rltcAbUNSsdRBNnkxm2Xbt+/wA7ueeMZ6Gu28d+Hb3xJYx2dtd6ZHZkMLi21LTBfQzZwVO3ehDKRkHOOeRwKAMCf4u6D/ZulXdhZ6tqDahYy6mlvbwoskVtHnfI4kdRgEEYBJPYHiuttvE+jTeGLXxC+o21to1xFHMl1cyLEgV8bdxYgAkkDB78V54fg5La6bo8Wk+JZo76y0mfRZbm8tftHnW8pJwFDrtKk/LyQAAMHFT/ABO8B3knwIk8G+FYHvbmCG0ggR5ERpBHNGzMWYhQcKx6/SgDul8W+HH0uXU18QaQ2nQyeVJdC9jMSP8A3S+7APsTSP4v8NJHayP4h0dUu08y3Y3sQEy7tuUO75hu4yO/Fecap8FG1S5vdTvPELLrtzqsOqedbWzwQK0SFFQRpMJBwT8wlDZ6Ec5s6B8FdN0/XtG1C+bTbu306KdfsX2GR43kkcOJczzSsGB56nnkYoA9BTxV4efULqwTXtJa+tVZ57cXkZkhVfvF1zlQO5PSoU8aeFpLEXqeJdEazMogE638RjMhBITduxuwCcdeK4e3+Ek8XgbV/Bba9G3hy9Mrx4sSt5G7SCQFpvN2yAMOcoCRxkVTsfgqYLjT7mbWLc3Vtq1jqks8dtcs9z9mWRVRzNdS4yHwGXGAMYPGADrNa+KXhPSb3QIJdWtJ4dZkkjgu7e5haBNnVnfeMLn5cjPPFdJ4g13TPD9ibvWNQsrGI5VGurhYVdsEhQWIyTjpXm9l8H5tObS59P1+JL3TtautXhaWwLxETjBiZBIp4AGGDD6V0/jvwVN4k13w7rFjqUVjfaMbjyxPam4ikWaPY2VDoQwAyGzx6GgCHwd8StF1rwVoniDWrvTtBbVA5itru+QElXZMKzbd33c8DvXRXfifQLPVE0y71zS4NRkUMlrLdxrKwIyCEJyRgeleSx/AGKHTNIt117z5LTTX0u4WeCdYLmJpml5SG4jYcvgguynAOM811Xhr4b3nhm91b+xtYtE03VlT7Xbz2DyyKyxeX+6l84FV6EBw5Hqck0AdR/wm3hU2Ul4PE2h/Y4yqvP8Ab4vLUtnaC27Azg49cGnXnjHwxZC0N54j0W3F2gkt/Nvok85ScBky3zDPGRXmqfAbT7bw34as9O1GK01fRpHd9QhtXh+2lsg+aIpUkyAcAiTIGexIpus/BO8vvDdroFp4p/s/RorOS1bT7e3uPs+9pWk81VN1uJGQNsjSL1wBxgA9TuPE2g22rxaVca3pcWqS7fLs3u41mfd93CE7jntgc07TPEeiatfXFlpWsabe3luMzQW10kkkfOPmVSSOeOa8/g+E9zD4kg1K28Qmwh/dC8j06KeB79Y4/LCzE3DRnjPIjB5696X4bfCOPwTq9ldDUYr9LGCW3t3ljuROkbsW25Ny0IGTyFiXPXg5NAGmvxQ0o+P9Z8PS3Gk2tno8KSXl9d6kkRDN/CiFcMFO0MSy7SwGOmejm8Z+F4IIJp/Emixwzu0cUj30QWRlOGVTuwSDwQOhrjfFfwn/ALfl8fv/AG19n/4SuOyjx9l3/Zfs4Az98b92P9nHvUXiL4P2t3PM/h28stEiutHfRbqBdOEkRhd97PGqugjkJJ5+Yd8Z5oA2PGMfgHXNT+w+KNbs3uFMcT6bLrjwxsc+Yge2EoRicgjcpJGOoArr9G1XTdYs/tGi39nf2qsY/NtJllQMOq5UkZHHFeUz/A+FodWgt9ekSC9l0p0Etr5jRrYxiMBm3jeXAyTgY9DXdeBvCP8Awit34lmF79qGs6rLqe3yvL8neFGz7x3Y29ePpQB1VFFFAHK/DT/kXLz/ALDWrf8ApxuKKPhp/wAi5ef9hrVv/TjcUUAHxL/5Fyz/AOw1pP8A6cbeuqFcr8S/+Rcs/wDsNaT/AOnG3rqhQAGvi/8AbHLH4o6eDMjqNKjxGDyn7yTr9a+0D0r4R/akuhc/GrWEQ5EENvF9D5YP/s1Nbiex5MWA6kCuv+Fnji8+H/jC01qz3yW4/d3lupwJ4SfmX6jqD6gV9J/sl+E9Im+G0mrXumWtzeXd7Lia4gVyETCgKSOBnd075rwj9oPwTbeBviLc2enOn9n3sf263hXrArMQYz7Ag49sU73Fax94aPqFrq2lWeo6fMs1ndRLNDIOjIwyD+Rq5Xmf7N0c0fwU8MC4YsxhkZcjoplcqPyxXplSUecfFvxle+G7/wAPaZayadY22sNcxz6nqKs0Nv5cW5UwHT53JwuWHToa8a8E/EvXvCPw38HaVo9hpyRSaZNdJd6nJHFDNJ9qkXyQ8k8SoQOScu3I+QjmvqyigDx+x+Jmp3viXULK8u/D/h9LWK3kt7O+Bmn1HzIg58iRZkQjPygqJM9faubh+LfjmHwJoXiPU9M0BLXWrhI4bm3Vylog3BjMJZY0BYgBcyqOuT0FfQlFAHzxr/xv1zTfCumXTLokeuTWc91JbRrHdWswjkZcx3C3aqDhf9WvmuD2rUsvjDq1x4u0uxeHTPsd/HbNBbWAS9uWZ4RI6yYuEeDBIUFomA6k17nRQB4t8Ivinr/jHxJDZ6tZaRbW00ErvBHcRJdWsiPgK0RneVxgckxR4J6Y5NXxZ8Q9X8O+LfG8WnQ2rm01HR7SM3UlxKm24jO8+WZdiEdtgTP8W4817nRQBwXw38X6lrtt4sj1tdPFzoWqT2HnW4aCKVI1BDkMzlOvPJxXnem/F7xXf6H4jntYNFutV0i0+3vbWsAuLYwiTDBbqK6cM4jy20ohz2Ir6Bqpq2nW2r6Xd6dfo0lpdRNDMiyMhZGGCNykEZB7EUAeH6l8YtfXwpbeJLeDQ7TSb++uBafbHRbn7FEAPMEMlxF5zs2flVhgbeG3VRh8feIbTx7qupfbjcwTeGodRstGuLaW3N44jLMIYmmO1wwLNgOdoI5xur37SNOtNI0u007TYFt7K0iWGGJc4RFGAOeTwOpq3QB8veN/iBqfizwPq1jeNpeoWkS6Vef2hpcbpDFLJcR7rZ9zvl1+oPByorqpviRq2k6lrcEKWVpbN4pk02TVNRkuJ7ayiEaMGkVpcLuJICq0aA9hXu9FAHk/xq1y9t/gBq+r6VrkUt6I4Gj1PSHaFHzcRgtGVdiAQSPvnvzXkuq+KdXh0TxXBp+t6lc266ppn2aXTNbmvYYkfiSGO8cq5ds5KkgD9a+sqKAPFbLwr46u7S5iliB0c63FewaXrmrPJOLaIbljedRPkGUI+0s2AuM813vw00bV9B0a8sdYjsYYvts01lDaXLzrBDI2/wAss8aE7WZ8cfdwO1dbRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyupf8lT8Pf8AYF1P/wBH2FdVXK6j/wAlT8O/9gXU/wD0fYUAdVXjH7WeinVPhHc3UaBpNLuYrv3252N+j5/CvZ64X46Tw23wg8WvcjMZ0+SMf7zDav8A48RQB8d/Bjw1B4iTxu1ztxZ+HbmWLIziT5Sp/wDHT+dVvgDo7a98XfDNuUDRw3H2yTPQCIF/5gD8a639mSwkvI/iEEkCE+Hpbfn+8+cH8Np/Om/sfXEEPxZMc65ln02aOE+jBkY/+Oq1USfbYpHwBn0p1IwzUlHi3xG1fV7D4z6XaNrkVjot5ok6rb3AcRTyhsFAPMVWmII2nBIB+61cn8JvHup+GPCHhrSrv7EdJl8O3WowzR2ksk1u8Ujj51D/AL1e+Bs+oxmvpaigD5V8RfFrxP4j8PaqtneW9jFp9zp10uoWUZiZoJWIYSCO5lCgNjI8zoCpCk8ey/Evxte+Ffh/pet6ddaTey3NxawveGNvsrpKQGlQCThccj5zx3PWvRayvEnh7S/EtjFZ61a/abeKdLlE8xkxIhyrZUg8Ht0oA8RvPjT4jg0tZYrLS7m3bWZ9OXXYottjJFGoKuBJOigsSRkzbflOCTxWnofxK8ba74g8NaXZWnhaGS90ttRvne5aeJVjuWifypYXZDlVyAScEnJ4xXuFFAHzvD8bfEQ0/W5HtdIur6zgE4jsIxdWkEbTrGJHuorl9wVSWKGONu/ABrT/AOFs+In+zW9muiXiTeJ7bQ4tYht5DaXMUqMWeNBKfmQgA/vCDmvdaKAPIvCWpSeMtHbxf4hSzXV/ClzqVtAiSeRZO6qF859+4p8oxksQoLH6Xfgv4/1HxpJqsGrtZG6sliMi2ECtbozgnC3KXEyS8Y7IR6enqFFAHzL8LfHV14f1R9Hsnsb6K+8Q6mbyziheS7to1+bz/lc/JxjaU5wcH00tE+OOt6hcazFbroV1HDo51Gxubgpp6NIJ1i2S5uZVQHeMB2Rs4BAyDX0RRQB89zfGvXV8OafeW9tZTNPqUljcX72aRWlsURTgMbwxSbmJAfz1X5TxnGef1Xxhql1rd94nvILKPVB4DkkeOxvi8O5dRK5Sa3lzg4z8smR0zwa+pKKAPAH+LfiW1kvnS20h9P07UtO09onimM0qXEYLN5hkOGB7lTnPPTnR8OfFfxFqnxIOiXOm6VaWS6lNYyW1xcQw3aRqPklUNPvkyedqw4x0Y849uooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlfhp/yLl5/wBhrVv/AE43FFHw0/5Fy8/7DWrf+nG4ooAPiX/yLln/ANhrSf8A0429dUK5X4l/8i5Z/wDYa0n/ANONvXVCgAr4B+LOk3urfHzXNJ+b7ZfassEXGcLJtCH6bSPyr7j8Z6/H4X8Laprc9vNcx2MDTGGEZd8dh6e57DJr5N+D6ax8Xfjp/wAJXqTwW66Y0d5N5CYUBfliiX1PHJJzgGhCZ9eaBpFnoOjWWl6ZCkFlaRLDEijAAA/mepPcmvlD9taz8rxjoF5kfv8AT3iwDzlJCf8A2evr8V5V8cvhHafEmziuoruW01uygdLVsgxSZ5COOuMjqOme9CHudj8NLOLT/h34Ztbcq0cWm24DL0b92pJ/E810teA/syeI9U06zn8BeLbG/tNW013Np58LbGh4JTf0+UkkHOCrDHSvfqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuV1H/kqfh3/sC6n/AOj7CuqrldR/5Kn4d/7Aup/+j7CgDqq85/aJtmuvgt4qjQcrbLL+CSKx/QGvRqzPE2nxat4d1TTrgKYbu1lgcHphkI/rQB8hfst2F5exfEE2SOd+iNbqVH/LVw2wfXg1jfsnW7z/ABl010BxbWlxI/HQbNn82FesfsTmIeFvEqBf9IW+Tew6FfLwv6hvzrO/ZMsLWf4heP8AVbcKqQyfZ4E7rHJM7f8Asi07isfUVFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr8NP+RcvP+w1q3/pxuKKPhp/yLl5/wBhrVv/AE43FFAB8S/+Rcs/+w1pP/pxt66oVleJ9Fj8QaQ1hLdXNp++guEnttnmRyQypKhG9WU/NGvBUgjNZX/CL6v/AND34k/78ad/8i0AdQ6K6kMAQRgg8giqelaRp2kRSRaVYWtlFI5kdLaFYwzHqSFAyaw/+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWgDqqTFct/wi+r/APQ9+JP+/Gnf/ItH/CL6v/0PfiT/AL8ad/8AItAHUkA+tLXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVUVyv8Awi+r/wDQ9+JP+/Gnf/ItH/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVUVyv8Awi+r/wDQ9+JP+/Gnf/ItH/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVUVyv8Awi+r/wDQ9+JP+/Gnf/ItH/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVUVyv8Awi+r/wDQ9+JP+/Gnf/ItH/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVUVyv8Awi+r/wDQ9+JP+/Gnf/ItH/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VcpqP/JU/D3/YG1P/ANH2FL/wi+r/APQ9+JP+/Gnf/ItVJPA17JqtvqT+NvEhvbeGW3jk8qw+WORo2cY+y4OTFGckZG3jqcgHa1wfxqufE9v8P9QXwTp5vtUnHkEI3zwxsCGkRf4mHAA7ZzzjFaX/AAi+r/8AQ9+JP+/Gnf8AyLSf8Itq3/Q9eJP+/Gnf/ItAHm/7J3hPWvC3g/Vxr9hNp8t1e7ooJ02ybVQDcR6E9Pp71xHwp8L/ABD8GfGzVHttEeTQ7+9kjvLiTCQPCXLLKh/vAHgDPUjjqPoD/hF9X/6HvxJ/3407/wCRaT/hFtX/AOh68Sf9+NO/+RaAOqGe9LXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVUVyv8Awi+r/wDQ9+JP+/Gnf/ItH/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVUVyv8Awi+r/wDQ9+JP+/Gnf/ItH/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVUVyv8Awi+r/wDQ9+JP+/Gnf/ItH/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVUVyv8Awi+r/wDQ9+JP+/Gnf/ItH/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVUVyv8Awi+r/wDQ9+JP+/Gnf/ItH/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAB8NP+RcvP+w1q3/pxuKK1fDGix+H9IWwiurm7/fT3Dz3OzzJJJpXlcnYqqPmduAoAGKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For example, immunologic but IgE-independent, or nonimmunologic (direct mast cell activation).",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      For example, after an insect sting, reduced blood pressure might be the only manifestation of anaphylaxis; or, after allergen immunotherapy, generalized hives might be the only initial manifestation of anaphylaxis.",
"      <br>",
"       &Delta; Low systolic blood pressure for children is defined as less than 70 mmHg from 1 month to 1 year, less than (70 mmHg + [2 x age]) from 1 to 10 years, and less than 90 mmHg from 11 to 17 years. Normal heart rate ranges from 80 to 140 beats/minute at age 1 to 2 years; from 80 to 120 beats/minute at age 3 years; and from 70 to 115 beats/minute after age 3 years. In infants and children, respiratory compromise is more likely than hypotension or shock, and shock is more likely to be manifest initially by tachycardia than by hypotension.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br/>",
"     <ol>",
"      <li>",
"       Clinical criteria for the diagnosis of anaphylaxis: The clinical criteria pictured are based upon Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report: Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. J Allergy Clin Immunol 2006; 117:391-7. Anaphylaxis with involvement of only one body organ system and anaphylaxis in infants and young children are described in Simons FER, Ardusso LRF, Bilo MB, et al. World Allergy Organization guidelines for the assessment and management of anaphylaxis. J Allergy Clin Immunol 2011; 127:127: 587-593.e1-e22.",
"      </li>",
"     </ol>",
"     <br/>",
"     Reproduced with permission from: Simons FER, Ardusso LRF, Beatrice Bilo M, et al. World Allergy Organization guidelines for the assessment and management of anaphylaxis. WAO Journal 2011; 4:13. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33514=[""].join("\n");
var outline_f32_46_33514=null;
var title_f32_46_33515="Causes of low QRS voltage";
var content_f32_46_33515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of low voltage QRS complexes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Adrenal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anasarca",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artifactual or spurious, eg, unrecognized standardization of ECG at one-half the usual gain (ie, 5 mm/mV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac infiltration or replacement (eg, amyloidosis, tumor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac transplantation, especially with acute or chronic rejection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiomyopathy, idiopathic or secondary*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic obstructive pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constrictive pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism, usually with sinus bradycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left pneumothorax (mid-left chest leads)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial infarction, extensive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocarditis, acute or chronic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal variant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial tamponade, usually with sinus tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural effusions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dilated cardiomyopathy may be associated with the combination of relatively low limb lead voltages and prominent precordial voltages.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33515=[""].join("\n");
var outline_f32_46_33515=null;
var title_f32_46_33516="ACC AHA choice imaging risk I";
var content_f32_46_33516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Cardiac stress imaging as the initial test for risk stratification of patients with chronic stable angina who are able to exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that cardiac stress imaging as the initial test for risk stratification of patients with chronic stable angina who are able to exercise should be performed in the following manner:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Among patients who do not have left bundle branch block or an electronically paced ventricular rhythm but have either an abnormal ECG or are taking digoxin, exercise myocardial perfusion imaging (MPI) or exercise echocardiography to identify the extent, severity, and location of ischemia.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Among patients with left bundle branch block or an electronically paced ventricular rhythm, dipyridamole or adenosine MPI.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Among patients with left bundle branch block, dobutamine stress echocardiography.*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; When assessing the functional significance of coronary lesions, exercise MPI or exercise echocardiography.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The weight of evidence or opinion is less well established for the usefulness of cardiac stress imaging as the initial test for risk stratification of patients with chronic stable angina who are able to exercise in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Exercise echocardiography in the presence of left bundle branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Exercise, dipyridamole, or adenosis MPI or exercise or dobutamine echocardiography in patients who have a normal rest ECG and are not taking digoxin.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that cardiac stress imaging as the initial test for risk stratification of patients with chronic stable angina who are able to exercise is not useful in in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Exercise MPI in the presence of left bundle branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Severe comorbidity that is likely to limit life expectation or prevent revascularization.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Modified from: Fleisher, LA, Beckman, JA, Brown, KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:e418.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gibbons, RJ, Abrams, J, Chatterjee, K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149. Copyright 2003 by the American College of Cardiology and American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33516=[""].join("\n");
var outline_f32_46_33516=null;
var title_f32_46_33517="Impotence in men by age";
var content_f32_46_33517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Increasing incidence of erectile dysfunction in men with age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 258px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Aging is associated with a progressive increase in the frequency of moderate and complete erectile dysfunction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study.&nbsp;J Urol 1994; 151:54.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33517=[""].join("\n");
var outline_f32_46_33517=null;
var title_f32_46_33518="Total body water";
var content_f32_46_33518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Total body water and its major subdivisions as a function of age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 338px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Friis-Hansen B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics 1961; 28:169.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33518=[""].join("\n");
var outline_f32_46_33518=null;
var title_f32_46_33519="SFU grading fetal hydronephr";
var content_f32_46_33519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Society of Fetal Urology grading system for hydronephrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 149px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Grade 0: no dilation (not shown). Grade 1: renal pelvis is only visualized. Grade 2: renal pelvis as well as a few, but not all, calyces are visualized. Grade 3: virtually all calyces are visualized. Grade 4: similar to Grade 3 but, when compared to the normal centralateral kidney, there is parenchymal thinning.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_46_33519=[""].join("\n");
var outline_f32_46_33519=null;
